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ABSTRACT 
 Many of the pharmaceutical agents that are used clinically were developed from natural 
products and their derivatives. Natural products are often observed to have potent and specific 
interactions with biological targets, and are produced by a variety of macro and microorganisms. 
Actinomycetes have been an especially prolific source of natural products with antimicrobial 
applications and are responsible for approximately 70% of all clinically used agents. This has 
resulted in extensive investigation of these bacteria for the discovery of novel secondary 
metabolites, causing reisolation of known compounds to occur frequently. Novel techniques are 
needed to identify the production of new natural products to continue investigating natural 
sources for the discovery of new pharmaceutical agents. 
 To overcome the reisolation issue that hinders natural products discovery, a chemical 
based screening method was employed to prioritize strains for scale-up and further investigation. 
This method involved analyzing crude fermentation extracts using LC-HRMS, followed by 
principal component analysis to visualize the results. Utilization of this technique to analyze 
libraries of actinomycetes resulted in the identification of novel natural products more effectively 
than the tradition bioassay-guided method. This led to the selection of Streptomyces sp. RKKD-
790 and Kitasatospora cystarginea NRRL B-16505 for further investigation. 
 A novel lasso peptide natural product tentatively named RKKD790_1592, was isolated 
from the fermentation broth of Streptomyces sp. RKKD-790. This group of peptides are 
characterized by their unique threaded structures, which provide them with superior stability 
compared to linear peptides. Computation modelling, MS/MS and stability assays were used to 
confirm that this novel peptide contained the characteristic threaded structure. 
 The strain K. cystarginea was found to produce three novel natural products, 
cystargamide, and cystargolides A and B. Unique structural features of cystargamide include the 
presence of the non-proteinogenic amino acids 4-hydroxyphenyl glycine and 5’-hydroxy 
typtophan and 2,3-epoxydecanoyl group. Cystargamide displayed the ability to activate 
production of pigmented metabolites by Streptomyces coelicolor in a disk diffusion assay. This 
interesting result indicated that cystargamide may be involved in bacterial communication, and 
may induce natural product biosynthesis in other bacteria. The gene cluster responsible for 
producing this novel lipopeptide was determined bioinformatically from the whole genome 
sequence of K. cystarginea. Cystargolides A and B are novel β-lactone containing peptides that 
were also produced by K. cystarginea. These peptides have very unique structures, and are the 
only natural products to have been described that contain a carboxyl and isopropyl substituted β-
lactone group. Cystargolides A and B were found to be inhibitors of human 20S proteasome, 
showing that they are an excellent candidate for development as antiproliferating agents to treat 
cancer. Further investigations of these applications are ongoing by members of the Kerr group. 
The gene cluster involved in production of cystargolides A and B was predicted using 
bioinformatics and confirmed by generating a gene disruption mutant. 
The discovery of these novel bioactive natural products represent exciting opportunities 
for development as an inducer of bacterial natural products, and an anticancer agent. Members of 
the Kerr group are continuing to explore these interesting applications. Identification of their 
unique structures and biosynthesis also extend our knowledge of the natural product production 
capabilities of bacteria.   
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CHAPTER 1: AN INTRODUCTION TO 
NATURAL PRODUCTS AND THEIR 
IMPORTANT ROLE IN DRUG 
DISCOVERY 
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1.1 Natural products and structural classifications 
Natural products, or secondary metabolites are molecules that are produced by 
living organisms that are not required for the basic functions of life, but instead confer 
some kind of evolutionary advantage to the producer1. Natural products are produced by 
a variety of organisms ranging from single celled microorganisms to plants, marine 
organisms and mammals. As evident in Figure 1.1, the structural diversity of natural 
products is extremely vast, and consequently, they have been grouped together into the 
following classes based on structural features and biosynthetic origins: alkaloids, 
terpenoids, polyketides and peptides (Figure 1.1)2,3. Alkaloids are defined as heterocyclic 
nitrogen containing metabolites that are biosynthesized through extensive modification of 
amino acid building blocks. Alkaloids are a very complex and structurally diverse class 
of natural products that include subgroups like purine alkaloids (caffeine), tropane 
alkaloids (cocaine) and benzylisoquinoline alkaloids (morphine) to name a few. 
Terpenoids is the largest class of natural products to date, and contains metabolites that 
are derived from the 5-carbon building block isoprene. Isoprene can be produced using 
two distinct pathways, the mevalonate pathway, or the desoxyxyulose phosphate pathway 
(non-mevalonate pathway). Commonly known examples of terpenes include, paclitaxel, 
humulone, and β-carotene. Polyketides are metabolites that generally contain several 
acetate and malonate units, and differ from fatty acids in retention of oxygen containing 
functional groups. Polyketides are biosynthesized by large, multimodular enzymes 
referred to as polyketide synthases. Examples of bioactive polyketides include 
resveratrol, erythromycin and tetracycline. Peptide natural products contain amino acids 
that are linked through peptide bonds. They differ from proteins in that they are much 
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smaller in size, and commonly contain non-proteinogenic amino acids, modifications, 
and additional structural motifs including fatty acids, sugars and polyketides. Some 
biologically relevant examples of peptide natural products include cyclosporine, 
vancomycin and conotoxins. Similar to proteins, they can be biosynthesized by the 
ribosome to produce ribosomally synthesized post-translationally modified peptides 
(RiPPs) or they can be produced by large, multimodular enzymes referred to as non-
ribosomal peptide synthetases (NRPSs) and be classified as non-ribosomal peptides 
(NRPs). Hybrid natural products that include structural features from more than one class 
of natural product are also observed. This creates an extreme amount of structural 
diversity throughout the different types of natural products. 
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Figure 1.1. Well-known examples of natural products from each class showing structural 
diversity.  
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1.2 Ecological role of natural products 
Many natural products play an important ecological role in the survival of their 
producing organism and provide advantages including defense mechanisms, 
communication, nutrient transport, and other competitive advantages4. Toxic metabolites 
are commonly produced by a variety of plant species that make the plant tissue 
undesirable for consumption by insects or bird predators5. Antimicrobial and antifungal 
metabolites are often produced by plants and microorganisms to protect themselves 
against other pathogenic microorganisms6. Some predatory organisms produce paralyzing 
agents or venoms that assist them when hunting their prey7. Chemical communication 
can be achieved through the use of natural products, and play a role in bacterial quorum 
sensing and regulation of gene expression8. Metal chelators can play an important role in 
nutrient sequestering and transport9. Lastly, natural products can act as antifouling agents 
and prevent microbial, plant, algae, or animal competitors from adhering to the area 
surrounding the producing organism10. The aforementioned examples represent a small 
sample of the many ecological roles that natural products exhibit in their producing 
organisms, and the true role of natural products often remains a mystery. 
1.3 Biological applications of natural products  
 Because of the biological activity that is often displayed by natural products, they 
have long been exploited for their pharmaceutical applications to benefit human health11. 
Thus, natural products have played a very important role in drug discovery programs for 
centuries. Of the total 1 562 new drugs approved between 1981 and 2014, 4.3 % are 
unaltered natural products (N), 0.6 % are botanical drugs (defined mixtures) (NB), 20.5 
% are natural product derivatives (ND), 3.9 % are synthetically produced with a natural 
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product pharmacophore (S*), 10.4 % are synthetically produced with a pharmacophore 
that is a natural product mimic (S*/NM), 11 % are synthetically produced with structural 
features that mimic the natural substrate (S/NM), 16 % are biologics that consist of large 
peptides or proteins (B), 6.5 % are vaccines (V), and 26.9 % are totally synthetic drugs 
that are not found in nature (S) (Figure 1.2)11. This highlights the important influence that 
natural products have played in the development of pharmaceutical agents. 
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Figure 1.2. New drugs approved from 1981-2014 grouped by category of origin using the 
following categories:  
Unmodified natural product (N), natural product derivative (ND), natural botanical (NB), 
biologic (B), vaccine (V), synthetic with a natural pharmacophore (S*), totally synthetic 
(S), natural product/substrate mimic (NM). Figure created by D.J Newman and G.M 
Cragg11. 
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Disease treatments with the highest percentage of natural product drugs are 
anticancer and antibacterial agents11. Of the 246 anticancer drugs that were approved 
between 1940 and 2014, only 19 % are S, 38 % are N, ND and NB, 15 % are V and B, 
and the remaining 28 % are S* and /NM. If vaccine and biologics are excluded, a total of 
77 % of all small molecules approved for the treatment of cancer are derived or inspired 
by natural products. This is an extremely significant portion of small molecule cancer 
treatments, and highlights the important role that natural products have played in the field 
of anticancer drug discovery.  
Drugs that have been approved to treat bacterial infectious disease are also 
dominated by natural products and their derivatives11. Of the 141 antibacterial drugs 
approved between 1981 and 2014, 58 % are natural products or derivatives. Natural 
products also play a significant role in the treatment of other infectious diseases such as 
parasitic diseases. Of the 15 antiparasitic drugs, 46.6 % are natural products or 
derivatives. Other approved antiinfectives such as antifungal and antiviral agents include 
fewer natural products and their derivatives. In 2014 the World Health Organization 
(WHO) published a comprehensive Global Report on Surveillance of antimicrobial 
resistance12. This report highlighted the high levels of microbial resistance found in all 
assessed regions across the world, and included the resistance to antibiotics that are used 
as last resort treatment options. This shows that microbial infections may rapidly become 
untreatable and could result in a fatal prognosis if no new methods to combat 
antimicrobial resistance and infectious disease are developed. As a result, the WHO 
released a call to action for the development of new antimicrobial agents to combat this 
formidable global health concern. Since natural products have historically been the 
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greatest contributor to antibacterial agents, this highlights the importance of more natural 
products based drug development programs to help combat the growing crisis of 
antimicrobial resistance and untreatable infectious diseases.  
Natural products are produced by organisms from all kingdoms of life. The 
kingdom first used by people for medicinal applications were plants, and they have 
continued to be fruitful sources ever since. In addition to plants, mammals, bacteria and 
fungi have also been producers of a significant number of natural products approved by 
the FDA as pharmaceuticals. Of the FDA-approved small molecule entities that are 
natural products or their derivatives (excluding mammalian metabolites), 45 % are 
derived from plant sources, 29 % from bacteria, and 22 % from fungi13. This shows the 
significant role that plant natural products have played in the treatment of a variety of 
human diseases including anticancer agents, analgesics and cholesterol lower agents. 
Taking into account only antibacterial approved drugs, the role of microorganisms 
becomes more significant. Of all approved antibacterial agents, 69 % are derived from 
natural products, and of these agents, 97 % originate from microbial sources. A total of 
51 % of all antibacterial natural products are produced by bacteria and 46 % by fungi 
while only 3 % are produced by plants14. This highlights the important impact that 
microbial natural products have had on human health, and highlights the importance of 
continuous investigation of microbial sources for novel natural products.  
Not only is it important to continue involving natural products discovery in drug 
development programs to treat cancer and infectious disease, it is also important for 
existing, emerging and orphan diseases. The structures of natural products have evolved 
over billions of years to specifically interact with molecular targets, and have an effect on 
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biological systems. By determining this role and biological target, natural products can 
continue to be exploited as pharmaceutical agents to benefit human health.  
1.4 Microbial natural products 
 Since the discovery of penicillin in 1928 by Sir Alexander Fleming, microbes 
have been investigated for the production of bioactive secondary metabolites. These 
investigations have resulted in the identification of over 23 000 bioactive metabolites, 
with antiinfective, anticancer, antiviral, immunosuppressive and antiobesity activity 
among others14. Microbial natural products have had the most significant impact on 
clinically used antimicrobial agents, and are responsible for several classes of clinically 
used antimicrobial agents including the penicillins, cephalosporins, tetracyclines, 
aminoglycosides, chloramphenicol, macrolides, ansamycins, polyenes, and 
glycopeptides15. 
As stated in section 1.3, 97 % of all FDA approved antibiotic natural products and 
their derivatives originate from microbial sources13. These antibiotics are primarily 
produced by the the bacterial phylum actinomycetes and the fungal phyla ascomycetes 
and basidiomycetes14. Streptomyces is the largest genus of actinomycetes, and is the most 
frequent producer of bioactive natural products. Streptomcyes are gram-positive bacteria 
with relatively large genome sizes that posess the genetic ability to produce several 
different natural products per strain. This has made Streptomyces an ideal source to 
investigate for natural product discovery programs, which has resulted in extensive 
investigation of this bacterial genus15.  
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1.5 Limitations of natural products discovery and strategies to 
overcome them  
 Despite the success that natural products based discovery has enjoyed for the 
development of anticancer and antibacterial agents, there are also several limitations. One 
of the major issues associated with natural products research is securing a sustainable 
supply. Gathering enough plant or animal tissue to purify the large quantities of natural 
products that are required for characterization, preclinical and clinical development and 
especially widespread distribution can have serious environmental impacts16. Synthetic 
and semisynthetic approaches to create a sustainable supply of natural products have seen 
some success, but due to the complex structures of natural products, synthetic approaches 
may not always be possible. Using microbes as part of natural products drug discovery 
programs has also been helpful for overcoming supply issues. Microbes like bacteria and 
fungi can be excellent producers of natural products, and unlike their plant and animal 
counterparts, they only need to be collected from their environment once15. After that 
they can be cultivated in laboratories for a constant and sustainable supply of the desired 
compound. Microbes have also been very beneficial as heterologous producers of natural 
products, or their precursors. Genetically engineering microbial strains to produce natural 
products that were isolated from other sources has been very successful at addressing 
issues with sustainable supplies of natural products17.  
 Another issue associated with natural products research is the pace at which 
discoveries occur. It can be difficult to adapt natural products drug discovery in the high-
throughput manner desired by pharmaceutical companies. Excellent advances have been 
made to generate large extract or fraction libraries, and to screen these libraries for 
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various biological activities, however the characterization of the metabolites in these 
large libraries still remains a bottleneck18. Increasingly sensitive analytical chemistry 
tools, including high resolution mass spectrometers and high-field cryoprobe NMR, have 
greatly assisted with improving this bottleneck, however it still remains a time consuming 
step in the drug development process.  
 A significant challenge of natural products discovery is the rediscovery of 
previously described metabolites. This is especially difficult when working with bacterial 
strains that are members of the genus Streptomyces, which has been extensively studied 
for the past several decades19. Many Streptomyces spp. share the same biosynthetic gene 
clusters and are able to produce the same metabolites. This causes the rate of reisolation 
of known natural products to be very high, especially when common bioassays like 
anticancer and antibacterial assays are used to screen these libraries. This creates serious 
issues with natural products discovery programs because it causes researchers to waste 
significant periods of time and resources isolating known compounds20. Many research 
groups today are focusing on the development of alternative methods to bioassay-guided 
isolation in order to overcome this barrier. These screening techniques involve analyses 
that provide more information about the chemical composition of extracts and some 
recently developed methods include metabolomics analyses of LC-MS21,22 or NMR 
profiles23 and molecular networking of LC-MS/MS profiles24. The continuation of 
development of these types of screening methods will help to efficiently dereplicate 
natural products libraries against known natural products, and help researchers prioritize 
hits based on chemical novelty, and eliminate or reduce the instances of reisolating 
known compounds.  
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 Another way to overcome the issue of rediscovery is to investigate organisms 
from unique environments for the production of natural products. Organisms that have 
adapted to live in unique environmental niches are different than the organisms that live 
in commonly explored environments25. Exploring these unique locations can increase the 
likelihood of obtaining novel organisms, and therefore are more likely to produce novel 
natural products. There are several environmental niches that remain underexplored for 
natural products discovery. The marine environment is relatively underexplored 
compared to terrestrial environments26. Advances in self-contained underwater breathing 
apparatus (SCUBA) and especially remotely operated underwater vehicles (ROVs) have 
allowed researchers to access organisms and sediment samples from great depths. Cold 
and temperate environments are also less extensively explored for natural product 
discovery25. Tropical areas have been largely explored for natural products producing 
organisms because of their great biodiversity, which has left temperate and cold 
environments less extensively explored. Investigating organisms from such environments 
increases the likelihood that novel species, and therefore new natural products will be 
discovered.  
 Advances in sequencing technology and genetic engineering have revealed that 
many microbes have the genetic capability to produce several more natural products than 
what has been isolated from fermentation extracts18. This technology has sparked a great 
deal of interest in genome mining strategies for the discovery of novel natural products. 
These techniques can involve heterologous expression of entire gene clusters that 
produce putatively novel metabolites. Other techniques have involved activation of silent 
or cryptic gene clusters using epigenetic modifiers27, or mimicking their natural 
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environment using mixed cultures28, or environmental extracts29. Activation of these 
cryptic gene clusters will provide access to new natural products that were previously 
inaccessible using traditional fermentation methods. The more information that is 
available about biosynthetic gene clusters, and their regulation, the more successful 
genome based natural product discovery programs will be since it will be easier to predict 
the gene functions and resulting structures to find novel natural products.  
1.6 Research objectives  
 The overall goal of this research project was to identify and characterize novel 
microbial natural products. In order to achieve this goal, and avoid some of the common 
limitations of the traditional natural products discovery pipeline, several strategies were 
used, which are described in Chapter 2. Firstly, to avoid downstream issues with supply 
and sustainability of natural products, bacterial strains were chosen as the source 
organisms to investigate. A library of actinobacteria were selected to investigate because 
historically, this group of bacteria has been the greatest microbial producers of natural 
products14. The second strategy involved selection of unique bacterial strains to avoid 
reisolation of known metabolites. A library of actinomycetes that were collected from 
marine sediment in the intertidal zone of temperate waters, was selected. A library of the 
less extensively studied actinomycete genus, Kitasatospora was also selected to increase 
the likelihood of identifying novel metabolites. The third strategy involved the use of a 
chemical based screening approach that combined liquid chromatography high-resolution 
mass spectrometry with multivariate analysis. This allowed for efficient dereplication of 
bacterial extract libraries against databases of known metabolites, and prioritization of 
strains producing putatively novel natural products. It also limited the number of known 
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metabolites that were isolated based on biological activity alone. These strategies for the 
discovery of novel natural products resulted in the efficient identification of three novel 
peptide natural products. The screening process of these bacterial libraries is described in 
Chapter 2, and characterization of these novel metabolites are described in Chapters 3-5.  
 The final aim of this research project was to sequence the genome of one of the 
bacterial strains that produced novel metabolites, Kitasatospora cystarginea, and identify 
the gene clusters that are responsible for the biosynthesis of these natural products. The 
bioinformatics analysis and gene disruption experiments used to identify these 
biosynthetic gene clusters are described in Chapter 6. 
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CHAPTER 2: LC-MS/PCA SCREENING 
METHOD FOR THE IDENTIFICATION 
OF UNIQUE METABOLOMES AMONG 
LIBRARIES OF ACTINOMYCETES 
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2.1 INTRODUCTION 
 Natural products have historically been an essential component for drug discovery 
programs11. Traditionally, the most common strategy for identifying new natural products 
with drug potential was bioassay-guided fractionation30. This process typically involved 
iterative rounds of chromatographic separation and bioassays until a pure, bioactive 
compound was identified. In the early stages of natural products research this technique 
proved very useful for identifying new drug candidates from natural sources. However, 
after several decades of natural products discovery, using this technique results in a high 
rate of rediscovery of known natural products. This creates a bottleneck in natural 
products research where identifying novel metabolites using traditional techniques 
becomes very challenging and time consuming.  
 To overcome some of the barriers of traditional natural products discovery 
methods, many researchers have begun using techniques that include more information 
about the chemical composition of extracts instead of the biological activity alone,21,22, 
31,32,33. These strategies involve untargeted metabolomics of spectrometric or 
spectroscopic profiles of crude extracts or fractions. Using liquid chromatography high-
resolution mass spectrometry (LC-HRMS) to analyze extracts or fractions provides 
information about the composition of the extract provides more information about each 
constituent that is present including the mass, polarity, and some structural fragments. 
These data can then be analyzed using multivariate data analyses to visualize the results 
in a way that allows researchers to quickly identify putatively novel natural products.  
There are several multivariate data analyses that may be employed to visualize 
LC-HMRS profiles of microbial fermentation extracts31. One effective strategy is to use 
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principal component analysis (PCA) for visual representation of large data sets21,22. 
Principal component analysis is a visualization technique that describes the variance 
among a data set by breaking down a data matrix into a set of uncorrelated variables 
called principal components (PCs)34. The first PC describes the most variance, and then 
each successive PC is orthogonal to the previous, and describes the next highest variance. 
Each data point in the matrix receives a score for each principal component, which are 
then plotted on a scores plot. Scores plots reveal clusters or outliers among the complex 
data matrix in an efficient manner. The loadings plots display the data values, in this case 
m/z ratio, that correspond to each data point in the scores plot. This technique is 
extremely useful for visualizing complex LC-HRMS profiles from a large library of 
bacterial fermentation extracts22,21. The use of PCA can allow for chemical dereplication 
of libraries by clustering of bacterial extracts that produce the same metabolites, and 
rapid identification of putatively novel natural products based on outliers.  
LC-MS/PCA metabolomics screening is especially useful for identifying new 
natural products from actinomycetes21. Actinomycetes are an order of bacteria that have 
been the most prolific bacterial producers of bioactive natural products35. These bacteria 
are responsible for producing approximately one third of all clinically used antibiotics. 
Because of their historic importance for antibiotic discovery, this order of bacteria has 
been extensively mined for natural product production. This makes the issue of re-
discovery extremely important, and highlights the need for new techniques to discovery 
novel natural products.  
Streptomyces is the largest and most frequently studied genus of actinomycetes 
for natural product production14,15. They are gram positive, mycelia-forming bacteria in 
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the family Streptomycetaceae. Streptomyces are ubiquitous throughout the world and are 
commonly found growing in soil and marine sediments. Several clinically used 
antimicrobial agents are produced by Streptomyces spp. including tetracycline36, 
vancomycin37, erythromycin and more recently, daptomycin38. Genome sequencing of 
several Streptomyces strains has revealed the presence of 20-30 secondary metabolite 
biosynthetic gene clusters in each genome sequence showing that there is an even greater 
genetic potential to produce than what was assumed based on the number of compounds 
isolated from fermentations39. This shows that Streptomyces still remains an excellent 
source to evaluate for the discovery of new bioactive natural products, and that new 
techniques must be used to access these novel compounds19.  
Another closely related genus in the Streptomycetaceae family that is also 
proficient at producing natural products is Kitasatospora40. Members of this genus have 
very similar morphology, conserved gene sequences and natural product production 
abilities to their sister genus Streptomyces41. Since the first description in the 1980s, their 
classification has been debated, and in 1992 was altered to have all members of the 
Kitasatospora genus reclassified as Streptomyces42. The genus was re-established as a 
separate genus shortly after in 199743. Kitasatospora and Streptomyces can be 
differentiated based on the stereochemistry of the amino acid diaminopimelic acid that is 
present in the cell wall. Kitasatospora contain meso and LL-diaminopimelic acid (DAP), 
while the cell wall of Streptomyces are composed primarily of only LL-DAP40,44. 
Classification of Kitasatospora spp. cannot be differentiated from Streptomyces using 
phylogenetic analysis of 16S ribosomal RNA sequences, and instead, multiple gene 
phylogenies including the β-subunit of RNA polymerase (rpoB), and DMP ligase (murE) 
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are required to distinguish these closely related genera44,45. Kitasatospora is comparable 
to Streptomyces in the relatively large genome sequences, and abundant presence of 
secondary metabolite gene clusters. Despite the characterization of only four natural 
products from Kitasatospora setae, the whole genome sequence contains 24 putative 
biosynthetic gene clusters46. Kitasatospora are much less abundant and less extensively 
studied than Streptomyces for the production of secondary metabolites. This shows that 
Kitasatospora spp. remain a prolific yet underexplored resource for the discovery of 
novel bioactive natural products.  
Due to their abundant natural product production, libraries of actinomycetes were 
evaluated for the presence of novel compounds. Strains from the RKKD section of the 
Kerr Lab microbial library were isolated from marine sediment collected from Bonne 
Bay, Newfoundland Canada, and the Bay of Fundy, New Brunswick Canada47,48. The 
Kitasatospora library was obtained from the Agriculture Research Services Culture 
Collection, and were all originally isolated from soil samples from various locations. In 
this chapter, the screening of these bacterial libraries for the production of new natural 
products is presented. The traditional method of bioassay-guided screening was used as 
well as the more modern metabolomics approach of LC-MS/PCA in combination to 
efficiently identify novel secondary metabolite production, and prioritize strains for 
further investigation. 
2.2 MATERIALS AND METHODS 
2.2.1 Small scale fermentation of RKKD library 
 A total of 68 strains from the RKKD bacterial library were selected for evaluation 
of their natural product production by antimicrobial screening and metabolomics 
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analysis. All strains were streaked onto ISP249 agar plates and incubated for 7-10 days at 
30 ºC. Single colonies were used to inoculate 10 mL of ISP2 broth containing 2-5 glass 
beads and incubated with agitation at 200 rpm at 30 ºC for 72 hours (seed culture). After 
incubation, 10 mL of fresh ISP2 was inoculated with 500 µL of seed culture and 
incubated under the same conditions for an additional seven days. 
2.2.2 Small scale fermentation of Kitasatospora library 
Twelve strains of Kitasatospora spp. were streaked onto ISP349 agar plates and 
incubated for 4-7 days at 30 ºC. A single colony from each plate was used to inoculate 10 
mL of seed medium (10 g/L glucose and 10 g/L yeast extract) contained in 25 x 150 mm 
culture tubes containing 2-5 glass beads. Seed cultures were incubated at 30 ˚C for 48 
hours with agitation at 200 rpm. A second 10 mL seed culture using the same medium 
was inoculated with 500 µL of stage one, and incubated under the same conditions for an 
additional 48 hours. A fermentation tube containing 10 mL of a lean production medium 
(1045 medium) consisting of 1.6 g/L dextrin, 0.8 g/L galactose, 0.8 g/L maltose, 0.8 g/L 
bacto-soytone, 0.4 g/L glucose and 0.3 g/L ammonium sulfate, or ISP249 was then 
inoculated with 750 µL of the second seed culture and fermented for 72 hours under the 
same conditions. Fermentations were repeated in triplicate for each bacterial strain in 
both media and un-inoculated medium blanks were included as negative controls50,51. 
2.2.3 Extraction and LC-MS analysis 
Fermentation broths of all RKKD isolates and Kitasatospora strains as well as un-
inoculated medium blanks were extracted twice with 10 mL ethyl acetate (EtOAc), and 
the organic fractions were combined and evaporated to dryness. Extracts were partitioned 
between 10 mL of 80 % aqueous acetonitrile and 10 mL of hexane. The acetonitrile phase 
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was removed and evaporated to dryness. The acetonitrile fractions were analyzed by LC-
HRMS using a Thermo Q Exactive HPLC system with a Core Shell 100 Å C18 column 
(Kinetex, 1.7 µm 50 x 2.1 mm). The solvents used were diH2O/0.1 % formic acid 
(solvent A1) and acetonitrile/0.1 % formic acid (solvent B1). A linear solvent gradient 
from 5 to 100 % solvent B1 over 4.8 minutes followed by an isocratic elution with 100 % 
solvent B1 for 3.2 minutes with a flow rate of 500 µL/min was used. Eluent was detected 
by ESI-MS monitoring m/z 190-2000 in positive mode, ELSD, and PDA 200-600 nm.  
2.2.4 Data processing and statistical analysis 
LC-HRMS files (.RAW) were converted to netCDF files using Xcalibur™ and 
then imported into MZmine 252. MZmine was used for the following data processing 
steps to generate a peak list containing retention time, mass to charge ratio (m/z) and 
intensity for each metabolite detected in the LC-HRMS profiles of all of the fermentation 
extracts: Mass detection (1E5 threshold for RKKD library and 1E4 for Kitasatospora 
library), chromatogram building, deisotoping, alignment (mass and retention time 
tolerances set to 0.005 and 0.1 min respectively) and binning. Processed data was then 
exported as CSV files for further analysis. Artifact suppression and intensity 
standardization were carried out using Microsoft Excel. Intensity values above zero were 
replaced with a value of one, to remove bias introduced by abundant metabolites. Artifact 
suppression was performed by removing all features corresponding to those that were 
also detected in medium blanks, reserpine (reference standard), and methanol blanks 
from the peak lists of fermentation extracts. CSV files were then imported into The 
Unscrambler 10.1 (Camo Software) for data analysis. Analysis of the RKKD library and 
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Kitasatospora library were performed separately. Principal component analysis was used 
to analyze the processed peak lists using default settings provided by The Unscrambler. 
2.2.5 Antimicrobial assays 
All fermentation extracts from the RKKD library were tested for antimicrobial 
activity against the microbial pathogens, methicillin-resistant Staphylococcus 
aureus ATCC 33591 (MRSA), vancomycin-resistant Enterococcus faecium EF379 
(VRE), Staphylococcus warneri ATCC 17917, and Candida albicans ATCC 14035. All 
assays were carried out according to Clinical Laboratory Standards Institute testing 
standards in a 96-well plate53. Control antibiotics used were vancomycin for MRSA 
and S. warneri, rifampicin for VRE, and nystatin for C. albicans. Cell growth was 
determined by measuring the optical density at 600 nm (OD600) at time zero and after 
incubation for 22 hours at 37 ºC using a Thermo Scientific Varioskan Flash plate reader. 
The change in OD600 after incubation was compared to untreated negative control wells 
and plotted as percent growth inhibition. A single concentration of 50 µg/mL was used 
for each extract. 
2.2.6 General fractionation and structure determination experimental procedures 
 Crude fractionation of fermentation extracts was achieved with reverse phase 
flash chromatography using a CombiFlash Rf (Teledyne ISCO) with a 15.5 g C18 column 
(High Performance GOLD, RediSep Rf). A linear gradient with diH2O (solvent A2) and 
MeOH (solvent B2), that increased from 10 % to 100 % solvent B2 over 13 minutes 
followed by a 5 minute wash with 100 % solvent B2 and a flow rate of 30 mL/min was 
used.  
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Tandem MS analysis was performed using a Thermo LTQ Orbitrap Velos mass 
spectrometer. MS/MS spectra were acquired by direct infusion at a rate of 2 µL/min 
using an ESI source and fragmented by higher energy collisional dissociation (HCD). 
NMR spectra were obtained on a 600 MHz Bruker Avance III spectrometer equipped 
with a 1.7 mm inverse probe.  
2.3 RESULTS AND DISCUSSION 
2.3.1 Selection of RKKD library for screening 
 The library of actinomycetes that was isolated from sediment consisted of over 
800 bacterial isolates. Due to the difficulty of taxonomic dereplication of actinomycete 
libraries, this library was classified to the genus level, and primarily consisted of closely 
related Streptomyces spp.47,48. The large size of this actinomycete library made 
fermenting and screening the entire library without high throughput equipment a time 
consuming and daunting task, however because of the similarity of several of the strains, 
this was determined to be redundant and unnecessary. Therefore, a subset of this large 
library consisting of 68 isolates was selected for evaluation. The subset was selected 
using several criteria including 16S phylogenetic analysis, presence of natural product 
biosynthetic gene clusters and morphology in order to optimize the possibility of 
identifying novel natural products. Reasons for strain selection are summarized in Table 
2.1. 
 The main criterion for selection of the library subset was based on phylogenetic 
analysis of 16S rRNA sequences. A phylogenetic tree was constructed using partial 16S 
rRNA sequences for each isolate47,48, and a representative isolate from each clade in this 
phylogenetic tree was selected to ensure a diverse representation of the library. Partial 
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16S rRNA sequences were compared to sequences within the NCBI database using the 
Basic Local Alignment Search Tool (BLASTN)54. Isolates that exhibited less than 98 % 
identity to strains in GenBank were selected. The typical threshold to delineate species of 
actinomyetes is a sequence identity of 99 % between 16S rRNA sequences55, however 
given that partial 16S rRNA sequences were used (~500 bp), a conservative level of 98 % 
was used instead. Any strain whose closest BLAST relative was a rare actinomycete 
genus was also selected. These isolates were chosen on the basis that unique strains are 
more likely to produce unique metabolites. Rare actinomycetes are less extensively 
studied than Streptomyces and therefore represented a good opportunity to identify novel 
metabolites.  
 A PCR-based assay to detect the presence of secondary metabolite biosynthetic 
gene clusters was also used to select strains. Degenerate PCR primers that were designed 
to amplify conserved regions in biosynthetic gene clusters were used to screen the library 
for the presence of HMG-CoA reductase and dNDP-glucose 4,6 dehydratase56. HMG-
CoA reductase is an enzyme involved in the biosynthesis of terpene natural products57 
and glucose dehydratase is involved in glycosylation of natural products58. Isolates that 
contained these biosynthetic genes and possess the ability to produce these classes of 
natural products were identified by the amplification of the appropriately sized PCR 
amplicon using these degenerate PCR primers. Strains containing these putative 
biosynthetic gene clusters were selected as part of the subset library. 
Lastly, gross morphology and pigment production on solid media were the final 
criteria for selection. Pigment production was utilized as a criterion because natural 
products often absorb in the UV-Vis range and appear coloured, thus providing an easily 
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detectable indication of natural product production. Unique morphology was also used to 
select isolates, since unique morphology often indicates a unique strain, and may suggest 
differing metabolic potential and natural product production.   
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Table 2.1. Subset of the RKKD library that was selected for LC-MS/PCA metabolomics 
and antimicrobial screening, and a summary of the reasons for selection.  
Several strains were selected based one or more criteria. Criteria are ordered based on 
most to least important from left to right respectively. NB = New Brunswick, NL = 
Newfoundland 
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RKKD 199 NB           
RKKD 370 NB           
RKKD 272 NB           
RKKD 550 NL           
RKKD 686 NL           
RKKD 365 NB           
RKKD 012 NB           
RKKD 143 NB           
RKKD 234 NB           
RKKD 412 NB           
RKKD 097 NB           
RKKD 031 NB           
RKKD 049 NB           
RKKD 075 NB           
RKKD 746 NL           
RKKD 770 NL           
RKKD 146 NB           
RKKD 374 NB           
RKKD 351 NB           
RKKD 808 NL           
RKKD 151 NB           
RKKD 395 NB           
RKKD 517 NL           
RKKD 563 NL           
RKKD 669 NL           
RKKD 760 NL           
RKKD 793 NL           
RKKD 799 NL           
RKKD 003 NB           
RKKD 051 NB           
RKKD 059 NB           
RKKD 074 NB           
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RKKD 079 NB           
RKKD 090 NB           
RKKD 123 NB           
RKKD 148 NB           
RKKD 160 NB           
RKKD 181 NB           
RKKD 194 NB           
RKKD 211 NB           
RKKD 216 NB           
RKKD 240 NB           
RKKD 260 NB           
RKKD 262 NB           
RKKD 328 NB      
RKKD 360 NB           
RKKD 403 NB           
RKKD 459 NB           
RKKD 469 NL           
RKKD 498 NL           
RKKD 516 NL           
RKKD 544 NL           
RKKD 551 NL           
RKKD 555 NL           
RKKD 593 NL           
RKKD 604 NL           
RKKD 649 NL           
RKKD 727 NL           
RKKD 736 NL           
RKKD 738 NL           
RKKD 790 NL           
RKKD 800 NL           
RKKD 804 NL           
RKKD 096 NB           
RKKD 161 NB           
RKKD 185 NB           
RKKD 667 NL           
RKKD 815 NL           
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2.3.2 Prioritization of the RKKD library using multivariate data analysis and 
antimicrobial activity. 
 All 68 isolates that were selected for metabolomics analysis were fermented, 
extracted and analyzed by LC-HRMS. Chemical profiles were processed and analyzed by 
PCA to efficiently identify strains that produced unique metabolites. Due to the large size 
of the resulting data matrix, a high threshold of 1E5 was used during peak detection in 
order to ensure that only abundant metabolites contributed to prioritization of strains for 
isolation of metabolites. A total of 366 distinct mass features were detected using 
MZmine 2. Of those features, 16 were detected in MeOH blanks, media blanks, or 
internal reserpine blanks (calibration standard) and were removed from the features list. 
Peak intensities were normalized to a value of one for all detected features to remove bias 
associated with abundance. Principle component analysis was then used to visualize the 
processed data matrix using The Unscrambler. Scores plots of PC1 vs. PC2 to PC15 vs. 
PC16, shown in Figure 2.1, were used to analyze the metabolomes of isolates from the 
RKKD library. Based on the scores plots, 10 strains clustered away from the other 
strains, suggesting the presence of mass features that are not observed in the majority of 
strains. The following initial hits were identified: RKKD-808 from PC1 vs. PC2; RKKD-
240 from PC3 vs. PC4; RKKD-161 from PC5 vs. PC6; RKKD-412 and RKKD-760 from 
PC9 vs. PC10; RKKD-790, RKKD-555 and RKKD-760 again from PC11 vs. PC12; 
RKKD-074, RKKD-374 and RKKD-790 again from PC13 vs. PC14; RKKD-234 from 
PC15 vs. PC16.  
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Figure 2.1. Principal component analysis scores plots of RKKD library in ISP2 medium. 
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Figure 2.1. Continued from previous page. 
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Figure 2.1. Continued from previous page. 
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Figure 2.1. Continued from previous page. 
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 The fermentation extracts of all 68 isolates from the RKKD library were 
investigated for antimicrobial activity against four bacterial pathogens and one fungal 
pathogen. The results of these bioassays are shown in Figure 2.2, and strains displaying 
activity are summarized in Figures 2.3 and 2.4. Extracts were considered active if they 
inhibited the growth of one or more of the microbial pathogens by greater than 70 %. 
Based on the results from the antibacterial assays, 11 strains were identified as producers 
of metabolites with antibacterial activity. Eight strains inhibited the growth of both 
MRSA and VRE (RKKD-059, RKKD-074, RKKD-123, RKKD-240, RKKD-260, 
RKKD-412 and RKKD-808), three strains inhibited the growth of only MRSA (RKKD-
090, RKKD-234, and RKKD-498), and one strain inhibited the growth of only VRE 
(RKKD-790). It is worth noting that RKKD-234 showed moderate growth inhibition 
against VRE as well, but lower than the threshold selected to be classified as a hit. 
RKKD-790 also displayed weak growth inhibition against MRSA, and RKKD-412 also 
inhibited the growth of P. vulgaris but at levels below the threshold.  
The antifungal activity against C. albicans was also evaluated. Antifungal hits 
were selected based on growth inhibition of 70 % or greater against C. albicans. A total 
of 12 antifungal hits were identified as follows: RKKD-051, RKKD-148, RKKD-234, 
RKKD-262, RKKD-272, RKKD-374, RKKD-412, RKKD-469, RKKD-593, RKKD-779, 
RKKD-804, and RKKD-808 all inhibited the growth of C. albicans. 
  
35 
 
 
Figure 2.2. Percent growth inhibition of RKKD subset library against five microbial 
pathogens  
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Figure 2.3. Summary of the percent growth inhibition of extracts from the RKKD library 
that displayed activity against four human bacterial pathogens. 
 
Figure 2.4. Summary of the percent growth inhibition of extracts from the RKKD library 
that displayed activity against Candida albicans. 
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 Some strains were identified as hits by more than one of the bioassays or 
metabolomics screen. A total of three strains were identified as hits using all three 
screening methods: RKKD-234, RKKD-412 and RKKD-808. These strains were given 
the highest priority. Four strains were selected as hits in the LC-MS/PCA screen, and also 
displayed either antibacterial or antifungal activity and were classified as the next highest 
priority. Three of the strains were considered hits from the metabolomics screen but did 
not have any antimicrobial activity. Lastly, there were 13 strains that were active in either 
the antibacterial or antifungal assay alone. Strains that were hits in a single screening 
method were given the lowest priority. 
To further prioritize the strain list, raw LC-MS data was used to assess the 
putative novelty and relative abundance of the metabolites each strain produced using the 
ELSD chromatogram to determine the practicality of scale-up fermentations and 
compound purification. After analyzing the LC-MS chromatograms of each prioritized 
strain, some were removed from the list based on observations from the ELSD 
chromatogram. The ELSD signal can show relative abundance of each metabolite. Some 
strains were deprioritized because they produced a very low abundance of the metabolites 
detected by MS, and it would be very challenging to obtain enough material for full 
characterization. The strains that were deprioritized because of low abundance included: 
RKKD-059, RKKD-123, RKKD-148, RKKD-262, RKKD-498, RKKD-593 and RKKD-
804.  
Several strains were also grouped together because they produced the same 
metabolites. RKKD-051, RKKD-090, RKKD-272, RKKD-374, RKKD-469 and RKKD-
779 all produced the same two metabolites with exact masses of m/z 912.6269 [M+H]+ 
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(RKKD_912) and m/z 445.1140 [M+H]+ (RKKD_445). At the time, Hebelin Correa 
another member of the Kerr lab was investigating other strains from the RKKD library 
for the production of novel metabolites and found several strains that also produced these 
same metabolites. She was working on determining the identity of these compounds, 
therefore, all of these strains were removed from this priority list. Upon full 
characterization she determined that RKKD_445 was enterocin59 and RKKD_912 was 
the recently described metabolite, reginamide A60.  
Three other strains were grouped together because of similar metabolite 
production. RKKD-074, RKKD, 555 and RKKD-260 all produced two metabolites with 
m/z 828.4741 [M+NH4]
+ and two metabolites with m/z 870.4822 [M+NH4]
+. Upon 
searching these masses in AntiBase, RKKD_828 corresponded to eight known 
compounds. The rationale for deprioritizing these strains was that they had a lower 
likelihood of producing novel compounds because their metabolite profiles were not 
unique among this relatively small strain library even though they were isolated from 
different locations. There were also several known compounds in the database that 
corresponded to the exact mass. The aim of this investigation was to identify metabolites 
with novel and unique structures, therefore these strains were deprioritized.  
To further prioritize strains by dereplicating against known natural products, the 
pseudomolecular ion for each metabolite was determined, and database searches using 
AntiBase 2007 and SciFinder Scholar were used to determine if the exact mass 
corresponded to any previously described natural products. Because of the accuracy of 
the high resolution MS data, metabolites could be identified as known compounds or 
putatively novel compounds with relatively high confidence. Many strains were 
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deprioritized based on the putative production of known natural products. Additional 
information like the producing organism, UV absorbance, MS/MS fragmentation, and 
NMR were also used to confirm the identity of these known compounds.   
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Table 2.2. Summary of hits from the LC-MS/PCA screen and antimicrobial screens 
showing the criteria for prioritizing and deprioritizing strains.  
Strain 
Higher Priority Lower Priority 
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RKKD-790        
RKKD-240        
RKKD-161        
RKKD-412        
RKKD-808        
RKKD-234        
RKKD-760        
RKKD-123        
RKKD-498        
RKKD-059        
RKKD-148        
RKKD-262        
RKKD-593        
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RKKD-374        
RKKD-090        
RKKD-051        
RKKD-272        
RKKD-469        
RKKD-779        
RKKD-074        
RKKD-555        
RKKD-260        
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2.3.3 Identification of metabolites from RKKD library 
RKKD-234 was selected because of its observed antimicrobial activity in both the 
antibacterial and antifungal assays, and the LC-MS/PCA chemical screening method. The 
LC-MS chromatogram showed that RKKD-234 produced a single metabolite in high 
abundance, and was labelled RKKD234_467 (Figure 2.5). The pseudomolecular ion was 
determined to be m/z 467.2088 [M+H]+ and upon searching in AntiBase, this query 
returned the natural product staurosporine with a mass difference of 2.14 ppm compared 
to the predicted mass (m/z 467.2078 [M+H]+ calc for C28H27N4O3
+). This value is within 
the accepted 5 ppm variance for HRMS. NMR spectra acquired with the crude extract 
were used to confirm that the structure of RKKD234_467 was the same as staurosporine 
(Appendix Figure 8.1). Staurosporine was the first member of the bis-indole family of 
alkaloid natural products to be described in the literature61,62. It was originally isolated 
from Streptomyces staurosporius, although it has been isolated from several different 
Streptomyces strains since its initial isolation62. It has a diverse array of reported 
biological activities, however the most extensively studied is inhibition of protein kinase, 
which results in broad cytotoxic activity63. The observed antibiotic and antifungal activity 
of RKKD234_467 corresponded to the bioactivity reported for staurosporine and further 
supported the identification of RKKD234_467 as staurosporine. 
RKKD-412 was also a strain that was identified as a hit using all three screening 
methods. The LC-MS data revealed the production of one major and one minor 
metabolite (Figure 2.6). Fractionation of the crude extract led to identification of a 
metabolite RKKD412_613 with m/z 613.2413 [M+H]+. Database queries of this exact 
mass showed that the structure of RKKD412_613 likely corresponded to the known 
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natural product, novobiocin. Novobiocin is one of the most commonly isolated natural 
products from many Streptomyces, and is an aminocoumarin natural product that has 
potent antimicrobial activity64,65. This metabolite was likely responsible for the 
antimicrobial activity that was observed for the crude extract from RKK-412. Novobiocin 
was first isolated from the strain Streptomyces niveus and has been referred to by several 
other names including streptonivicin, albamycin and cathomycin66. 
The third and final strain that had positive results in all three screening methods 
was RKKD-808. The most abundant metabolite produced had an exact mass of m/z 
765.4832 [M+H]+ (Figure 2.7). This strain produced several closely related metabolites 
that all differed by 14 mass units, which likely corresponded to the presence or absence 
of additional methylene groups. These metabolites were identified from their exact 
masses as members of the nactin family of cyclic polyether natural products67. This 
family of natural products is commonly produced by several Streptomyces strains and 
have been reported as antimicrobial and cytotoxic agents68. Due to the similarity in exact 
masses of several of these metabolites, similar observed bioactivity, and isolation source, 
the metabolites produced by RKKD-808 were tentatively determined to be members of 
the nactin family of natural products. This strain was not investigated further for its 
metabolite production.  
The strain RKKD-760 was prioritized based on results from the chemical profile 
screen. This strain produced two major metabolites with exact masses of m/z 825.4401 
[M+H]+ and 839.4579 [M+H]+ (Figure 2.8). Database searches of the pseudomolecular 
ion 825 matched the exact mass of arylomycin A2 and A3 within 0.9 ppm69. The 
aryolomycins are lipopeptide natural products that were isolated from Streptomyces sp. 
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Tu 6075. Due to the similarity in molecular weight and producing strains, RKD760_825 
was tentatively assigned as arylomycin. RKKD760_839 had a mass difference of 14 
compared to RKKD760_825, which corresponds to the mass of an additional methylene. 
Because of the similarity in retention time, UV spectrum and mass difference 
corresponding to an additional methylene compared to RKKD760_825, RKKD760_839 
was tentatively assigned as an arylomycin analog. This strain was not investigated any 
further for its natural product production. 
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Figure 2.5. A. Chromatograms of the crude extract from RKKD-234 grown in ISP2.  
Three detectors were used to generate 3 chromatograms for the same sample: PDA, 
ELSD and +ESI-MS. B. The high resolution mass spectrum of RKKD234_467. C. The 
molecular structure of staurosporine.  
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C 
A 
45 
 
 
Figure 2.6. A. Chromatograms of the crude extracts from RKKD-412 grown in ISP2.  
Three detectors were used to generate 3 chromatograms for the same sample: PDA, 
ELSD and +ESI-MS. B. The high resolution mass spectrum of RKKD412_613. C. The 
molecular structure of novobiocin.  
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Figure 2.7. A. Chromatograms of the crude extracts from RKKD-808 grown in ISP2.  
Three detectors were used to generate 3 chromatograms for the same sample: PDA, 
ELSD and +ESI-MS. B. The high resolution mass spectrum of RKKD808_751 C. The 
molecular structure of monactin D. The high resolution mass spectrum of 
RKKD808_765. E. The molecular structure of dinactin.  
  
B 
C 
A 
47 
 
 
 
 
 
 
 
 
 
Figure 2.7. Continued from previous page.  
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Figure 2.8. A. Chromatograms of the crude extracts from RKKD-760 grown in ISP2.  
Three detectors were used to generate 3 chromatograms for the same sample: PDA, 
ELSD and +ESI-MS. B. The high resolution mass spectrum of RKKD760_825 C. The 
molecular structure of the arylomycin A2.  
  
A 
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After deprioritizing the strains RKKD-234, RKKD-412, RKKD-808 and RKKD-
760 based on depreplication against known natural product databases, three strains 
remained for investigation. The strain RKKD-161 was initially prioritized because of its 
unique chemical profile. When a large scale fermentation extract of this strain was 
analyzed by LC-MS, the metabolite profile was different than what was observed for the 
initial small scale extract. Since the fermentation results were not reproducible, this strain 
was deprioritized. Efforts were focused on investigating other strains that produced 
putatively novel compounds and therefore this strain was not investigated any further for 
its natural product production. This example highlights the importance using replicate 
fermentations when analyzing the metabolite production of a library of bacterial strains. 
All subsequent small-scale fermentations that were used for LC-MS/PCA screening for 
the identification of novel metabolites were performed in triplicate.  
RKKD-240 was a strain that was prioritized because of its unique chemical 
profile and antibacterial activity against MRSA and VRE. This strain was fermented on a 
larger scale, and fractionated to identify the metabolites that were produced. This resulted 
in the isolation of the metabolite labelled RKKD240_401 which had an exact mass of m/z 
401.2678 [M+H]+. The MS fragmentation pattern of RKKD240_401 showed similarity to 
a minor metabolite present in a different fraction that was labelled RKKD240_563, which 
had an exact mass of m/z 563.3216 [M+H]+ (Figure 2.9). At the time of isolation, no 
known natural products in Antibase (2007) corresponded to this exact mass. Both MS 
spectra contained the fragment m/z 383.2580, which would correspond to the fragments 
[M-H2O+H]
+ and [M-C6H12O2+H]
+ for RKKD240_401 and RKKD240_563 respectively. 
This suggested that RKKD240_563 and RKKD240_401 had the same parent structure 
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differing in that RKKD240_563 was glycosylated and RKKD240_401 was hydroxylated. 
The NMR spectra of RKKD240_401 revealed that the structure was the same as the 
recently described actinopyranone natural product PM05046370 (Appendix, Figure 8.2). 
The glycosylated analog PM050511 had the same parent structure with the addition of D-
glucose, and matched the exact mass of RKKD240_563. These metabolites were isolated 
after 2007, and consequently were not present in the 2007 version of AntiBase. These 
natural products were isolated from Streptomyces albus POR-04-15-053, which like 
Streptomyces sp. RKKD-240 was also cultured from marine sediment. These metabolites 
were reported to have cytotoxic activity against breast (MDA-MB-231), colon (HT29) 
and non-small cell lung (A549) cancer cell lines. Other members of the actinopyranone 
family of natural products have been isolated from different strains of Streptomyces and 
are reported as antimicrobial and cytotoxic agents71,72.  
RKKD-790 was selected for further investigation of its metabolite production due 
to observed antibacterial activity against VRE, and its unique metabolome identified by 
LC-MS/PCA. RKKD-790 produced two distinct metabolites: RKKD790_1128 and 
RKKD790_1592 with exact masses of m/z 1128.6648 and 1592.8184 (Figure 2.10). 
Database searches revealed no previously identified natural products for 
RKKD790_1592. Fractionation of a large-scale extract from RKKD-790 revealed that 
RKKD790_1128 was responsible for the observed antibacterial activity. Closer 
investigation of the mass spectrum of purified RKKD790_1128 revealed that the base 
peak with an exact mass m/z 1128.6648 was the ammonium adduct and m/z 1111.6466 
was the proton adduct. The structure of RKKD790_1128 was determined to be 
valinomycin using tandem MS (Appendix, Figure 8.3) 73,74. Valinomycin is a cyclic 
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peptide that has reported antimicrobial activity, similar to that observed for 
RKKD790_1128 against VRE75. The putatively novel compound, RKKD790_1592 was 
also purified from the large-scale extracts of RKKD-790. Although fractions containing 
this metabolite were not active in the antibacterial assay, it was purified because of its 
putative structural novelty. The structure of RKKD790_1592 was solved using extensive 
1D and 2D analysis and was determined to be a lasso peptide that was a novel metabolite 
at the time of isolation. The full characterization of this new natural product is discussed 
in Chapter 3. 
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Figure 2.9. A. Chromatograms of the crude extracts from RKKD-240 grown in ISP2.  
Three detectors were used to generate 3 chromatograms for the same sample: PDA, 
ELSD and +ESI-MS. The fourth chromatogram shows SIM of the minor metabolites 
RKKD240_401 and RKKD240_563. B. The high resolution mass spectrum of 
RKKD240_401 C. The molecular structure of the actinopyranone natural product, 
PM05046. D. The high resolution mass spectrum of RKKD240_563. E. The molecular 
structure of PM050511.  
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Figure 2.8. Continued from previous page.  
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Figure 2.10. A. Chromatograms of the crude extracts from RKKD-790 grown in ISP2.  
Three detectors were used to generate 3 chromatograms for the same sample: PDA, 
ELSD and +ESI-MS. B. The high resolution mass spectrum of RKKD790_1128 C. The 
molecular structure of valinomycin.   
C 
A 
B 
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2.3.4 Multivariate analysis of small scale fermentations: Kitasatospora library 
Twelve strains of Kitasatospora were investigated for their metabolite production 
using the LCMS/PCA based chemical profile screen. All twelve strains were fermented 
in triplicate, extracted and analyzed by LC-HRMS. To ensure continuity, methanol 
blanks were used at the beginning, end and internally for each LC-HRMS sequence, and 
a retention time standard sample containing reserpine was injected at the beginning of 
each sequence. Raw LC-MS profiles were grouped and processed and then visualized 
using principal component analysis. A threshold of 1E4 was used during peak detection 
in order to ensure that only metabolites and not artifacts were detected and contributed to 
prioritization of strains for the isolation of metabolites. A total of 642 distinct mass 
features were detected after data processing with MZmine 2. Of those features, 190 were 
detected in MeOH blanks, media blanks, or internal reserpine blanks and were removed 
from the features list. Peak intensities were normalized to a value of one for all detected 
features to remove intensity bias associated with highly abundant metabolites. Principle 
component analysis was then used to visualize the processed data matrixes using The 
Unscrambler. Results from fermentations in ISP2 medium and lean production medium 
(1045) were visualized using separate principal component analyses. Scores plots of PC1 
vs. PC2 to PC3 vs. PC4 were used to analyze the metabolomes of isolates from the 
Kitasatospora library, which are shown in Figures 2.11 and 2.12. 
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Figure 2.11. Principal component analysis scores plots of Kitasatospora library grown in 
1045 medium. 
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Figure 2.12. Principal component cnalysis ccores clots of PC1 vs PC2 of Kitasatospora 
library grown in ISP2 Medium. 
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Based on the scores plots, four strains were identified as producers of unique 
metabolites and selected as hits from the LC-MS/PCA screen. The following hits were 
identified: Kitasatospora cystarginea NRRL B-16505 in 1045 and ISP2 from PC1 vs. 
PC2; K. kifunensis NRRL B-24284, K. griseola NRRL B-16229 and K. griseola MF730-
N6 BP-1045 in 1045 from PC3 vs. PC4. These strains were considered hits since they 
clustered away from all of the other strains in the corresponding scores plots, and all three 
replicate fermentations clustered together indicating consistent production of metabolites 
in replicate fermentations. No other scores plots for analyses of either fermentation 
medium showed strains that produced unique and consistent chemical profiles, as 
visualized using PCA. The strain K. griseola MF730-N6 BP-1045 was deprioritized 
because at the time it was under investigation by another member of the Kerr lab. Upon 
further investigation, the novel natural product satosporin was identified by Jennifer C. 
Arens from this strain76.  
2.3.5 Identification of metabolites: Kitasatospora library 
 The three remaining strains from the Kitasatospora library that were identified as 
hits from the LC-MS/PCA chemical screening method were fermented in larger volumes. 
K. cystarginea NRRL B-16505 was selected because of its unique metabolite profile 
when fermented in both ISP2 and lean production medium 1045. Metabolites were 
produced at a higher abundance when fermented in 1045 medium, therefore 1045 
medium was used for all subsequent fermentation scale ups. The initial small scale 
fermentation resulted in the production of three major metabolites: 16505_357, 
16505_371 and 16505_954. These metabolites did not correspond to any known 
compounds and were subsequently identified as novel natural products. The full 
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characterization of these compounds are discussed in Chapters 4 and 5. Several large-
scale fermentations of this strain were performed, which resulted in extensive analysis of 
the metabolite production (Figure 2.13). In addition to the novel metabolites that were 
identified, this strain also produced several known compounds. The metabolite with an 
exact mass of m/z 211.0868 [M+H]+ corresponded to the known compound 1-acetyl-β-
carboline within 0.95 ppm of the predicted mass77. The identity of this metabolite was 
confirmed using NMR (Appendix, Figure 8.4). A minor metabolite that was detected in 
fractions of subsequent large-scale fermentations of this strain had an exact mass of m/z 
490.2848 [M+H]+. Database searches revealed that this exact mass was the same at the 
known compound migrastatin within 1.8 ppm78. NMR spectra of fractions containing this 
metabolite confirmed that the structure was the same as migrastatin (Appendix, Figure 
8.5). Lastly, several members of the fattiviracin family of natural products were produced 
by K. cystarginea B-16505. Fattiviracin FV-10 and FV-13 as well as a fattiviracin analog 
with an exact mass of m/z 1529.9984 [M+H]+ were identified using HRMS and MS/MS 
and NMR (Appendix, Figure 8.8)79.  
 The strain K. kifunensis NRRL B-24284 was identified as a hit from the LC-
MS/PCA chemical screening method. Analysis of the small scale fermentation extract 
using LC-MS revealed that this strain produced a very complex mixture of metabolites 
making it difficult to dereplicate using databases (Figure 2.14). After fractionation of the 
crude extract, one fraction primarily contained a single metabolite with an exact mass of 
m/z 720.2941[M+H]+. This exact mass corresponded to naphthomycin when queried in 
AntiBase within 0.3 ppm. The UV absorbance, and NMR spectra were used to confirm 
that the structure was naphthomycin (Appendix, Figure 8.7)80. 
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 K. griseola NRRL B-16229 was investigated for the production of novel 
metabolites. When fermented on a small scale, one major and one minor metabolite were 
produced. The exact masses of these metabolites did not correspond to any known natural 
products and therefore this strain was prioritized. The exact masses of these putatively 
novel metabolites were m/z 542.3230 [M+H]+ and m/z 556.3386 [M+H]+. All subsequent 
fermentations of this strain produced either none or a very low abundance of these two 
metabolites and the identities of these compounds were not determined.  
 K. mediocidica NRRL B16109 was not identified as a hit from the LC-MS/PCA 
screen however based on the raw LC-MS profile of the crude extract it produced a 
relatively simple mixture of metabolites when fermented in ISP2. The most abundant 
metabolite had an exact mass of m/z 686.4716 [H+H]+ (Figure 2.15). This exact mass 
corresponded to the hexapeptide, pepstatin A within 1.7 ppm compared to the predicted 
mass81. NMR was used to confirm that the identity of 16109_686 was pepstatin A. 
Pepstatin A is a commonly produced metabolite that has been isolated from several 
different actinomycetes81 (Appendix, Figure 8.8). 
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Figure 2.13. A. Chromatograms of the crude extracts from K. cystarginea NRRL B-
16505 grown in 1045.  
Three detectors were used to generate 3 chromatograms for the same sample: PDA, 
ELSD and +ESI-MS. The fourth, fifth and sixth chromatograms show SIM of the minor 
metabolites 16505_211, 16505_490 and 16505_1501 respectively. B. The high resolution 
mass spectrum of 16505_211. C. The molecular structure of 1-acetyl-β-carboline. D. The 
high resolution mass spectrum of 16505_490. E. The molecular structure of migrastatin. 
F. The high resolution mass spectrum of 16505_1501. G. The molecular structure of 
fattiviracin FV13.   
C 
A 
B 
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Figure 2.13. Continued from previous page.   
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Figure 2.14. A. Chromatograms of the crude extracts from K. kifunensis NRRL B-24284 
grown in 1045.  
Three detectors were used to generate 3 chromatograms for the same sample: PDA, 
ELSD and +ESI-MS. B. The high resolution mass spectrum of 24284_720. C. The 
molecular structure of naphthomycin A.   
C 
A 
B 
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Figure 2.15. A. Chromatograms of the crude extracts from K. mediocidica NRRL B-
16109 grown in ISP2.  
Three detectors were used to generate 3 chromatograms for the same sample: PDA, 
ELSD and +ESI-MS. B. The high resolution mass spectrum of 16109_686. C. The 
molecular structure of pepstatin A.   
A 
B 
C 
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2.3.6 Comparison of screening methods 
 The approach used for this natural product discovery program involved the 
combination of antimicrobial assays and LC-MS/PCA based chemical screening for the 
rapid identification of novel, bioactive natural products. When used alone for the 
identification of bioactive metabolites from Streptomyces, bioassay driven strain 
prioritization often returns primarily known natural products that have already been 
investigated35. The results observed in this study for the RKKD library followed this 
same trend. Six Streptomyces strains were selected and five were investigated further for 
production of bioactive natural products. Known compounds were identified from all of 
these strains. The strain RKKD-790 highlights the efficiency of LC-MS/PCA to identify 
putatively new compounds and known compounds. When bioactivity was used to isolate 
active metabolites from this strain, a known compound was identified (valinomycin). 
However, RKKD-790 also produced a novel lasso peptide that was not active in the 
bioassays and was instead identified as putatively novel from the LC-MS/PCA screen. If 
bioactivity alone was used, the known antimicrobial compound valinomycin would have 
been the only metabolite identified from this strain, and the new lasso peptide would have 
been missed. This highlights the importance of using a chemical screening approach, or a 
combination of screening methods in order to identify new metabolites. 
 The usefulness of LC-MS/PCA not only allows for identification of metabolites 
that are not active in specific bioassays, but it also allows for much more rapid 
identification of known compounds, and therefore efficient strain selection for 
fermentation scale ups. The strain RKKD-760 was prioritized because of its unique 
metabolite profile that was identified by LC-MS/PCA. The metabolites produced by this 
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strain were very efficiently identified as members of the arylomycin family of natural 
products from a single small scale fermentation. No additional fermentations of this strain 
were required to characterize these metabolites, which highlights how using LC-MS/PCA 
streamlines the process of novel metabolite discovery. This method allows for more 
efficient and informed strain selection for downstream characterization which are often 
very time consuming.  
Based on the results from the RKKD library, it was observed that the LC-
MS/PCA screening approach was efficient at identifying putative identities of natural 
products and was a useful method to prioritize and select strains for larger scale 
investigations. In contrast, bioactivity screening alone did not result in the identification 
of any novel natural products from this bacterial library. Based on these results, the 
Kitasatospora library was screened using LC-MS/PCA alone.   
The effectiveness of LC-MS/PCA at identifying stains with unique metabolomes 
is also highlighted for the strain K. cystarginea NRRL B-16505. The chemical screening 
approach showed that this strain had a significantly different chemical profile than the 
rest of the Kitasatospora strains that were analyzed. Upon further investigation, it was 
identified that this strain produced a novel lipopeptide and two novel β-lactone containing 
natural products. After characterization these novel natural products they were evaluated 
for antimicrobial activity. None of these novel compounds possessed antimicrobial 
activity against the pathogens showing that if bioassay-based prioritization using 
antimicrobial assays was used to screen the Kitasatospora library, then this strain would 
have been overlooked and these novel compounds would not have been discovered. A 
chemical screening approach like LC-MS/PCA, a high-content bioassay or a combination 
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of both are the most efficient and effective way to analyze natural product libraries for 
drug discovery programs in the 21st century20.  
2.4 CONCLUSIONS 
 Two libraries of actinomycetes were investigated for the production of novel 
natural products using an LC-MS/PCA metabolomics screening approach. This method 
was utilized to efficiently prioritize strains for downstream characterization based on the 
production of unique metabolites among a library of similar bacterial isolates. A library 
consisting primarily of Streptomyces spp. was selected based on a number of criteria to 
investigate for novel natural products. Members of the RKKD library were cultured from 
temperate marine sediment in Newfoundland and New Brunswick, Canada47,48. The areas 
where these isolates were collected represent unique biological niches, which correlates 
to unique biological diversity of the microbiome47,48. Members of this library represented 
an opportunity to investigate for novel metabolites since greater biological diversity 
directly correlates to greater chemical diversity15. Investigation of this library resulted in 
identification of a novel lasso peptide at the time of isolation, using only a single culture 
medium. Given the use of a single culture medium, and the extensive investigation of 
Streptomcyes spp. for natural product production in the literature, identification of this 
novel lasso peptide from this Streptomyces library was an exciting discovery. This 
highlights the effectiveness of the LC-MS/PCA screening approach to identify the 
production of novel metabolites among libraries that produce several known compounds, 
and is useful for dereplication of such libraries.  
A library consisting of Kitasatospora spp. was also investigated for the 
production of novel natural products using LC-MS/PCA. . Genome sequencing has 
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revealed that Kitasatospora possess a similar number of biosynthetic gene clusters as 
their close relative Streptomyces. However, this genus has not been investigated to the 
great extent that Streptomyces has for drug discovery programs, making them a useful 
resource for discovering novel metabolites. Two novel compounds were identified from 
this small library, which shows that members of the genus Kitasatospora represent a 
unique, and underexplored resource for the discovery of novel metabolites.  
  LC-MS/PCA was used to screen both bacterial libraries, and antimicrobial assays 
was used for one of the libraries to prioritize strains and isolate bioactive metabolites. In 
contrast to bioassay screening, which only lead to the isolation of known natural 
products, LC-MS/PCA helped to highlight the production of several novel metabolites. A 
new lasso peptide was identified from the fermentation extracts of Streptomyces sp. 
RKKD-790, and a novel lipopeptide and two β-lactone containing peptides were isolated 
from K. cystarginea NRRL B-16505.  
 Using LC-MS/PCA to analyze and visualize the variance in metabolite profiles is 
a very useful tool to rapidly dereplicate bacterial libraries and prioritize strains for 
additional investigation21. The time consuming process of scaling up fermentations, 
purification of metabolites, and structural characterization by analysis of spectroscopic 
data makes selection of strains an essential step for natural product programs22. LC-
MS/PCA allows for the identification of unique metabolomes and dereplication against 
known natural products through the use of high resolution mass spectrometric analysis 
and comprehensive natural product databases21,22. Using LC-MS/PCA to screen microbial 
libraries for the production of unique metabolites greatly improves the efficiency of 
natural product discovery programs.   
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CHAPTER 3: ISOLATION AND 
CHARACTERIZATION OF A TYPE II 
LASSO PEPTIDE PRODUCED BY 
STREPTOMYCES SP. RKKD-790 
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3.1 INTRODUCTION 
The identification of new natural products has long been used for the development 
of pharmaceutical agents. In the 21st Century, a new major class of natural products has 
been identified and named ribosomally-synthesized and post-translationally modified 
peptides (RiPPs)82,83. As the name suggests, RiPPs are peptide natural products that, 
unlike other peptides that are synthesized by non-ribosomal peptide synthetase enzymes, 
are synthesized directly through translation by the ribosome. They are then modified to 
varying degrees by tailoring enzymes to generate the final natural product structure. 
RiPPS have become a very large and structurally diverse class of natural products that 
has rapidly grown due to advances in genome sequencing efforts. Several members of 
this natural product class have very potent biological activities, with the most commonly 
observed application being antibacterial activity.  
Lasso peptides are a group of RiPP natural products characterized by their unique 
knotted structure84. The lasso fold is formed by threading of the C-terminal linear tail 
through a macrolactam ring formed between the amine group of either glycine, alanine, 
serine or cysteine residue at position 1, and the side chain carboxylic acid group of either 
glutamic acid or aspartic acid at position 7, 8 or 985. There are three classes of lasso 
peptides that are characterized by the presence of disulfide bridges between cysteine 
residues in which class I contains two86,87,88, class II contains zero 89,90,91,92,93, and class III 
contains one94,95 intramolecular disulfide bridge as shown in Figure 3.1. The disulfide 
bridges assist in stabilizing the threaded structures of class I and III, while class II are 
stabilized by bulky side chains in the loop region directly above the ring, and the tail 
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region below the ring that prevent unthreading84,85. Synthetic approaches to obtain the 
knotted structure of lasso peptides have been unsuccessful to date96. 
Lasso peptides have been found to have a wide variety of biological activities84,85. 
Many act as receptor antagonists as well as possess antimicrobial properties against 
bacteria closely related to their producing bacterium. Peptides generally have high 
specificity for their molecular targets and low toxicity; however their use as clinical 
agents is limited due to poor pharmacokinetic properties97, 98. Since the threaded 
structures of the lasso peptides cause them to be extremely stable to heat, chemical and 
proteolytic degradation, they may be useful for overcoming the rapid degradation 
observed by less stable peptides99. The lasso peptide microcin J25 (MccJ25) has been 
shown to assist in overcoming these limitations by acting as an effective molecular 
scaffold. Integrin proteins have been shown to play a role in angiogenesis and tumor 
growth. Integrins interact with a specific peptide sequence Arg-Gly-Asp (RGD), named 
the integrin binding motif. The RGD integrin binding motif was grafted onto the loop 
region of MccJ25, which resulted in a highly stable and nontoxic peptide with high 
binding affinity towards αvβ3 integrin99. This is an excellent example of the usefulness of 
this unique class of natural products as pharmaceutical agents.  
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Figure 3.1 General conformations of the three classes of lasso peptide natural products84.  
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By utilizing a metabolomics screening approach involving principal component 
analysis (PCA) described in Chapter 2, the fermentation extract of Streptomyces sp. 
RKKD-790 was identified as unique based on the metabolite profile. Streptomyces sp. 
RKKD-790 produced the secondary metabolite referred to as KG790_1592, which was 
responsible for the unique profile. Herein the isolation, structure elucidation, 3D 
molecular modeling and biological activity assessment of KG790_1592 is reported. 
3.2 MATERIALS AND METHODS 
3.2.1 Fermentation, extraction and purification of KG790_1592 
Streptomyces sp. RKKD-790 was cultured from marine sediment collected from 
Bonne Bay, Newfoundland, Canada48. Streptomyces sp. RKKD-790 was streaked onto an 
ISP349 agar plate and grown at 30 ºC for 5 days. A single colony was used to inoculate 50 
mL x 3 of ISP249 broth in 250 mL flasks and cultivated at 30ºC with shaking at 200 rpm 
for 3 days. In 2.8 L fernbach flasks, 4 L of fresh ISP2 broth (1 L x 4) was inoculated with 
250 mL of the seed culture and cultivated at 30ºC with shaking at 200 rpm for 7 days. 
Fermentation broth was extracted by partitioning with 4 L of ethyl acetate and dried by 
evaporating under reduced pressure. The extract was dissolved in 500 mL of 8:2 
acetonitrile:diH2O and partitioned with 500 mL of hexanes. 
The aqueous acetonitrile fraction was separated by reverse phase flash 
chromatography using a CombiFlash Rf (Teledyne ISCO) with a 15.5 g C18 column 
(High Performance GOLD, RediSep Rf), and was eluted with diH2O (solvent A1) and 
MeOH (solvent B1). A linear gradient was used, increasing from 10 % to 100 % solvent 
B1 over 13 minutes followed by a 5 minute wash with 100 % solvent B1. A flow rate of 
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30 mL/min was used and eluent was detected by UV (214 nm). The desired metabolite, 
KG790_1592 eluted at 12.5 minutes. 
KG790_1592 was purified using a Thermo HPLC system with a semi-preparative 
Gemini 110 Å C18 5µm 250x10.00 mm column (Phenomenex) using diH2O/0.1 % formic 
acid (solvent A2) and MeOH/0.1 % formic acid (solvent B2). KG790_1592 was eluted 
with a linear gradient increasing from 50 % to 80 % solvent B2 over 17 minutes, 
followed by a 100 % solvent B2 wash for 14 minutes. KG790_1592 eluted at 14.9 
minutes and was detected by ELSD and UV at 220 nm and 280 nm.  
LC-MS was used to monitor fractions for the presence of KG790_1592 by 
detecting m/z 1592.8079 using the standard Kerr lab “Chemical Screening” LC-MS 
method. This method uses a Thermo Q Exactive HPLC system with an analytical Core 
Shell 100 Å C18 1.7 µm 50 x 2.1 mm column (Kinetex) with diH2O/0.1 % formic acid 
(solvent A3) and acetonitrile/0.1 % formic acid (solvent B3). A linear solvent gradient 
from 5 to 100 % solvent B3 over 4.8 minutes followed by a 3.2 minute wash with solvent 
B3 was used with a flow rate of 500 µL/min. Eluent was detected by ESI-MS monitoring 
m/z 190-2000 in positive mode, ELSD, and PDA 200-600 nm. 
Additional 5 L and 6 L fermentations of RKKD-790 were also cultivated, 
extracted and purified using the same methods described above in order to obtain enough 
pure KG790_1592 to perform full characterization and evaluation of biological activity. 
3.2.2 Structure elucidation of KG790_1592 
NMR spectra were obtained on a 600 MHz Bruker Avance III spectrometer 
equipped with a 1.7 mm inverse probe. For structure assignments, 1H, COSY, TOCSY, 
75 
 
ROESY, HSQC, HMBC and NOESY experiments were performed, and analyzed using 
Bruker TOPSPIN 2.1. Chemical shifts (δ) are reported in ppm and were referenced to the 
DMSO-d6 residual peaks at δH 2.50 ppm and δC 39.51 ppm and coupling constants (J) are 
reported in Hz. NOE cross-peak volumes were integrated manually using Bruker 
TOPSPIN 2.1 to obtain distance constraints. 
High-resolution mass spectra were measured on a Thermo LTQ Orbitrap Velos 
mass spectrometer. Tandem MS spectra were acquired by direct infusion of KG790_1592 
at a rate of 2 µL/min using an ESI source and fragmented by higher energy collisional 
dissociation (HCD) at 29 eV. 
KG790_1592: White powder; 1H and 13C NMR see Table 3.1; (+) HRESIMS m/z 
1592.8077 [M+H]+ (calculated for C77H110N17O20, 1592.8113, Δppm -2.16).  
3.2.3 Stereochemical analysis by Marfey’s Method. 
Amino acid absolute configurations were determined by Marfey’s Analysis of 
hydrolyzed KG790_1592100. 10µL of KG790_1592 (10 mg/mL in MeOH) was reacted 
with 200 µL of 6M HCl and heated to 120ºC for 24 hours.  The reaction mixture was 
cooled and neutralized to pH 7 using 1N NaHCO3. To the reaction vial, 10 µL of 1-
fluoro-2,4-dinitrophenyl-L-alanine (L-FDAA) (10 mg/mL in acetone) was added 
followed by 50 µL of acetone and 100 µL of NaHCO3. The reaction was heated to 80 ºC 
for 30 minutes before quenching with 500 µL of 1M HCl. The reaction mixture was 
analyzed by LC-MS and compared to authentic derivatized amino acid standards. 
Derivatized amino acids were analyzed by LC-MS using an LTQ Orbitrap Velos 
(ThermoScientific) HPLC system with Hypersil Gold 100Å 1.9µm C18 50 x 2.1mm 
column (Thermo). A linear gradient from 95 % water/0.1 % formic acid (solvent A3) and 
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5 % acetonitrile/0.1 % formic acid (solvent B3) to 40 % solvent B3 over 55 minutes 
followed by a rapid increase to 100 % solvent B3 for 3 minutes was used with a flow rate 
of 400 µL/min. Eluent was detected by +ESI-MS monitoring m/z 120-800 and UV 200-
600 nm. Racemization of tryptophan occurred under high reaction temperatures so 
reactions were repeated using milder conditions. 100 µg of KG790_1592 was reacted 
with 6M HCl at 80 ºC for 6 hours, followed by neutralization with 1N NaHCO3. 10µL of 
L-FDAA (10 mg/mL in acetone) was added to the reaction vial followed by 50 µL of 
acetone and 100 µL of NaHCO3 and heated to 40 ºC for 2 hours.  The reaction was 
quenched with 500 µL of 1M HCl, and analyzed by LC-MS using the conditions 
described above. 
3.2.4 3D Molecular modelling 
To further elucidate the structural details of KG790_1592, the three-dimensional 
structure was modelled computationally. Six candidate structures were built and 
optimized using the Merck Molecular Force Field (MMFF) in the Spartan package 
(Spartan ’08; Wavefunction, Inc). Experimental inter-hydrogen distances were calculated 
by integrating NOE cross-peak volumes manually using Bruker TOPSPIN 2.1. 
Experimentally determined inter-atomic distance constraints were then gradually 
implemented followed by refining and reoptimizing the resulting structures in a step-wise 
manner starting with the loop region, then the chain region, and finally H-H distances 
between the loop and chain region. 
Once all experimental constraints were applied and the six candidate structures 
were built, all experimental constraints were relaxed and the structures were reoptimized 
using the more robust PM3 semi empirical method101,102. This resulted in a predicted 
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minimum energy geometry for each of the six candidate geometries. The experimental H-
H distances could then be compared to the predicted structures for each geometry.  
3.2.5 Stability assays 
The stability of KG790_1592 was evaluated in the presence of purified 
carboxypeptidase Y. Carboxypeptidase Y (0.1 mg of , 95 U/mg, Sigma) was dissolved in 
250 µL of 20 mM TRIS buffer (pH = 8.0). To the solution, 5 µL of KG790_1592 (10 
mg/mL in DMSO) was added and incubated at 37 ºC. Aliquots of 50 µL were removed at 
the following intervals: T = 0h, 1h, 2h, and 3h. Once removed, the aliquots were diluted 
with 200 µL of 20 mM TRIS and incubated at 65 ºC for five minutes to inactivate the 
enzyme. The resulting solutions was analyzed by LC-MS using a Thermo Q Exactive 
HPLC system for the presence of intact KG790_1592 using the chemical screening 
conditions described above. The portion of intact RKKD790_1592 was calculated by 
comparing the peak area detected by +ESI-MS to the peak area at T=0 h.  
The physiological stability of KG790_1592 was also evaluated in the presence of 
human serum. 50 µL of KG790_1592 (10 mg/mL in DMSO) was added to 500 µL of 
human serum type AB male (Sigma) and incubated at 37 ºC. 50 µL aliquots were 
removed at the following time (T) intervals: T= 0h, 1h, 2h, 3h, 7h, 12h, 24h, and 48h. At 
the time of removal, 200 µL of cold MeOH was added to precipitate large proteins and 
stop degradation. Reactions were centrifuged at 10,000 rpm for 15 minutes at 4 ºC, and 
supernatant was analyzed by LC-MS using a Thermo Q Exactive HPLC system for the 
presence of intact KG790_1592 using the chemical screening method described above. 
The percentage of intact RKKD790_1592 was calculated by comparing the peak area 
detected by +ESI-MS to the peak area at T=0 h. 
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3.2.6 Biological activity assays 
Purified KG790_1592 was tested for antimicrobial activity against a panel of 
human microbial pathogens consisting of methicillin-resistant Staphyloccocus aureus 
ATCC 33591 (MRSA), vancomycin resistant Enterococcus faecium EF379 (VRE), 
Staphylococcus warneri ATCC 17917, Pseudomonas aeruginosa ATCC 14210, Proteus 
vulgaris ATCC 12454 and Candida albicans ATCC 14035. All assays were carried out 
according to Clinical Laboratory Standards Institute testing standards in a 96-well plate 
and in triplicate53. Control antibiotics used were vancomycin for MRSA and S. warneri, 
rifampicin for VRE, or nystatin for C. albicans. Cell growth was determined by 
measuring the optical density at 600 nm at time zero and after incubation for 22 hours at 
37ºC using a Thermo Scientific Varioskan Flash plate reader. The change in OD600 after 
incubation was compared to untreated negative control wells and plotted as percent 
growth inhibition. KG790_1592 was dissolved in sterile 20 % DMSO and assayed at a 
final concentration of 50µg/mL.  
KG790_1592 was also tested for antibiotic activity against Arcanobacterium 
pyogenes (AVC 3), Corynebacterium pseudotuberculosis (AVC 15), Dermatophilus 
congolensis (AVC 17), Micrococcus luteus (AVC 35), Rhodococcus equi (AVC 57) and 
Mycobacterium smegmatis in a disk diffusion assay. Assay conditions were performed in 
accordance with Kirby-Bauer disk diffusion susceptibility test protocol103. KG790_1592 
was evaluated at a concentration of 10 µg/disk in MeOH. Penicillin G (2 µg), 
vancomycin (5 µg), rifampicin (2 µg) and gentimicin (10 µg) were used as positive 
controls and MeOH was used as a negative control. Zones of inhibition were measured 
with calipers after 24 h of growth.  
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KG790_1592 was evaluated for cytotoxicity against human breast 
adenocarcinoma cells (ATCC HTB-26) and human foreskin BJ fibroblast cells (ATCC 
CRL-2522). Breast adenocarcinoma cells were grown in Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture F-12 Ham containing fetal bovine serum (10%), penicillin 
(100 µU/mL) and streptomycin (0.1 mg/mL) with 5% CO2 at 37ºC. Human foreskin BJ 
fibroblast cells were cultured in Eagle’s minimal essential medium containing fetal 
bovine serum (10%), penicillin (100 µU/mL) and streptomycin (0.1 mg/mL) with 5% 
CO2 at 37ºC. Both cells lines were grown to 80 % confluency and diluted with their 
respective growth medium without antibiotics. To a microwell plate, 90 µL of BJ 
fibroblast cells were added at a concentration of 1 x 104 cells/well and 90 µL of HTB-26 
at a concentration of 5 x 103 cells/well and incubated with 5 % CO2 at 37ºC for 24 hours. 
After 24 hours cells were treated with 10 µL of KG790_1592 at final concentrations 
ranging from 1 µg/mL to 128 µg/mL in sterile DMSO. Blank wells containing only 
growth medium and DMSO were used as positive controls, untreated wells containing 
growth medium, DMSO and cells were used as negative controls, and wells treated with 
either doxorubicin (HTB-26) or zinc pyrithione (fibroblast BJ) were used as positive 
treated controls. All samples were repeated in triplicate. Microwell plates were incubated 
with 5 % CO2 at 37ºC for 72 hours (HTB-26) or 24 hours (fibroblast BJ). After 
incubation, alamarBlue® was added at a final concentration of 10 % v/v. Fluorescence 
was measured at 560 excitation and 590 nm emission at time zero, and four hours after 
addition of alamar blue using a Thermo Scientific Varioskan Flash plate reader. The 
change in fluorescence was used to calculate the percent viability of each treatment 
compared to negative control wells. The concentration required to reduce the cell growth 
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by 50 % (GI50), were calculated by Prism 6.0 (GraphPad Software) using a nonlinear 
regression dose-response, variable slope model based on triplicate measurements ± 
standard deviation. 
3.3 RESULTS AND DISCUSSION 
3.3.1 Identification of Streptomyces sp. RKKD-790 
The 16S rRNA gene sequence was used to identify the producing bacterium 
encoded RKKD-790. A nucleotide BLAST of the 16S gene sequence (1549 bp) showed 
similarity to 54 Streptomyces strains with less than 2 base pair differences. Due to the 
similarity of 16S rRNA sequences of the genus Streptomyces, this technique is only 
capable of identification at the genus level, and not robust enough to differentiate species 
within the genus Streptomyces104. The bacterial strain responsible for production of 
KG790_1592 was therefore classified as Streptomyces sp. RKKD-790. 
3.3.2 Large-scale fermentation, extraction and purification of KG790_1592 
Through the use of principal component analysis, Streptomyces sp. RKKD-790 
was found to have a unique chemical profile among the subset of the RKKD bacterial 
library that was analyzed. Database searches of the compound with a pseudomolecular 
ion, [M+H]+ m/z= 1592.8077 returned no previously discovered natural products. This 
lead to the selection of Streptomyces sp. RKKD-790 for fermentation scale up. A larger 
scaled fermentation was undertaken, culture broths were extracted with ethyl acetate, and 
the resulting organic extract was fractionated by reverse phase liquid chromatography 
and further purified using RP-HPLC to yield 3.5 mg of pure KG790_1592. 
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3.3.3 Structure elucidation and absolute configuration of KG790_1592 
The molecular formula of the protonated adduct was calculated to be 
C77H110N17O20
+ from the exact mass m/z 1592.8077 [M+H]+ and 1D and 2D NMR were 
used for complete structure elucidation (Appendix, Figures 8.9-8.17). All chemical shifts, 
and key 2D NMR correlations used for structure elucidation are listed in Table 3.1. 
COSY and TOCSY spectra were used in combination for assignment of amino acid side 
chain proton signals, and the HSQC spectrum was used for assigning carbon signals with 
the exception of quaternary carbons. The ROESY spectrum was used for sequence 
determination based on correlations observed between amide protons and α-protons of 
adjacent amino acids. Pro-6 contains a tertiary amide and therefore lacks an amide 
proton. Pro-6 instead was assigned based on the HMBC correlation between Ile-7 NH 
and Pro-6 αCH, the ROESY correlation between Ile-7 NH and Pro-6 βCH2’, and between 
Pro-6 δCH2, δCH2’ and Lys-5 αCH. Ile-7 lacked TOCSY correlations between NH and 
βCH, γCH3, γCH2 and δCH3 and therefore signals were assigned using COSY and 
HMBC correlations between adjacent protons. TOCSY patterns were used to discern 
signals in regions of the spectra with overlapping signals. The two proton signals with 
chemical shifts of 4.53 ppm were determined to be two distinct signals based on the two 
different carbon signals found in the HSQC spectrum. They were assigned to Ile-7 αCH 
and Ser-13 αCH based on the TOCSY correlations to Ser-13 βCH2 and βCH2’ at 3.66 and 
3.36 ppm as well as the TOCSY correlations to Ile-7 NH. The overlapping signals in the 
aliphatic region of the 1H spectrum (0.43-1.11 ppm) were assigned using TOCSY 
patterns from NH or αCH signals which usually appeared in less crowded regions of the 
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spectra. Strong NOEs between Gly-1 NH and Asp-8 βCH2 signals revealed the internal 
macrolactam ring structure. The planar structure of KG790_1592 is shown in Figure 3.2. 
The amino acid sequence and lasso structure were confirmed based on MS/MS 
fragmentation patterns (Appendix, 8.10). The expected oxonium (b) and ammonium (y) 
cations that form through cleavage of peptide bonds were observed in the MS/MS 
spectrum, and are summarized in Table 3.2105. The unique b+y ion complexes that are 
commonly observed for lasso peptides, occur when the loop region of the linear tail 
fragments, but the tail remains threaded through the ring resulting in both distinct 
fragments contributing to the detected mass despite no longer being covalently attached. 
This pattern is characteristic of the threaded structure of lasso peptides and is observed in 
microcin J25 and capistruin92. 
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Figure 3.2. Molecular structure of RKKD790_1592.  
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Table 3.1. 1H (600 MHz) and 13C (150 MHz) and key 2D NMR data for RKKD790_1592 
in DMSO-d6. 
Amino 
Acid 
Position 
δ1H 
ppm 
δ13C 
ppm 
COSY ROESY HMBC 
Gly1 
NH 7.70     
αCH2 4.03 43.04 G1-NH F2-NH  
αCH2' 3.05 43.04 G1-NH, αCH2 F2-NH  
Phe2 
NH 8.59     
αCH 3.89 56.35 F2-NH G3-NH  
βCH2 3.40 33.44 F2-αCH   
βCH2' 3.33 33.44 F2-αCH   
Ar: 
H2,6 
7.18 127.7 F2-Ar:H3,5   
Ar:H3,5 7.30 128    
Ar:H4 7.19 125.9 F2-Ar:H3,5   
Gly3 
NH 7.87     
αCH2 4.29 43.29 G3-NH S4-NH  
αCH2' 3.22 43.29 G3-αCH2 S4-NH  
Ser4 
NH 7.43     
αCH 4.43 55.49 S4-NH K5-NH  
βCH2 3.51 62.63 S4-OH, αCH, βCH2'   
βCH2' 3.71 62.63 S4-OH, αCH   
OH 4.89     
Lys5 
NH 8.88     
αCH 4.80 49.68 K5-NH P6-δCH2, 
δCH2' 
 
βCH2 1.54 31.23 K5-αCH, βCH2'   
βCH2' 1.68 31.23 K5-αCH   
γCH2 1.22 19.79 K5-βCH2, βCH2', δCH2   
γCH2' 1.38 19.79 K5-βCH2, βCH2', δCH2   
δCH2 1.30 25.82 K5-εCH2, εCH2', δCH2'   
δCH2' 1.48 25.82 K5-εCH2, εCH2'   
εCH2 2.53 37.51 K5-δCH2'   
εCH2' 2.67 37.51 K5-δCH2'   
Pro6 
αCH 4.30 56.72  I7-αCH I7-NH 
βCH2 2.02 29.03 P6-αCH   
βCH2' 1.92 29.03 P6-αCH, βCH2 I7-NH  
γCH2 1.8 25.21 P6-βCH2, βCH2', δCH2, δCH2', 
γCH2' 
  
γCH2' 2.16 25.21 P6-βCH2, βCH2', δCH2, δCH2', 
γCH2' 
  
δCH2 3.62 46.98 P6-δCH2'   
δCH2' 3.85 46.98    
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Amino 
Acid 
Position 
δ1H 
ppm 
δ13C 
ppm 
COSY ROESY HMBC 
Ile7 
NH 6.58     
αCH 4.53 58.88 I7-NH D8-NH, P6-
αCH 
I7-γCH3 
βCH 2.04 40.4 I7-αCH  I7-γCH3, I7-δCH3 
γCH2 1.31 23.4 I7-βCH  I7-γCH3, I7-δCH3 
γCH2' 1.11 23.4 I7-βCH, γCH2  I7-γCH3, I7-δCH3 
γCH3 0.80 15.3 I7-βCH   
δCH3 0.78 11.6 I7-γCH2, γCH2'   
Asp8 
NH 8.44     
αCH 4.73 48.6 D8-NH S9-NH  
βCH2 3.58 36.04 D8-αCH S9-NH, G1-NH  
βCH2' 2.72 36.04 D8-αCH, βCH2 G1-NH  
Ser9 
NH 8.15     
αCH 3.80 59.54 S9-NH F10-NH  
βCH2 3.25 60.15 S9-αCH, OH   
βCH2' 3.40 60.15 S9-αCH, OH   
OH 4.88     
Phe10 
NH 8.11     
αCH 4.61 52.89 F10-NH G11-NH  
βCH2 2.75 37.88 F10-αCH, βCH2'   
βCH2' 3.10 37.88 F10-αCH   
Ar: 
H2,6 
7.04 128.7 F10-Ar:H3,5   
Ar:H3,5 7.18 128.9    
Ar:H4 7.09 125.9 F10-Ar:H3,5   
Gly11 
NH 7.36     
αCH2 3.47 42.68 G11-NH, αCH2' L12-NH  
αCH2' 4.11 42.68 G11-NH   
Leu12 
NH 8.33     
αCH 4.07 51.41 L12-NH S13-NH  
βCH2 0.73 37.4 L12-αCH, βCH2', 
γCH 
 L12-δCH3, L12-
δCH3' 
βCH2' 1.77 37.4 L12-αCH  L12-δCH3, L12-
δCH3' 
γCH 1.52 23.22 L12-βCH2, βCH2'  L12-δCH3, L12-
δCH3' 
δCH3 0.80 15.35 L12-γCH   
δCH3' 0.54 18.81 L12-γCH  L12-δCH3 
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Amino Acid Position δ1H ppm δ13C ppm COSY ROESY HMBC 
Ser13 
NH 9.31     
αCH 4.53 53.76 S13-NH W14-NH  
βCH2 3.36 61.88 S13-αCH, βCH3'   
βCH2' 3.66 61.88 S13-αCH   
OH      
Trp14 
NH 7.46     
αCH 4.87 53.87 W14-NH L15-NH  
βCH2 3.05 25.21 W14-αCH, βCH2'   
βCH2' 3.52 25.21 W14-αCH   
Ar: NH 10.95     
Ar:H1 7.87 124.5 W14-ArNH   
Ar:H2 7.59 119.2 W14-ArH3   
Ar:H3 6.92 117.9 W14-ArH2, ArH4   
Ar:H4 7.02 120.4 W14-ArH5  W14-Ar:H2 
Ar:H5 7.29 110.5 W14-ArH4   
Leu15 
NH 7.14     
αCH 3.92 52.17 L15-NH   
βCH2 0.85 42.32 L15-αCH   
βCH2' 0.53 42.32 L15-αCH, βCH2  L15-δCH3, L15-δCH3' 
γCH 0.77 23.22 L15-βCH2  L15-δCH3' 
δCH3 0.43 22.01 L15-γCH   
δCH3' 0.49 22.3 L15-γCH  L15-δCH3 
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Table 3.2. RKKD790_1592 fragment ions observed in the tandem mass spectra. 
Fragment Ion Fragment type Observed [M+H] Calculated Δppm 
GFGSKPIDSFGLSWL Parent 1592.8078 2.19 
GFGSKPIDSFGLS b13 1275.6355 1.02 
GFGSKPIDSFGL b12 1188.6041 0.59 
GFGSKPIDSFG b11 1075.5201 1.12 
GFGSKPIDSF b10 1018.4986 1.18 
GFGSKPIDS b9 871.4303 1.15 
GFGSKPID b8 784.3984 1.27 
SFGLSWL y7 809.4188 0.49 
FGLSWL y6 722.3868 0.55 
GLSWL y5 575.3183 0.87 
LSWL y4 518.2969 0.77 
SWL y3 405.213 0.49 
WL y2 318.1812 0.00 
GFGSKPID+GLSWL b8+y5 1358.7086 1.25 
GFGSKPID+LSWL b8+y4 1301.6867 1.61 
GFGSKPID+SWL b8+y3 1188.6041 0.59 
GFGSKPID+WL b8+y2 1101.572 0.73 
GFGSKPIDS+GLSWL b9+y5 1445.7408 1.04 
GFGSKPIDS+LSWL b9+y4 1388.7192 1.22 
GFGSKPIDS+SWL by+y3 1275.6355 1.02 
GFGSKPIDS+WL b9+y2 1188.6041 0.59 
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Marfey’s Method was used to determine the stereochemistry of each amino 
acid100. Retention times of derivatized peptide hydrolysate were compared to that of 
authentic amino acid standards (Appendix, Figure 8.18, 8.19). The amino acid standards 
eluted at the following retention times: L-Lys: 12.37 min and 15.40, L-Ser: 14.34 min, L-
Asp: 16.31 min, L-Pro: 22.08 min, L-Ile: 34.43 min, D-Ile: 40.58 min, L-Leu: 35.49 min, 
D-Leu: 41.17 min, L-Trp: 34.99 min and L-Phe: 35.57 min. Because of the presence of 
two free amine groups on L-Lys, FDAA can react with both creating two retention times 
for L-Lys. The FDAA derivatized peptide hydrolysate peaks were identified based on 
expected exact masses and eluted at 12.34 and 15.28, 14.24 min, 16.18 min, 22.00 min, 
34.28 min, 35.38 min, and 35.57 min corresponding to L-Lys, L-Ser, L-Asp, L-Pro, L-Ile, 
L-Leu, and L-Phe respectively. Retention times corresponding to both D-Trp and L-Trp 
were present, so milder reaction conditions were employed to reduce racemization. Using 
a lower reaction temperature, tryptophan was derivatized without racemizing and a single 
diastereomer eluted at 35.35 min corresponding to L-Trp. 
3.3.4 3D Molecular modelling of KG790_1592 
To confirm that KG790_1592 was a member of the lasso peptide family, the 3D 
conformation was determined. To show that the linear tail was threaded through the ring, 
and the extent to which this occurs, computational modelling was used.  
Six theoretical conformations were optimized and compared to the experimentally 
determined H-H distances. A total of 55 NOE parameters were compared and the total 
errors, the mean absolute deviation (MAD) and the maximum deviation are summarized 
in Table 3.3. Based on these results, the linear tail of KG790_1592 is likely threaded 
through the ring between Ser-13 and Trp-14 in a right hand conformation, which is 
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shown in Figure 3.3. These computational results agree with predictions based on mass 
spectrometry data where b8+y2 and b9+y2 fragments are observed. Interestingly, all 
other instances of lasso peptides previously reported exhibit the right handed 
conformation (loop type A) as well, which further supports the theoretical conclusions84. 
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Table 3.3. Error values of H-H distances between experimentally determined interatomic 
distances and theoretical conformation predictions.  
 
Candidate Total Error (A) MAD (A) 
Max  
Deviation (A) 
N > 1 N  1 
ALeu  91.55 1.66 8.52 27 28 
ASer  64.43 1.17 3.96 26 29 
ATrp  63.82 1.16 4.07 22 33 
BLeu  84.37 1.53 6.5 25 30 
BSer  69.35 1.26 4.65 26 29 
BTrp  78.74 1.43 7.18 25 30 
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Figure 3.3. The peptide backbone of the 3D conformation of RKKD790_1592 
determined by computational modelling.  
The backbone of the ring portion is coloured green and the threaded linear tail in blue. A. 
Cyclization occurs between the amino group of Gly-1 and Asp-8 which is coloured red. 
B. Side view of the threaded conformation showing the bulky side chains of Trp-14 and 
Leu-15 in purple. C. Bottom view of the threaded structure showing the side chains of 
Trp-14 and Leu-15 in purple. The large side of the bulky groups relative to the size of the 
ring shows that the steric bulk is responsible for locking the linear tail in place.  
  
A B 
C 
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The lack of cysteine residues in the structure of KG790_1592 causes it to be 
classified as a class II lasso peptide. Lasso peptides are a rapidly growing family of 
RiPPs. KG790_1592 consists of 15 amino acids and is the smallest lasso peptide that has 
been reported to date. It contains a ring consisting of 8 amino acids and a tail with 7 
amino acids; 5 above the ring and 2 below. The bulky side chains of both Trp-14 and 
Leu-15 contribute to the steric lock responsible for holding the tail within the ring. Two 
amino acids is the shortest sequence located below the ring, and is only observed in 
KG790_1592 and microcin J2590. KG790_1592 also contains a loop consisting of 5 
amino acids, which is shorter than the loop of many lasso peptides and is only one 
residue longer than the shortest observed loop regions in lariatin A91 and RES-701-187. 
The macrolactam ring of other class II lasso peptides is formed between glycine and 
either glutamic acid at position 8, or aspartic acid at position 985. The ring in 
KG790_1592 is formed between glycine and aspartic acid at position 8, which is the first 
peptide with a confirmed lasso structure to contain this shorter linkage consisting of 25 
atoms rather than 26 or 28. The combination of the small size of the ring, tail and loop 
region observed in the structure of KG790_1592 may provide an example of the 
minimum geometry required for a lasso fold. This example of the minimum structural 
features required to result in the stable and valuable lasso fold provides useful 
information for the characterization of this class of peptides and assists in the discovery 
of additional members. 
3.3.5 Stability assays 
 A significant challenge for becoming drug candidates that peptides face is a lack 
of stability in biological systems97,98. Lasso peptides are able to overcome this stability 
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issue because their unique threaded structure allows them to be more resistant to heat, 
chemical and enzymatic degradation than other peptides85. To evaluate the stability of 
RKKD790_1592 in physiological conditions, it was incubated with the peptide degrading 
enzyme, carboxypeptidase Y, and human serum. The amount of intact RKKD790_1592 
after incubation was measuring using LC-HRMS at varying time points (Figure 3.4). 
When RKKD790_1592 was incubated with carboxypeptidase Y, approximately all of the 
RKKD790_1592 remained intact for two hours. After three hours of incubation 
RKKD790_1592 began to degrade and approximately 68 % of the original amount of 
RKKD790_1592 remained intact. Compared to linear peptides that degrade within 
minutes of incubation with carboxypeptidase Y, RKKD790_1592 was found to be 
extremely resistant to peptidase degradation.  
 RKKD790_1592 was also incubated with human serum to evaluate its 
physiological stability. The remaining amount of intact RKKD790_1592 was 
approximately 100 % for all time points that were evaluated, up to 48 hours. This shows 
the extreme stability of RKKD790_1592 in the presence of human serum, and shows that 
like other lasso peptides, the threaded structure of RKKD790_1592 causes it to be very 
resistant to degradation. This shows that RKKD790_1592 has to the potential to 
overcome the stability challenges of peptides associated to drug development challenges.  
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Figure 3.4. Evaluation of the physiological stability of RKKD790_1592 in the presence 
of A. Carboxypeptidase Y and B. human serum.  
  
0
20
40
60
80
100
0 0.5 1 1.5 2 2.5 3 3.5
P
er
ce
n
t 
o
f 
in
ta
ct
 R
K
K
D
7
9
0
_
1
5
9
2
 r
em
ai
n
in
g
Time (Hours)
Carboxypeptidase Y Stability Assay
0
20
40
60
80
100
0 10 20 30 40 50 60
P
er
ce
n
t 
o
f 
in
ta
ct
 R
K
K
D
7
9
0
_
1
5
9
2
 R
em
ai
n
in
g
Time (Hours)
Human Serum Stability Assay
A 
B 
95 
 
3.3.6 Biological activity and assays 
KG790_1592 was evaluated for antimicrobial activity and cytotoxicity in multiple 
activity assays. No growth inhibition was observed at 50 µg/mL against methicillin-
resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, 
Staphylococcus warneri, Proteus vulgaris, Pseudomonas aeruginosa, and Candida 
albicans.  
Many lasso peptides have antibiotic activity against bacterial taxa that are closely 
related to the producing bacterium, and therefore KG790_1592 was evaluated for growth 
inhibition against Arcanobacterium pyogenes, Corynebacterium pseudotuberculosis, 
Dermatophilus congolensis, Micrococus luteus, Rhodococcus equi and Mycobacterium 
smegmatis in a disk diffusion assay. No zones of inhibition were observed in the presence 
of KG790_1592 for all 6 bacteria.  
Cytotoxicity was also evaluated against a human breast adenocarcinoma and 
human foreskin BJ fibroblast cell lines. No growth inhibition was observed up to a 
concentration of 128 µg/mL for both the cancerous and normal cell lines.  
Other class II lasso peptides that were found to have no antimicrobial activity 
include BI-3216995, RES-701-187, caulosegnins I-III93 and anantin106. Most of these lasso 
peptides that do not display antimicrobial activity possess very specific receptor 
antagonist or enzyme inhibition activity85. BI-32169 is a glucagon receptor antagonist95, 
RES-701 is an antagonist of the endothelin type-B receptor87 and anantin is an inhibitor 
of the atrial natriuretic factor106. KG790_1592 does not display any antimicrobial activity 
against several bacterial taxa, and no cytotoxicity against cancerous or healthy human 
cells. While the results of these assays do not reveal the potential applications of 
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KG790_1592, the lack of cytotoxicity shows the capability of having a very high 
therapeutic ratio. Biological activity may be highly specific and in combination with high 
stability and very low cytotoxicity, KG790_1592 may have the potential to be an 
effective therapeutic agent against a specific molecular target, or use as a moleulcar 
scaffold.  
3.4 CONCLUSION 
 The discovery of KG790_1592 represented an exciting opportunity to describe a 
new member of the relatively new, but rapidly growing group of RiPPs, the lasso 
peptides. KG790_1592 possessed several structural features that made it unique 
compared to other members of this class of natural products. At the time of isolation it 
was the smallest lasso peptide that had been described, and allowed the boundaries for 
minimum size requirements to produce a lasso fold to be adapted to include 
KG790_1592.  
 KG790_1592 was evaluated for biological activity in several different bioassays. 
It displayed no antibiotic activity against any of the microbial pathogens that it was 
evaluated against, as well as no anticancer activity. However KG790_1592 was also not 
active against healthy human cell lines, and is extremely resistant to protease, heat and 
chemical degradation suggesting that it may have the potential for pharmaceutical 
applications if specific enzyme inhibition activity is found because of its stability and 
potential for a high therapeutic window.   
The structure of this new lasso peptide was also discovered and described by Prof. 
Dong-Chan Oh’s research group who isolated the same lasso peptide from a similar 
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Streptomyces sp. isolated from deep sea sediment off the coast of Jeju Island, Korea107. 
They named this lasso peptide sungsanpin and found that it can inhibit cell invasion of 
A549 lung cancer cells.  
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CHAPTER 4: ISOLATION, STRUCTURE 
ELUCIDATION OF CYSTARGAMIDE: A 
LIPOPEPTIDE NATURAL PRODUCT 
FROM KITASATOSPORA CYSTARGINEA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is a modification of the material published as 
Gill, K.A., Berrue, F., Arens, J.C., and Kerr, R.G. Isolation and structure elucidation of 
cystargamide, a lipopeptide from Kitasatospora cystarginea. J. Nat. Prod. 2014, 77(6), 
1372-1376.  
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4.1 INTRODUCTION 
Peptides encompass an enormous class of natural products with great diversity in 
both structure and biological applications108. Peptide natural products are often split into 
two classes based on their biosynthetic origin. Peptides synthesized by the ribosome are 
classified as ribosomally synthesized post-translationally modified peptides (RiPPs)83, 
and peptides that are biosynthesized by modular enzymes that are distinct from the 
ribosome are classified as non-ribosomal peptides (NRPs)108. NRPs are biosynthesized by 
nonribosomal peptide synthetases (NRPS), which are large multifunctional enzymes that 
have conserved modes of synthesis108-110. NRPS enzymes often incorporate non-
proteinogenic amino acids and peptide modifications including methylation, 
hydroxylation, acylation, and glycosylation, which results in a vast amount of structural 
diversity observed in this class of natural products111. NRPs have also been observed as 
linear, cyclic and branched-cyclic, which further contributes to the structural diversity of 
these natural products111,112. 
An interesting and pharmaceutically significant group of acylated cyclic NRPs is 
the cyclic lipopeptides112. Several examples of members of this natural product group are 
shown in Figure 4.1. This group of NRPs is classified by the addition of a medium to 
long chain fatty acid that is attached to a cyclic or branched cyclic peptide. The fatty acid 
groups are often essential for biological activity. One of the most studied cyclic 
lipopeptides is daptomycin, which was isolated from Streptomyces roseosporus113and is 
approved by the FDA for treatment of skin and soft tissue infections and MRSA in the 
blood stream38. There are also several other lipopeptides with potent antibiotic activity 
including the Calcium Dependent Antibiotics (CDAs)114, friulimicin115, 
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laspartomycins116, and surfactin117. Discovering new members of the cyclic lipopeptide 
group of natural products offers excellent opportunities to discover novel antibiotics that 
may be useful for combatting multi-drug resistant microbial pathogens. 
Members of the genus Kitasatospora are classified as rare Actinobacteria and 
have been found to be prolific sources of bioactive secondary metabolites46. Natural 
products produced by this genus include the bafilomycins118, talosins119, and more 
recently the satosporins76. In this chaper, the purification, structure elucidation and 
biological activity of the novel peptide, cystargamide will be discussed. Cystargamide is 
a cyclic lipopeptide that is cyclized by an ester linkage between the C-terminus acid and 
the hydroxy group of a threonine side chain. Cystargolide contains a 2,3-epoxy fatty acid 
chain that is linked to the threonine amine. It has structural similarities to two 
lipopeptides, Q-6402 A and B, isolated from Streptomyces sp. Q-6402, which have been 
reported to inhibit phospholipase A2120. 
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Figure 4.1. Structures of lipopeptide natural products with antimicrobial activity.   
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4.2 MATERIALS AND METHODS 
4.2.1 Large scale fermentation, extraction and purification of cystargamide 
From an ISP349 agar plate grown at 30ºC for 4-7 days, a single colony of K. 
cystarginea was used to inoculate 10 mL of seed medium (10 g/L glucose and 10 g/L 
yeast extract) containing 2-3 glass beads and fermented at 30 ˚C with agitation of 200 
rpm for 48 hours. After 48 hours, 50 mL of seed medium in a 250 mL flask containing 3-
5 glass beads was inoculated with 2.5 mL of the first seed culture and incubated under the 
same conditions for 48 hours. Five, 2.8 L fernbach flasks containing 1 L each of lean 
production medium (0.4 g/L glucose, 0.8 g/L galactose, 0.8 g/L maltose, 1.6 g/L dextrin, 
0.8 g/L Bacto-soytone and 0.3 g/L ammonium sulfate) and 5-10 glass beads were 
inoculated with 50 mL each of second seed cultures and were incubated at 30˚C with 
agitation of 200 rpm for 72 hours.  Each fermentation flask was extracted with 500 mL 
and then 300 mL of EtOAc, which were then partitioned twice with equal volume of 
diH2O. After evaporation, the combined extract was dissolved in 10 mL of 80 % aqueous 
acetonitrile and partitioned with an equal volume of hexanes. The aqueous acetonitrile 
phase was evaporated to dryness in vacuo. 
The dried acetonitrile fraction was fractionated using automated reversed-phase 
flash chromatography with a 15.5 g C18 column (High Performance GOLD, RediSep Rf) 
and eluted at 30 mL/min with a linear gradient from 50 % H2O (solvent A1) and 50 % 
MeOH (solvent B1) to 100 % solvent B1 over 15 min. Cystargamide eluted at 10–11.5 
min. Cystargamide was purified using RP-HPLC with a Luna 110 Å phenyl hexyl 
column (5 μm, 250 mm × 10 mm, Phenomenex). An isocratic elution with 30 % H2O/0.1 
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% formic acid (solvent A2) and 70 % MeOH/0.1 % formic acid (solvent B2) over 20 min 
was used to elute cystargamide at 13.5 min. 
4.2.2. Structure elucidation of cystargamide 
Cystargamide: Yellow powder; [α]25D +7.4 (c 0.22, MeOH); 1H and 13C NMR data 
see Table 4.1. (+) HRESIMS m/z 954.4287 [M + H]+, (calcd for C49H60N7O13, 954.4244). 
Optical rotations were measured on a Rudolph Autopol III polarimeter using a 50 
mm microcell (1 mL). The infrared spectrum was recorded using attenuated total 
reflectance, on a Bruker Alpha FT-IR spectrometer. NMR spectra were obtained on a 600 
MHz Bruker Avance III NMR spectrometer. Chemical shifts (δ) were referenced to the 
DMSO-d6 residual peaks at δH 2.50 ppm and δC 39.51 ppm. LC–HRMS was performed 
using a Thermo Q Exactive HPLC instrument with hyphenated MS-ELSD-UV detection: 
Finnigan LXQ ion trap mass spectrometer fitted with an ESI source, PDA, and LT-ELSD 
Sedex 80. Tandem MS spectra were measured on a Thermo LTQ Orbitrap Velos mass 
spectrometer. Automated flash chromatography was performed on a Teledyne 
Combiflash Rf200 using C18 RediSep columns. HPLC purifications were carried out on a 
Thermo Surveyor coupled with an evaporative light-scattering detector Sedex 55. 
4.2.3 Stereochemical analysis by Marfey’s Method 
Amino acid absolute configurations were determined by Marfey’s method of 
hydrolyzed cystargamide100. To a microconical vial, 200 µg of cystargamide and 250 µL 
of HCl (6M) was added and heated to 70-80 ºC for 90 minutes. 1 mL of 1N NaHCO3 
followed by 20 µL of 1-fluoro-2,4-dinitrophenyl-L-alanine (L-FDAA) (10 mg/mL in 
acetone) were added to the reaction vial and heated at 30-40 ºC for one hour before 
quenching with 100 µL of 6M HCl. The reaction mixture was reduced in volume under 
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air, then diluted to 1 mL with 50:50 MeOH/H2O for LC-MS analysis. The resulting 
reaction mixture was analyzed by LC-MS using an LTQ Orbitrap Velos 
(ThermoScientific) HPLC system with a Hypersil Gold 100 Å column (Thermo, 1.9 μm 
C18 50 mm × 2.1 mm). A linear gradient of 95 % H2O/0.1 % formic acid (solvent A3) and 
5 % CH3CN/0.1 % formic acid (solvent B3) to 40 % solvent B3 over 55 min followed by 
a rapid increase to 100 % solvent B3 over 2 min then a hold for 3 min was used, with a 
flow rate of 400 μL/min. Retention times were compared with those of authentic 
derivatized standards to determine the amino acid configurations. 
Hydroxytryptophan degraded during acid hydrolysis involved in Marfey’s 
Method so an ozonolysis reaction was used to convert the hydroxyindole group to a more 
stable carboxylic acid so that Marfey’s Method could be used. To a reaction vial, 700 μg 
of cystargamide was added with 5 mL of MeOH. The solution was cooled to −78 °C, and 
ozone in oxygen was bubbled through the solution for 30 min, followed by addition of 20 
drops of 38 % H2O2 to quench the reaction. The reaction was heated to room temperature 
and evaporated under N2 until dry. Acid hydrolysis and derivatization with L-FDAA 
were repeated on the ozonolysis product followed by LC-MS analysis as described 
above.  
4.2.4 Antimicrobial assays 
Cystargamide was tested for antimicrobial activity against the human microbial 
pathogens, methicillin-resistant Staphylococcus. aureus ATCC 33591 (MRSA), 
vancomycin-resistant Enterococcus. faecium EF379 (VRE), Staphylococcus 
warneri ATCC 17917, and Candida. albicans ATCC 14035. All assays were carried out 
according to Clinical Laboratory Standards Institute testing standards in a 96-well plate 
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and in triplicate53. Control antibiotics used were vancomycin for MRSA and S. warneri, 
rifampicin for VRE, or nystatin for C. albicans. Cell growth was determined by 
measuring the optical density at 600 nm (OD600) at time zero and after incubation for 22 
hours at 37 ºC using a Thermo Scientific Varioskan Flash plate reader. The change in 
OD600 after incubation was compared to untreated negative control wells and plotted as 
percent growth inhibition. Cystargamide was evaluated at six concentrations ranging 
from 2 µg/mL to 64 µg/mL. 
Cystargamide was tested for antibiotic activity against Bacillus subtilis NRRL-B-
558 in a disk diffusion assay.  Assay conditions were performed at cystargamide 
concentrations of 2 µg/disk, in the presence and absence of 12 mM Ca2+. Penicillin G was 
used as a positive control. Zones of inhibition were measured with calipers after 24 h of 
growth. 
4.2.5 Phospholipase A2 inhibition assay 
Cystargamide was also evaluated for inhibition against human secretory 
phospholipase A2 type V. The assay was performed using the sPLA2 (Type V) inhibitor 
screening assay kit (Cayman Chemical Item No. 10004883) and the recommended 
protocol. The assay kit included sPLA2 assay buffer 10X (Item No. 765010), sPLA2 
DTNB (Item No. 765012), sPLA2 diheptanoyl thio-PC substrate (Item No. 765014), 
sPLA2 human type V (Item No. 10004913), 96-well solid plate for colorimetric assay 
and cover sheet (Item No. 400014, 400012). The assay was performed at room 
temperature, in triplicate and absorbance at 415 nm was measured using a Spectra Max 
M2 (Molecular devices) plate reader. Absorbance of cystargamide treated wells were 
compared to the untreated negative control wells and used to calculate the percent 
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enzyme activity at nine concentrations of cystargamide ranging from 0.16 µM to 40 µM. 
Thioetheramide-PC was used as a positive control at four concentrations ranging from 
0.62 µM to 40 µM. 
4.2.6 Activation of microbial secondary metabolites 
 To evaluate the effects of cystargamide on the growth and metabolite production 
of other actinomycetes, a disk diffusion assay was used. To a paper disk, 50 µL of 
cystargamide (10 mg/mL in EtOH) was added and allowed to dry. Dry disks were applied 
to ISP249 agar plates that were inoculated with 100 µL of a Streptomyces coelicolor spore 
suspension (1x106 spores/mL). The same concentration of surfactin was used as a 
positive control, and EtOH as a negative control. Plates were incubated at 30 ºC for 7 
days, and all conditions were repeated in triplicate.  
4.3 RESULTS AND DISCUSSION 
4.3.1 Fermentation, extraction and isolation of cystargamide 
Through the use of LC-MS/PCA metabolomics screening method described in 
Chapter 2, it was identified that Kitasatospora cystarginea produced three putatively 
novel metabolites. This led to the selection of K. cystarginea for fermentation scale up. A 
5 L scale-up fermentation was undertaken and culture broths were extracted with ethyl 
acetate. The resulting organic extract was fractionated by C18 liquid chromatography and 
further purified using RP-HPLC with a phenyl hexyl stationary phase to yield pure 
cystargamide. Several additional large scale fermentations were required to purify 
enough material for all structural characterizations and biological assessments. 
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4.3.2 Structure elucidation of cystargamide 
Cystargamide was isolated as a yellow solid, and HRMS supported the molecular 
formula C49H59N7O13 indicating 24 degrees of unsaturation. NMR data (Table 4.1) 
revealed the presence of six amide protons which was indicative of a peptidic structure. 
Seven distinct 1H spin systems were identified as six amino acid side chains and one 
oxidized fatty acid chain by interpretation of the TOCSY spectrum (Figure 4.2). Amino 
acid side chains were assigned primarily using 1H, HSQC, COSY, and HMBC spectra, 
and the amino acid sequence was assigned using the NOESY and HMBC spectra 
(Appendix, Figures 8.20-8.30). 
The glycine residue was assigned on the basis of the COSY correlation between 
Gly-NH (δH8.22)/H2α (δH 4.32, 3.56). The 4′-hydroxyphenylglycine residue (Hpg) was 
assigned on the basis of COSY correlations between Hpg-NH (δH 8.72)/Hα (δH 5.21); H-
2′ (δH 6.84)/H-3′ (δH 6.60); and the HMBC correlations from Hα to C-1′ (δC 127.7), C-2′ 
(δC 129.1); H-2′ to C-1′; and H-3′ to C-4′ (δC 156.3). A 4′-hydroxyphenolic group was 
supported by the characteristic 13C chemical shift at δC 156.3 and both 1H signals (H-2′ 
and H-3′) that each integrated for 2H. The 5-hydroxytryptophan (Htrp) was identified on 
the basis of COSY correlations between Htrp-NH (δH8.74)/Hα (δH 4.33); Hα/H2β 
(δH 3.00, 2.93); Htrp H-1 (δH 10.52)/H-2 (δH 7.04); H-7 (δH 7.08)/H-6(δH 6.57) in 
addition to HMBC correlations from H2β to C-3a (δC 127.6), C-3 (δC 107.9), C-2 
(δC 123.9); Htrp H-1 to C-7a (δC 130.0), C-3; H-2 to C-7a, C-3a, C-3; H-7 to C-5 
(δC 149.9), C-3a; H-6 to C-7a, C-4; H-4 (δH 6.85) to C-6, C-3, C-7a. The 13C resonance at 
δC 149.9 (C-5) was in agreement with a hydroxy substituent at the C-5 position. The 
glutamic acid residue was assigned by the interpretation of the TOCSY spectrum that 
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revealed the spin system Glu-NH (δH7.09)/Hα (δH 4.31)/H2β (δH 2.04, 1.92)/H2γ (δH 2.36, 
2.29) in addition to the key HMBC correlation from H2γ to COOH (δC 175.4). The 
phenylalanine residue was determined on the basis of COSY correlations that indicated 
the two spin systems: Phe-NH (δH 8.75)/Hα (δH4.47)/H2β (δH 3.15, 2.72) and H-2′ 
(δH 7.16)/H-3′ (δH 7.19)/H-4′ (δH 7.13); and the HMBC correlations from H2β to C-1′ 
(δC 137.7), C-2′ (δC 128.8); H-2′ to C-4′ (δC 126.0), and H-3′ to C-1′. The key COSY 
correlations between Thr-NH (δH 7.68)/Hα (δH 4.55), Hα/Hβ (δH 5.40), and Hβ/H3γ 
(δH 1.10) confirmed the presence of the amino acid, threonine. Finally, the interpretation 
of the TOCSY data revealed the last spin system H-2 (δH 3.42)/H-3 (δH 2.8)/H2-4 
(δH 1.56, 1.50)/H2-5 (δH 1.37)/four overlapping methylenes (δH 1.30–1.26)/H3-10 
(δH 0.89). The downfield resonances for H-2 and H-3 were characteristic of methine 
signals bearing a heteroatom. The COSY correlation between H-2 and H-3, the HMBC 
correlation from H-2 to Epd-CO and the NOESY correlation between Thr-NH and H-2 
indicated the presence of a 2,3-epoxide ring. The HRMS data supported this structure 
assignment on the basis of the additional degree of unsaturation and mass of an oxygen 
atom that were not yet attributed to the structure. 
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Table 4.1. 1H (600 MHz) and 13C (150 MHz) NMR Data for cystargamide in DMSO-d6. 
Position δC, type δH (J, Hz) COSY NOESY 
HMBC 
(HC) 
Epda 
CO 167.5, C     
2 53.3, CH 3.42, d (1.8) Epd-3 Thr-NH, Epd-4 Epd-CO 
3 57.5, CH 2.80, ddd (5.5, 5.5 1.8) Epd-2,Epd-4 Thr-NH, Epd-4  
4 30.5, CH2 1.56, m; 1.50, m Epd-3, Epd-5   
5 25.0, CH2 1.37, m Epd-4, Epd-6   
6d 28.5, CH2 1.30, m    
7d 21.9, CH2 1.28, m    
8d 28.7, CH2 1.26, m    
9d 31.1, CH2 1.26, m    
10 13.7, CH3 0.89, t (6.9) Epd-9   
Thr 
CO 168.0, C     
NH  7.68, d (8.9) Thr-α Epd-2, Epd-3 Epd-CO 
α 54.1, CH 4.55, dd (9.0, 1.5) Thr-NH, Thr-β Phe-NH Thr-CO, Epd-
CO 
β 70.2, CH 5.40, m Thr-α, Thr-γ Phe-NH Gly-CO 
γ 16.2, CH3 1.10, d (6.3) Thr-β  Thr-α, Thr-β 
Phe 
CO 169.8, C     
NH  8.75, m Phe-α Thr-α, Thr-β  
α 54.2, CH 4.47, ddd (9.3, 3.7, 
3.7) 
Phe-NH,Phe-β  Glu-NH Phe-CO, Thr-
CO 
β 36.8, CH2 3.15, dd (13.9, 3.6); 
2.72, dd (13.8, 3.5) 
Phe-α Phe-2’ Phe-1’, Phe-
2’, Phe-CO 
1’ 137.7, C     
2’ 128.8, CH 7.16, m Phe-3’ Phe-NH, Phe-α, 
Phe-β 
Phe-4’, Phe-β 
3’ 127.8, CH 7.19, m Phe-2’, Phe-4’  Phe-1’ 
4’ 126.0, CH 7.13, m Phe-3’  Phe-2’ 
Glu 
CO 168.1, C     
NH  7.09, m Glu-α Phe-α  
α 51.6, CH 4.31, m Glu-NH, Glu-β  Glu-CO 
β 28.3, CH2 2.04, m Glu-α, Glu-γ Htrp-NH  
  1.92, m    
γ 31.8, CH2 2.36, m; 2.29, m Glu-β  Glu-COOH 
COO
H 
175.4, C     
 
  
110 
 
Position δC, type δH (J, Hz) COSY NOESY 
HMBC 
(HC) 
Htrpb 
CO 171.2, C     
NH  8.74, m Htrp- α Htrp-2, Glu-α, 
Glu-β 
 
α 55.1, CH 4.33, m Htrp-NH, Htrp-
β 
Hpg-NH Htrp-CO, 
Glu-CO 
β 26.2, CH2 3.00, dd (14.1, 7.8); 
2.93, dd (14.2, 6.8) 
Htrp- α Htrp-4, Htrp-2 Htrp-CO, 
Htrp-3a, Htrp-
3, Htrp-2 
1  10.52, s Htrp-2  Htrp-3a, Htrp-
7a, Htrp-3, 
Htrp-2 
2 123.9, CH 7.04, s Htrp-1 Htrp-1 Htrp-3a, Htrp-
7a, Htrp-3 
3 107.9, C     
3a 127.6, C     
4 102.2, CH 6.85, d (2.3)  Htrp-β, Htrp-α Htrp-3, Htrp-
5, Htrp-6, 
Htrp-7a 
5 149.9, C     
6 111.0, CH 6.57, dd (8.6, 2.2) Htrp-7  Htrp-7a, Htrp-
4 
7 111.3, CH 7.08, d (8.6) Htrp-6  Htrp-5, Htrp-
3a 
 7a 130.0, C     
Hpgc 
CO 169.9, C     
NH  8.72, m Hpg-α Gly-NH, Hpg-2’, 
Htrp-α 
 
α 55.8, CH 5.21, d (8.4) Hpg-NH Gly-NH, Hpg-2’,  Htrp-CO, 
Hpg-CO, 
Hpg-1’, Hpg-
2’ 
1’ 127.7, C     
2’ 129.1, CH 6.84, d (8.9) Hpg-3 Hpg-NH, Gly-
NH, Hpg-α 
Hpg-4’, Hpg-
α 
3’ 114.6, CH 6.60, d (8.7) Hpg-2  Hpg-4’, Hpg-
1’ 
4’ 156.3, C     
Gly 
CO 168.2, C     
NH  8.22, d (5.8) Gly-α Hpg-NH, Hpg-α, 
Hpg-2’ 
Hpg-CO 
α 40.0, CH2 4.32, m; 3.56, m Gly-NH  Gly-CO, Hpg-
CO 
aEpd: 2,3-epoxydecanoyl, bHtrp 5’-hydroxytryptophan,  cHpg: 4’-hydroxyphenylglycine, doverlapping 
signals may be interchanged. 
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The NOESY signals between Gly-NH/Hpg-Hα; Hpg-NH/Htrp-Hα; Htrp-NH/Glu-
Hα; Glu-NH/Phe-Hα; Phe-NH/Thr-Hα revealed the sequence of amino acids to be Gly-
Hpg-Htrp-Glu-Phe-Thr. The HMBC correlation from Thr-Hβ to Gly-CO (δC 168.2) as 
well as the chemical shift of Thr-Hβ suggested that Gly-Thr were connected in a cyclic 
structure via an ester linkage. The epoxydecanoyl group was linked to the peptidic moiety 
according to the strong NOESY correlation between Thr-NH/H-2, as well as the key 
HMBC correlation from Thr-NH, Thr-Hα to Epd-CO (δC 167.5). The molecular structure 
of cystargamide and key NMR correlations used for structure elucidation are shown in 
Figure 4.2. The planar structure of cystargamide, and in particular the amino acid 
sequence, was confirmed by tandem mass spectrometry. 
Cyclic lipopeptides are characterized by the linkage of a polypeptide moiety to a 
fatty acid side chain. They often vary greatly in size, amino acid, and fatty acid 
composition and commonly contain non-proteinogenic amino acids112. Incorporation of a 
large assortment of fatty acid building blocks in combination with a number of non-
proteinogenic amino acids results in vast chemical diversity for this group of natural 
products. The 4′-hydroxyphenylglycine (Hpg) residue in cystargamide, is found in a 
number of different classes of natural products, including lipopeptides such as the 
CDAs114, enduracidins121, and ramoplanins122. However, the amino acid residue 5-
hydroxytryptophan (Htrp) is not as commonly incorporated, especially in microbial 
natural products. Htrp is a naturally occurring mammalian metabolite that is a 
biosynthetic precursor to the endogenous neurotransmitters serotonin and melatonin, and 
is rarely found in microbial natural products123. 
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Like other members of the lipopeptides including daptomycin and the CDAs, 
cystargamide is cyclized by an ester linkage between the C-terminal acid and the hydroxy 
group of a threonine side chain112. Cystargamide also contains a rare 2,3-epoxy fatty acid 
side chain that has only been reported once in the CDA type-lipopeptides CDA1, 2, 3b, 
and 4b114. It is worth noting that these CDAs possess the same trans configuration for the 
epoxide ring, but in this case, in a shorter fatty acid chain124. Therefore to the best of our 
knowledge, cystargamide is the first report of a natural product containing a 2,3-
epoxydecanoyl fatty acid side chain. 
4.3.3 Stereochemical analysis by Marfey’s Method 
The absolute configurations of the amino acids were determined using Marfey’s 
method100. Cystargamide was hydrolyzed using HCl and then derivatized with N-(2,4-
dinitro-5-fluorophenyl)-L-alaninamide (L-FDAA) and analyzed by LC-MS; retention 
times were then compared with those of derivatized standards (Appendix, Figures 8.23-
8.24). Standard amino acids eluted at 35.20 min (L-Phe), 18.00 min (L-Glu), 13.83 min 
(L-Hpg), 14.97 min (L-Thr), 20.60 min (D-Thr) and 15.50 and 17.67 min (DL-allo-Thr). 
Hydrolyzed cystargamide eluted at 35.25 min (L-Phe), 18.00 min (L-Glu), 13.82 min (L-
Hpg) and 14.94 min (L-Thr). 
All derivatized amino acids, with the exception of Htrp, eluted at retention times 
similar to those of their corresponding L-standards, revealing that cystargamide contained 
L-Hpg, L-Glu, L-Phe, and L-Thr. The Htrp residue was not detected, likely due to its 
lability; therefore cystargamide was reacted with ozone using an oxidative workup, 
followed by acid hydrolysis, derivatization with L-FDAA and analysis by LC-MS. 
Standard derivatized amino acids eluted at 16.28 min (L-Asp) and 18.73 min (D-Asp). 
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The derivatized ozonolysis product eluted at 16.30 min revealing L-Asp, which 
corresponded to the presence of L-Htrp in cystargamide. 
The relative configuration of the epoxide ring was determined by using the JHH 
coupling constant between H-2 and H-3. A small value of 1.8 Hz indicated that the 
vicinal protons had a trans relationship, revealing the relative configuration to be *2R, 
*3S125. This was also supported by a strong NOESY correlation between H-2 and H-4.  
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Figure 4.2. A. Molecular structure of cystargamide (1). 
B. The molecular structure of Q-6402 a (2) and b (3)120. C. Key COSY, NOESY and 
HMBC correlation used to elucidate the structure of cystargamide.  
  
A B 
C 
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4.3.4 Antimicrobial activity 
Due to the structural similarity between cystargamide and antibiotic lipopeptides 
like CDA, the antimicrobial activity of cystargamide was evaluated against methicillin-
resistant Staphyloccocus aureus (MRSA), vancomycin-resistant Enterococcus faecium 
(VRE), Staphylococcus warneri, and Candida albicans. Cystargamide displayed no 
significant growth inhibition against all four pathogens up to a concentration of 64 
μg/mL, which is displayed in Figure 4.3. Cystargamide was also tested in a disk-diffusion 
assay with Bacillus subtilis in the presence and absence of calcium to determine if 
calcium was required for activity, like what is observed for CDA. Cystargamide 
displayed no antibiotic activity under either condition up to 2.0 µg/disk. Although CDA 
and cystargamide are both cyclic lipopeptides that contain a similar 2,3-epoxy fatty acid, 
CDA contains a total of eleven amino acids with ten comprising the cyclic portion, while 
cystargamide only consists of six cyclized amino acids. They also have several 
differences in amino acid position around the macrocycle. These structural differences 
between CDA and cystargamide are likely the reason that cystargamide did not display 
similar antimicrobial activity compared to CDA. 
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Figure 4.3. The percent growth inhibition of cystargamide against four human microbial 
pathogens.  
  
117 
 
4.3.5 Phospholipase A2 inhibition assay 
Cystargamide shares significant structural similarities with the lipopeptides Q-
6402 A and B, however these compounds have only been reported in a conference 
abstract and there is no detailed spectroscopic information available120. Cystargamide and 
Q-6402 A and B differ in the structure of the fatty acid chain, by the presence of the non-
proteinogenic residue 2-methyl-1-amino-cyclopropanecarbocylic acid (MeACC) instead 
of glycine, and N-methylation of the phenylalanine residue (Figure 4.2). Q-4602 A and B 
were reported as inhibitors of rabbit platelet PLA2 with IC50 values of 9 µM and 6 µM 
for A and B respectively. Q-6402 B also exhibited anti-inflammatory activity with an 
ED50 value of 121 µM/ear in a mouse ear adema assay. When cystargamide was 
evaluated in a PLA2 inhibition assay it showed very weak activity, with an IC50 value 
greater than 40 µM (Figure 4.4). The difference in potency of cystargamide compared to 
Q-6402 A and B could be due to the structural differences, but it is more likely a result of 
different isoforms of the enzyme PLA2 that were used. Rabbit platelet PLA2 was used to 
evaluate inhibition of Q-4602 A and B, while human secretory type V PLA2 was used for 
cystargamide. Human secretory type V PLA2 was selected for the assay despite the 
differences to rabbit platelet PLA2 because the human isozyme is a more clinically 
relevant target to evaluate anti-inflammatory activity, and would result in a better 
indication in the potential in vivo anti-inflammatory activity of cystargamide. The lack of 
inhibition of gainst human PLA2 suggests that cystargamide is not a candidate for 
development as an anti-inflammatory agent. 
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Figure 4.4. A dose-response curve showing the percent enzyme inhibition of 
cystargamide against human sPLA2 type V. 
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4.3.6 Activation of microbial secondary metabolites 
 The lipopeptide surfactin has been shown to inhibit development of aerial mycelia 
and spores in Streptomyces coelicolor126. Since cystargamide is also a lipopeptide, a disk 
diffusion assay was used to determine whether cystargamide has similar effects on the 
growth cycle of S. coelicolor. When S. coelicolor was grown in the presence of 
cystargamide, it did not inhibit the growth of aerial mycelia, however a clear difference in 
the metabolite production compared to the negative control was observed. On surfactin 
and EtOH control plates, no pigments were produced, however on plates containing 
cystargamide, a dark purple pigment was observed in all replicates, which can be seen in 
Figure 4.5. The identity of these pigments were confirmed as actinorhodin and 
undecylprodigiosin using the LC-MS “chemical screening” method described previously 
(Chapter 2)127. This shows that cystargamide acted as an inducer of secondary metabolite 
production in the model organism S. coelicolor and may play a role in microbial 
communication as a signalling molecule. These preliminary results show that the addition 
of cystargamide to microbial fermentations for natural products discovery programs may 
be a useful strategy to activate secondary metabolite biosynthesis and access cryptic 
metabolites. This is very useful for the discovery of novel natural products that are 
otherwise inaccessible under standard laboratory techniques.   
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Figure 4.5. A disk diffusion assay showing Streptomyces coelicolor grown in the 
presence of A. ethanol, B. surfactin and C. cystargamide. 
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4.4 CONCLUSION 
 A novel lipopeptide natural product was isolated from the fermentation broth of a 
rare actinomycete K. cystarginea. The discovery of new natural products from this genus 
of bacteria shows that they are an excellent source for the isolation of novel bioactive 
metabolites. To the best of our knowledge, this is the first report of a natural product that 
contains a 2,3-epoxydecanoyl fatty acid coupled to a peptide. Cystargamide also contains 
the non-proteinogenic amino acids 4-hydroxyphenylglycine and the rare 5-
hydroxytryptophan. Lipopeptide natural products are a very complex and diverse family 
of natural products and the addition of cystargamide to this group adds unique features to 
the structural possibilities that bacteria are capable of biosynthesizing.  
 Cystargamide was evaluated for biological activity in several bioassays. While it 
showed little or no antimicrobial activity or inhibition of human sPLA2 enzyme, it 
showed promising activity in a preliminary secondary metabolite induction assay with the 
model organism S. coelicolor. The use of cystargamide as an inducer of natural product 
biosynthesis in actinomycetes is an exciting opportunity to access cryptic natural 
products that may have useful applications to benefit human health. 
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CHAPTER 5: ISOLATION STRUCTURE 
ELUCIDATION AND BIOLOGICAL 
ACTIVITY OF CYSTARGOLIDES A 
AND B: NOVEL β-LACTONE 
CONTAINING PEPTIDES FROM 
KITASATOSPORA CYSTARGINEA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is a modification of the material published as  
Gill, K.A. Berrue, F., Arens, J.C., Carr, G. and Kerr, R.G. Cystargolides, 20S proteasome 
inhibitors isolated from Kitasatospora cystarginea. J. Nat. Prod. 2015, 78(4), 822-826. 
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5.1 INTRODUCTION 
Natural products have been an excellent resource to explore for the discovery of 
pharmaceutical agents, especially with antibiotic and anticancer properties14. From the 
1940s to 2014, 75 % of all FDA approved anticancer drugs were derived in some way 
from natural products and are classified as members of groups other than synthetic 
including natural products, natural product mimics and derivatives, botanicals, biologics 
and synthetics with natural pharmacophores11. Unaltered natural products and their 
derivatives account for 49 % of all FDA approved anticancer drugs. This remarkable 
proportion of anticancer agents shows that it is important to continue to investigate 
natural products for their anticancer properties and to fuel anticancer drug development 
programs. 
A group of natural products that have been shown to have anticancer properties as 
well as other interesting biological applications are the β-lactone containing group of 
natural products. Tetrahydroxylipstatin (THL, Orlistat) is a derivative of the natural 
product lipstatin, and is a β-lactone containing compound that is approved by the FDA as 
a pancreatic lipase inhibitor used to treat obesity128,129. Other members of this class 
include belactosin A, salinosporamide A and omuralide, which are all reported as potent 
inhibitors of the 20S proteasome (Figure 5.1)130,131,132,133. The ubiquitin-proteasome 
pathway plays a major role in eukaryotic cellular protein degradation134. This system 
adjusts the level of proteins involved in regulating cellular processes such as signal 
transduction, immune responses and cell cycle progression135,136,137. Inhibitors of the 
proteasome have gained attention for their ability to block cell cycle progression and 
cause apoptosis, which makes them useful antiproliferative agents138. Bortezomib and 
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carfilzomib are proteasome inhibitors that have been approved by the FDA for treatment 
of multiple myeloma, and several other proteasome inhibitors are currently in clinical 
trials139,140.  
In order to identify novel natural products with potential applications in human 
health, a library of bacteria were screened using the metabolomics approach outlined in 
Chapter 2. In this chapter, the isolation, strucrure elucidation and biological activity of 
two novel β-lactone containing natural products, cystargolides A and B is described.  
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Figure 5.1 Molecular structures of β-lactone containing natural products.  
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5.2 MATERIALS AND METHODS 
5.2.1. Large scale fermentation and extraction of Kitasatospora cystarginea and 
purification of cystargolides A and B 
Kitasatospora cystarginea was fermented on a larger scale as described in 
Chapter 4.2.1. The 5 L fermentation was extracted as previously described with ethyl 
acetate and then partitioned between 80 % aqueous acetonitrile and hexanes. The 
acetonitrile phase was evaporated and analyzed for the presence of cystargolide A and B 
by LC-MS using the “chemical screening” method described previously (Chapter 2). 
The acetonitrile fraction was separated by reverse phase flash chromatography 
using CombiFlash Rf (Teledyne ISCO) with a 15.5 g C18 column (High Performance 
GOLD, RediSep Rf), and eluted with H2O (solvent A1) and MeOH (solvent B1) using a 
linear gradient from 50 to 100 % solvent B1 over 15 min followed by 100 % solvent B1 
for an additional 5 minutes. A flow rate of 30 mL/min was used and eluent was detected 
by UV (214 nm). A mixture of cystargolide A and B eluted from 6.0-8.5 minutes. 
Cystargolides were purified using a Thermo Surveyor HPLC system coupled with 
an evaporative light-scattering detector Sedex 55 with a Luna 110 Å phenyl hexyl 
column (5 µm, 250 x 10.00 mm, Phenomenex). A flow rate of 3 mL/min, using H2O/0.1 
% formic acid (solvent A2) and MeOH/0.1 % formic acid (solvent B2) was used to elute 
cystargolides A and B. The fraction containing cystargolides was separated using a linear 
gradient increasing from 50 % solvent B2 to 80 % solvent B2 over 17 minutes, followed 
by a ramp to 100 % solvent B2 over 2 minutes and then an isocratic wash with 100 % 
solvent B2 for an additional 12 minutes. Cystargolides A and B eluted at 12.1 and 10.2 
minutes respectively, which were detected by ELSD and UV (220 and 254 nm). To 
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obtain enough material for full biological testing seven additional large scale 
fermentations and purifications were done using the same methods. 
5.2.2 Structure elucidation of cystargolides A and B 
Cystargolide A: Pale yellow power; [α]25D -18˚ (c=0.29, MeOH); IR vmax 3294, 
2962, 1835, 1719, 1646, 1534, 1465, 1201, 1025 cm-1; 1H and 13C NMR see Table 5.1; 
(+) HRESIMS m/z 371.2177 [M+H]+ (calcd for C18H31N2O6, 371.21766). 
Cystargolide B: Pale yellow powder; [α]25D -28˚ (c=0.12, MeOH); IR vmax 3299, 
2964, 1838, 1723, 1648, 1529, 1467, 1157, 1024 cm-1; 1H and 13C NMR see Table 5.2; 
(+) HRESIMS m/z 357.2021 [M+H]+, (calcd for C17H29N2O6, 357.20201). 
Optical rotations were measured on a Rudolph Autopol III polarimeter using a 50 
mm microcell (1 mL). Infrared spectra were recorded using attenuated total reflectance, 
with samples deposited as a thin film on a Bruker Alpha FT-IR spectrometer. NMR 
spectra were obtained on a 600 MHz Bruker Avance III spectrometer equipped with a 1.7 
mm inverse probe. Chemical shifts (δ) are reported in ppm and were referenced to the 
DMSO-d6 residual peaks at δH 2.50 ppm and δC 39.51 ppm and coupling constants (J) are 
reported in Hz with the abbreviations (s) singlet, (d) doublet, (t) triplet, (q) quartet, (m) 
multiplet. LC-HRMS data were recorded used a Thermo Q Exactive fitted with ESI 
source, PDA, and LT-ELSD Sedex 80 detectors. High-resolution mass spectra were 
measured on a Thermo LTQ Orbitrap Velos mass spectrometer. Tandem MS analysis 
was conducted in positive mode by direct infusion of cystargolide A and B at a rate of 2 
µL/min using an ESI source and collision-induced dissociation (CID) energy of 35eV.  
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5.2.3 Stereochemical analysis by Marfey’s Method 
Amino acid configurations were determined by Marfey’s analysis of hydrolyzed 
cystargolides A and B100. To separate microconical vials, 20 µL of cystargolide A and B 
(10 mg/mL in MeOH) were added and then solvent was evaporated. HCl (250 µL of 6M) 
was added to each vial along with a stir bar and heated to 70-80 ºC for 75 minutes. Once 
the reaction mixtures had cooled, 1 mL of 1N NaHCO3 followed by 20 µL of 1-fluoro-
2,4-dinitrophenyl-L-alanine (L-FDAA) (10 mg/mL in acetone) was added to each 
reaction vial. The reactions were heated at 30-40 ºC for 1 hour before quenching with 100 
µL of 6M HCl. The reaction mixture was reduced in volume under air, then diluted to 1 
mL with 50:50 MeOH/H2O for LC-MS analysis. 10 μL of derivatized amino acids were 
analyzed by LC-HRMS with a Hypersil Gold 100 Å column (Thermo, 1.9 µm C18 50 x 
2.1 mm). Compounds were eluted using a linear gradient from 95 % diH2O/0.1 % formic 
acid (solvent A3) and 5 % acetonitrile/0.1 % formic acid (solvent B3) to 40 % solvent B3 
over 55 minutes followed by a ramp to 100 % solvent B3 over 2 minutes then a hold for 3 
minutes. A flow rate of 400 µL/min was used. Eluent was detected by ESI-MS 
monitoring m/z 120-800 in positive mode and UV (200-600 nm). Retention times were 
compared to that of authentic derivatized standards (Sigma Aldrich) to determine the 
amino acid configurations. 
5.2.4 20S proteasome inhibition assay 
Cystargolide A and B were evaluated for proteasome inhibition using purified 
human erythrocyte 20S proteasome (Enzo Life Sciences: BML-PW8720-0020). A 
solution of 20S proteasome was diluted to a final concentration of 3 μg/mL in assay 
buffer (50 mM Tris/HCl, pH 7.5, 25 mM KCl, 10 mM NaCl, 1mM MgCl2, and 0.03% 
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SDS), and incubated with varying concentrations of inhibitors at 30°C for 10 minutes. To 
determine the chymotrypsin-like activity, the reaction was initiated by the addition of the 
fluorogenic substrate Suc-LLVY-AMC (Enzo Life Sciences, BML-9802-9090) at a final 
concentration of 75 μM. The rate of cleavage of the substrate was determined by 
measuring the fluorescence using a Spectra Max M2 (Molecular Devices) plate reader 
with an excitation wavelength of 360 nm and emission of 460 nm. The fluorescence was 
recorded every 15 seconds for 30 minutes, and the linear regression between 15 and 30 
minutes were used to calculate the rate of substrate cleavage (AFU/s). Negative control 
wells were included that contained no inhibitor to show the maximum substrate cleavage 
rate, epoxomicin (0.5 μM) as a positive control and no enzyme (Blank) to show the 
minimum response. The concentration required to reduce the enzyme response by 50 %, 
(IC50) were calculated by Prism 6.0 (GraphPad Software) using a nonlinear regression 
dose-response, variable slope model based on triplicate measurements ± standard 
deviation. 
5.2.5 Human breast cancer and human fibroblast cell line cytotoxicity assays 
Cystagolides A and B were evaluated for cytotoxicity against human breast 
adenocarcinoma cells (ATCC HTB-26) and human foreskin BJ fibroblast cells (ATCC 
CRL-2522). Breast adenocarcinoma cells were grown in Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture F-12 Ham containing fetal bovine serum (10 %), penicillin 
(100 µU/mL) and streptomycin (0.1 mg/mL) with 5 % CO2 at 37ºC. Human foreskin BJ 
fibroblast cells were cultured in Eagle’s minimal essential medium containing fetal 
bovine serum (10 %), penicillin (100 µU/mL) and streptomycin (0.1 mg/mL) with 5 % 
CO2 at 37ºC. Both cells lines were grown to 80 % confluency and diluted with their 
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respective growth medium without antibiotics. To a microwell plate, 90 µL of BJ 
fibroblast cells were added at a concentration of 1 x 104 cells/well and 90 µL of HTB-26 
at a concentration of 5 x 103 cells/well and incubated with 5 % CO2 at 37ºC for 24 hours. 
After 24 hours cells were treated with 10 µL of cystargolide A or B at final 
concentrations ranging from 1µg/mL to 128 µg/mL in sterile DMSO. Blank wells 
containing only growth medium and DMSO were used as positive controls, untreated 
wells containing growth medium, DMSO and cells were used as negative controls, and 
wells treated with either doxorubicin (HTB-26) or zinc pyrithione (fibroblast BJ) were 
used as positive treated controls. All samples were repeated in triplicate. Microwell plates 
were incubated with 5 % CO2 at 37ºC for 72 hours (HTB-26) or 24 hours (fibroblast BJ). 
After incubation, alamarBlue® was added at a final concentration of 10 % v/v. 
Fluorescence was measured at 560/12 excitation and 590 nm emission at time zero, and 
four hours after addition of alamarBlue® using a Thermo Scientific Varioskan Flash 
plate reader. The change in fluorescence was used to calculate the percent viability of 
each treatment compared to negative control wells. The GI50 values, the concentration 
required to reduce the cell growth by 50 %, were calculated by Prism 6.0 (GraphPad 
Software) using a nonlinear regression dose-response, variable slope model based on 
triplicate measurements ± standard deviation.  
5.2.6 Developmental Therapies Program Single Dose Cytotoxicity 
Cystargolide B (10 mg) was sent to the National Cancer Institute (Bethesda, MD) 
for cytotoxicity evaluation against a panel of 60 cell lines at a single concentration of 10 
µM. The assays were performed as described by the Developmental Therapies Program, 
Drug Discovery and Development Services141. GI50 values in the presence of cystargolide 
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B were calculated based on the reduction in cell viability compared to untreated negative 
controls.  
5.3 RESULTS AND DISCUSSION 
5.3.1 Large scale fermentation, extraction and isolation of cystargolides A and B 
Using the metabolomics based chemical screening method described in Chapter 2, 
K, cystarginea was identified as the producer of unique metabolites based on the presence 
of two metabolites defined by the following two features: 3.0 min, m/z 371.2177 [M+H]+) 
and 2.8 min, m/z 357.2021 [M+H]+. Database searches (AntiBase 2012)142 for the exact 
masses of these protonated adducts returned no matches, which led to a further chemical 
investigation of the K. cystarginea metabolome. A larger scale fermentation was 
undertaken, culture broths were extracted with ethyl acetate, and the resulting organic 
extract was fractionated by C18 liquid chromatography and further purified using RP-
HPLC with a phenyl hexyl stationary phase to yield 2.5 mg and 3.1 mg of cystargolides 
A and B, respectively. 
5.3.2 Structure elucidation and absolute configuration of cystargolides A and B 
Cystargolide A was isolated as a pale yellow powder, and HRESIMS supported a 
molecular formula of C18H30N2O6 (m/z 371.2177 [M+H]
+, Δ=0.1 ppm), indicating five 
degrees of unsaturation. The NMR data (Table 5.1) revealed the presence of four 
carbonyls accounting for four of the five degrees of unsaturation in addition to two amide 
proton signals, which suggested that it was a peptide. Two amino acids were recognized 
as isoleucine and valine by interpretation of the 1H-1H COSY correlations identifying the 
two peptidic spin systems NHa (δH 8.12) to H3-6 (δH 0.82) and NHb (δH 8.53) to H3-5’ (δH 
0.81). 
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In a similar manner, COSY correlations assigned the third spin system H-2’’ (δH 
5.01) to H3-7’’ (δH 0.97). Key HMBC correlations between H-2’’ / C-1’’ (δC 167.3), C-4’’ 
(δC 169.8); H-3’’ (δH 3.50)/ C-1’’, C-4’’ and H-5’’ (δH 2.11) / C-4’’ unambiguously 
located the two carbonyl functional groups in position C-1’’ and C-4’’, respectively. The 
de-shielded resonances at δH 5.01 (H-2’’) and δC 69.9 (C-2’’) suggested that C-2’’ was 
attached to an oxygen atom. The connectivity between the isoleucine, valine and the third 
spin system was determined based on the key HMBC correlations H-2 (δH 4.16), NHa / 
C-1 (δC 172.8); H-2, NHa, H-2’ (δH 4.37) / C-1’ (δC 170.5); H-2’, NHb, H-2’’, H-3’’ / C-
1’’; and NHb / C-2’’ (δC 70.0). NOESY data supported the amino acid sequence 
assignment and showed strong correlations between NHa (δH 8.12) / H-2’ (δH 4.37); NHb 
(δH 8.53) / H-2’’ (δH 5.01), which was also supported by tandem mass spectrometry and 
the specific fragmentation pattern. 
The fifth degree of unsaturation was attributed to cyclization. Two options were 
therefore available: a macrolactone cyclization between C-1 and the C-2’’ hydroxy, or a 
β-lactone between C-4’’ and the C-2’’ hydroxy. The presence of IR absorption at 1835 
cm-1 was characteristic of a β-lactone carbonyl stretching band and therefore strongly 
supported cyclization between C-4’’ and the hydroxy at C-2’’143. The lack of HMBC 
correlation between H-2’’ and C-1 also supported a β-lactone cyclization. The presence 
of the β-lactone was further confirmed by the instability of cystargolide A in mild acidic 
conditions resulting in polymerization through condensation between two or three 
monomers144. To determine the relative configuration at the C-2’’ and C-3’’ positions on 
the β-lactone moiety, the 3JHH was used. A small 3JH2’’-H3’’ of 3.8 Hz revealed that H-2’’ 
and H-3’’ have a trans configuration, thus the relative configuration of the ring was 
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determined to be (2R*, 3S*)145,146. To the best of our knowledge, cystargolides are the 
first examples of β-lactone containing metabolites with a 3-isopropyl-4-oxo oxetate-2-
carboxyl moiety. The molecular structure of cystargolides A and B is shown in Figure 5.2 
as well as key NMR correlations used for structure elucidation. Chromatograms, MS, IR 
and NMR spectra for cystargolides A and B are shown in Appendix, Figures 8.31-8.52. 
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Figure 5.2. A. Molecular structure of cystargolide A (1) and B (2). B. Key NMR 
correlations used to determine the structure of cystargolide A.  
  
 
A 
B 
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Table 5.1. 1H (600 MHz) and 13C (150 MHz) NMR data for cystargolide A recorded in 
DMSO-d6. 
 
Position δC, type δH (J in Hz) 1H-1H COSY HMBC 
(HC) 
NOESY 
1 172.8, C     
2 56.4, CH 4.16, dd (7.1, 7.1) 3, NHa 1, 3, 4, 5, 1’ 3, 4, NHa 
3 36.0, CH 1.78, m 2, 4, 5  1, 2, 4, 5, 6 2 
4 15.3,CH3 0.86, m 3 3, 5  
5 24.5,CH2 1.43, m 3, 6  2, 3, 4, 6  
  1.19, m  3, 6 2, 3, 4, 6  
6 10.9, CH3 0.82, m 5 3, 5  
NHa  8.12, d (8.0) 2 1, 2, 3, 1’ 2, 5, 2’, 3’ 
1’ 170.5,C     
2’ 57.2, CH 4.37, dd (8.0, 8.0) 3’, NHb 1’, 3’, 4’, 5’, 
1’’ 
3’, NHa, 
NHb, 4’ 
3’ 30.7, CH 2.01, m 2’, 4’, 5’ 1’, 2’, 4’ 2’ 
4’ 18.8, CH3 0.87, m  3’ 2’, 3’, 5’  
5’ 17.4, CH3 0.81, m  3’ 2’, 3’, 4’  
NHb  8.53, d (9.0) 2’ 2’, 3’, 1’’, 
2’’ 
2’, 3’, 2’’ 
1’’ 167.3, C     
2’’ 70.0, CH 5.01, d (4.0) 3’’ 1’’, 3’’, 4’’, 
5’’ 
NHb, 3’’, 
5’’, 6’’ 
3’’ 62.6, CH 3.50, dd (4.1,8.1) 2’’, 5’’ 1’’, 2’’, 4’’, 
5’’, 6’’, 7’’ 
5’, 2’’, 5’’, 
7’’ 
4’’ 169.8, C     
5’’ 26.4, CH 2.11, m 3’’, 6’’, 7’’ 2’’, 3’’, 4’’, 
6’’, 7’’ 
2’’, 3’’ 
6’’ 19.0, CH3 1.00, d (6.7) 5’’ 3’’, 5’’, 7’’  
7’’ 19.2, CH3 0.97, d (6.7) 5’’ 3’’, 5’’, 6’’  
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Table 5.2. 1H (600 MHz) and 13C (150 MHz) NMR data for cystargolide B in DMSO-d6. 
 
Position δC, type δH (J, Hz) 1H-1H COSY HMBC (HC) NOESY 
1 172.5, C     
2 57.2, CH 4.12 dd (6.6, 
6.6) 
3,NHa 1,3,4,1’ 4 
3 29.4, CH 2.06 m 2,4,5 1,2,5  
4 17.7, CH3 0.89 m  5  
5 18.8, CH3 0.88 m  2,3  
NHa  8.11 d (8.1) 2 1,3,1’,2’ 5,2’,3’ 
1’ 170.5, C     
2’ 57.2, CH 4.38 t (7.7) 3’,NHb 5,3’,5’,1’’ 3’,NHa,NHb,4’ 
3’ 30.7, CH 2.01m 2’,4’,5’ 5,2’,4’  
4’ 18.9, CH3 0.86 m 3’ 2’,3’,5’  
5’ 17.6, CH3 0.82 d (6.7) 3’ 2’,3’,4’  
NHb  8.53 d (9.0) 2’ 2’,3’,1’’,2’’ 2’,3’,2’’ 
1’’ 167.0, C     
2’’ 69.9, CH 5.01 d (3.8) 3’’ 1’’,3’’,4’’, 5’’ 3’’,5’’,NHb,6’’ 
3’’ 62.5, CH 3.51 dd (3.9, 
8.1) 
2’’,5’’ 1’’,2’’,4’’,5’’,6’’,7’’ 2’’,5’’,6’’ 
4’’ 169.7, C     
5’’ 26.4, CH 2.12 m 3’’,6’’,7’’ 2’’,3’’,4’’,6’’,7’’ 3’’ 
6’’ 19.2, CH3 1.00 d (6.7) 5’’ 3’’,4’’,5’’  
7’’ 19.3, CH3 0.97d (6.5) 5’’ 3’’,4’’,5’’  
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The absolute configurations of the amino acids in cystargolide A were determined 
using Marfey’s analysis100. The peptides were hydrolyzed in HCl, derivatized using L-
FDAA and compared to authentic derivatized amino acid standards using LC-HRMS 
(Appendix, Figures 8.48, 8.49). Retention times of derivatized standards were as follows: 
L-Val: 28.70 min, D-Val: 35.03 min, L-Ile: 34.02 min, D-Ile: 40.44 min, L-allo-Ile: 34.27 
min and D-allo-Ile: 40.52 min. The derivatized hydrolysate of cystargolide A resulted in 
peaks that eluted at 28.8 and 34.0 minutes, which corresponded to L-Val and L-Ile 
respectively. Mosher’s method was attempted to determine the absolute configuration of 
the β-lactone moiety after hydrolysis of cystargolides with 1N NaOH. Unfortunately, 
neither R nor S Mosher’s derivatives were detected by LC-HRMS analysis which is most 
likely due to the instability of the β-lactone moiety leading to poly-condensation of 
cystargolide A and B. 
Cystargolide B was isolated as a pale yellow powder, and HR-ESIMS supported a 
molecular formula of C17H28N2O6 (m/z 357.2021 [M+H]
+, Δ=0.2 ppm), which suggested 
the absence of one methylene group compared to cystargolide A. The NMR spectra of 
cystargolide B closely resembled those of cystargolide A while HSQC correlations 
revealed the absence of two signals, δH 1.43 (H2-5a) and δH 1.19 (H2-5b), which were in 
agreement with valine replacing isoleucine (Table 5.2). The interpretation of COSY, 
HMBC, and tandem mass spectrometry data further confirmed these observations and 
indicated the replacement of isoleucine with a second valine residue. Marfey’s analysis 
indicated that both valine residues possessed an L-configuration (Appendix, Figures 8.47, 
8.50) and the 3JHH coupling constants similarly revealed a trans substituted β-lactone. 
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Since the publication of the cystargolide A and B structures, another research 
group was able to complete a total synthesis, and determine the absolute configuration of 
the β-lactone substituents147. They were able to synthesize both diasteriomers of 
cystargolide A and B, and compare 1H and 13C NMR spectra to the natural products. 
Based on the proton shifts of the lactone substituents and the methyl carbon signals the 
absolute stereochemistry at the 2’’ and 3’’ positions were determined to be (2R, 3S). 
5.3.3 Human 20S proteasome inhibition assay 
The presence of a β-lactone ring in the structures of cystargolide A and B 
suggested that these natural products may be proteasome inhibitors, and so they were 
evaluated for their ability to inhibit human 20S proteasome in an enzyme assay. Varying 
concentrations of cystargolide A and B were incubated with purified human 20S 
proteasome. To determine the chymotrypsin-like activity, the fluorogenic substrate Suc-
LLVY-AMC was added and fluorescence was recorded to measure the rate of enzyme 
activity. A dose-response curve was used to calculate IC50 values (Figure 5.3), which 
were determined to be 0.36 μM ± 0.017 and 0.93 μM ± 0.032 for A and B respectively. 
Cystargolide A was observed to be a more potent inhibitor than B suggesting that 
the additional methylene results in a small change to the bulkiness of the peptide side 
chain that increases the interaction with the 20S proteasome. The ability of cystargolide 
A and B to inhibit chymotrypsin-like activity of the proteasome is not surprising given 
their similarity to the natural products belactosins A and C. The β-lactone containing 
belactosins A and C, inhibit chymotrypsin-like activity of rabbit 20S proteasome both 
with an IC50 value of 0.21 μM131. This is similar to the value observed for cystargolide A, 
and slightly more potent than B. Several medicinal chemistry and structure activity 
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relationship studies of the belactosins have resulted in synthetic analogues and hybrids 
with increased potency and cell permeability leading to improved compounds for the 
development of antiproliferative agents148,149,150. The clinically used agents carfilzomib 
and bortezomib inhibit the proteasome in vitro with an IC50 value of 5 nM and a Ki value 
of 0.6 nM respectively139,140. The great potency of these compounds lead to their 
development for clinical use, which suggests that the cystargolides may benefit from 
further structure optimization to increase their potency. The cystargolides represent 
excellent leads for continued development as inhibitors of the ubiquitin-proteasome 
pathway and cell proliferation. 
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Figure 5.3. Dose-response curve showing the effects on the rate of Suc-LLVY-AMC 
cleavage by the human 20S proteasome (AFU/s Ex 360 nm, Em 460 nm) in the presence 
of increasing concentrations of cystargolides A and B and epoxomicin (0.5 µM) as a 
positive control. 
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5.3.4 Antiproliferating activity of cystargolides A and B 
Since cystargolides A and B displayed potent inhibition of the validated 
molecular target for anticancer agents, the human 20S proteasome, they were evaluated 
for cytotoxicity in cell based assays. Cytotoxicity was determined against a cancer cell 
line, human breast adenocarcinoma cells and a healthy cell line, human foreskin 
fibroblast BJ cells (Figure 5.4). After incubating cells with varying concentrations of 
cystargolides A or B, the difference in fluorescence compared to untreated wells was 
calculated and used to determine percent cell viability. The results were plotted as a dose 
response curve, and GI50 values were determined to be greater than 250 µM. The high 
concentrations of cystargolides A and B required to reduce the growth of breast 
adenocarcinoma cells show that the potency observed in the in vitro enzyme based assay 
does not translate into potent in vivo cell based activity.  
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Figure 5.4. The percent cell viability of a human breast cancer cell line (HTB26) and a 
human fibroblast cell line (CRL-2522) in the presence of increasing concentrations of 
cystargolide A and B. 
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Cystargolide B was sent to the National Cancer Institute for evaluation in the 
Developmental Therapies Program 60-cell-one dose screen. Growth inhibition of each of 
the 60 cell lines in the presence of cystargolide B were measured and calculated as 
percent growth inhibition compared to untreated controls. The calculated percent growth 
inhibition against each cell line is shown in Figure 5.5. The mean growth percent 
observed at a single dose (10-5 M) of cystargolide B was 97.03 % with a range of 45.69. 
The cell lines that were the most susceptible to cystargolide B were colon cancer HT29, 
non-small cell lung cancer NCI-H522 and breast cancer T-47D, which had percent 
growths of 68.12 %, 70.38 %, and 74.12 % respectively. Significant growth inhibition at 
the single dose was not observed so cystargolide B was not selected as an anticancer 
candidate to be further evaluated in the NCI 5-dose screen.  
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Figure 5.5. Antiproliferating activity of cystargolide B against the NCI-60 human tumor 
cell lines. 
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A significant decrease in potency was observed for in vivo cell based assays 
compared to that of an in vitro enzyme based assay. This decrease in potency could be 
caused by several reasons when a more complex whole cell system is used. Cystargolide 
B contains a relatively unstable β-lactone moiety that is required for activity, which could 
get hydrolyzed and therefore inactivated once it enters the cell. Cystargolide B may also 
be less potent because of off target interactions with other enzymes present in the cell. 
The lack of in vivo activity could also be a result of the inability to cross the cell 
membrane and enter the cell. Lack of cell permeability by cystargolides A and B would 
prevent the inhibitors from interacting with the proteasome and decrease their potency. 
Comparatively, the percent growth observed for breast adenocarcinoma cells HTB-26 is 
much lower than fibroblast BJ cells in the presence of high concentrations of 
cystargolides A and B. This shows that cystargolides A and B are selectively more toxic 
to cancer cells compared to normal cells and therefore have the potential for a large 
therapeutic window. 
5.4 CONCLUSION 
Two novel peptide natural products were isolated from the culture broth of the 
soil actinomycete K. cystarginea. These unique natural products contain a short, linear 
peptide chain coupled to an isopropyl and keto-substituted β-lactone group. To the best of 
our knowledge, these novel metabolites are the only natural products that have been 
described that contain this substitution pattern. This shows that cystargolide A and B 
were a unique discovery and contributes to the chemical space and biosynthetic 
capabilities of microorganisms.  
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Cystargolides A and B displayed potent inhibition of the human 20S proteasome, 
which is a validated molecular target for anticancer therapy. The potency of cystargolide 
A and B decreased when evaluated in a cell based assay, however they remained non-
toxic to normal human fibroblast cells even at very high concentrations. The potentially 
large therapeutic window and potent in vitro enzyme inhibition of cystargolide A and B 
make them an attractive candidate for improvement using a medicinal chemistry 
approach. Generating a library of analogs focusing on greater stability of the β-lactone 
group, increased cell permeability and more specific proteasome interaction could yield a 
synthetic analog with an increase in in vivo activity and result in an excellent candidate 
for use as a clinical antiproliferating agent for the treatment of cancer.  
The research group led by Dr. Tello-Aburto completed the total synthesis of 
cystargolides A and B. They were able to determine that the absolute stereochemistry was 
2R, 3S for both cystargolide A and B147. The completion of a total synthesis of 
cystargolides A and B also confirms the structure of these natural products.  
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CHAPTER 6: IDENTIFICATION OF THE 
BIOSYNTHETIC GENE CLUSTERS 
RESPONSIBLE FOR PRODUCING 
CYSTARGAMIDE AND 
CYSTARGOLIDES A AND B IN THE 
GENOME SEQUENCE OF 
KITASATOSPORA CYSTARGINEA 
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6.1 INTRODUCTION 
 Advances in molecular biology and sequencing techniques over the last two 
decades have allowed for an eruption of information about the genes and enzymes that 
are responsible for the biosynthesis of natural products. One class of natural products that 
has garnered a great deal of interest regarding their biosynthesis is nonribosomal peptides 
(NRPs). The biosynthesis of NRPs involves condensation of amino acids that is catalyzed 
by large multimodular enzymes, nonribosomal peptide synthetases (NRPSs)151. In 
addition to the 20 proteinogenic amino acid building blocks, NRPs commonly contain 
nonproteinogenic amino acids and can be linked to sugars, fatty acids, or polyketide 
groups152. Incorporation of these unusual amino acids and subsequent modifications 
results in a large amount of structural variety within this diverse group of peptide natural 
products.   
 NRPSs are large enzymes that catalyze the formation of peptide chains for 
NRPs153. In the canonical organization of these enzymes, they have a modular structure 
where each module is responsible for the addition of one amino acid in the growing 
peptide chain (Figure 6.1). The order of these modules is the same as the order in which 
each amino acid is incorporated and thus, determines the sequence of amino acids in the 
final structure. The genes that encode these modules are usually organized in the same 
order as the modules in the resulting enzyme. This is referred to as the colinearity rule. 
Each module contains three essential domains to catalyze the addition of a single amino 
acid, the adenylation domain (A), thiolation domain (T) and condensation domain (C). 
The A domain catalyzes the first step, and is responsible for activating the incoming 
amino acid by coupling of an adenylate group154. The A domain is highly specific, and 
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controls the identity of each monomer that gets incorporated. Each A domain contains a 
“specificity-conferring code” that consists of 10 amino acids that are involved in 
substrate binding154. The sequence of each code is specific for the amino acid that each A 
domain activates, and thus can be used to predict the identity of the amino acid 
incorporated by each A domain. This is very useful for predicting the amino acid 
sequence in the final natural product structure based on the gene sequence of adenylation 
domains. The thiolation domain (T) also referred to as peptidyl carrier protein (PCP) is 
responsible for tethering the activated amino acid to the NRPS enzyme155. The T domain 
contains a phosphopantethein arm that attaches to the activated amino acid via a thioester 
bond. The flexibility of the phosphopantethein arm allows for the tethered amino acid to 
extend and interact with adjacent domains that are involved in chain elongation and 
peptide modification. Lastly, the condensation domain is responsible for catalyzing the 
condensation reaction between the free amine of the incoming amino acid, and the 
growing peptide chain151.  
Other domains may be present within modules that are responsible for alterations 
to the peptide156. Epimerization (E) domains catalyze the epimerization of incoming 
amino acids from L to D, methyltransferase (MT) domains often catalyze the N-
methylation of amino acids, and cyclization (Cy) domains catalyze nucleophilic attack of 
thiol or hydroxyl side chains of cysteine, threonine or serine on the adjacent amide 
carbonyl, followed by dehydration to give five membered thiazoline or oxazoline rings. 
The thioesterase domain (TE) is usually the final domain at the terminal end of the 
NRPS, which catalyzed the release of the natural product from the enzyme by cleavage of 
the thioester bond either through hydration or macrocyclization156.   
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Figure 6.1. General mechanism for biosynthesis of nonribosomal peptides by 
Nonribosomal Peptide Synthetase enzymes (M. Strieker et. al.)152 
 
 
Figure 6.2. Molecular structures of cystargamide, cystargolide a and cystarolige B  
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In addition to modifications, NRPs can be hybridized with other types of natural 
products like polyketides (PKs), fatty acids (lipopeptides) and sugars (glycopeptides). 
The genes responsible for coupling these groups to the peptide chain are often located in 
close proximity to the NRPS genes, or may be ‘borrowed’ from primary metabolism and 
encoded elsewhere on the genome sequence153.  
 As described in preceding chapters, the peptide natural products cystargamide and 
cystargolides A and B were isolated from the fermentation broth of Kitasatospora 
cystarginea (Figure 6.2). The biosynthetic route for both of these types of natural 
products was predicted to involve NRPS enzymes due to the peptide chains in both 
structures. Cystargamide is a lipopeptide that contains non-proteinogenic amino acids and 
is coupled to a fatty acid group, with a similar structure to the calcium dependent 
antibiotic (CDA). It was hypothesized that the biosynthetic gene cluster responsible for 
producing cystargamide would have similar features to the gene cluster that produces 
CDA, and thus contain genes to encode NRPSs. The cystargolides contain a short linear 
peptide chain that is coupled to a very unusual β-lactone containing subunit. It was 
unclear what the origin of the β-lactone containing subunit is, but we hypothesized that 
the biosynthetic gene cluster would contain NRPS domains to synthesize the dipeptide 
chains, and link them to the acyl substituted β-lactone. To determine the gene clusters 
involved in biosynthesis of these novel natural products, the whole genome sequence of 
K. cystarginea was sequenced, and evaluated for the presence of putative biosynthetic 
gene clusters. Herein we describe the genome sequence, annotation, and identification of 
the gene clusters responsible for production of cystargamide and cystargolides A and B. 
152 
 
6.2 MATERIALS AND METHODS 
6.2.1 Genome sequencing, assembly and annotation 
K. cystarginea NRRL B-16505 was obtained from the Agriculture Research 
Services Culture Collection under the accession number NRRL B-16505. To isolate 
genomic DNA (gDNA), 10 mL of ISP249 broth was inoculated with 10 µL of a K. 
cystarginea spore stock (109 cfu/mL) and fermented at 30 ºC for 4 days. High molecular 
weight genomic DNA was isolated using the Qiagen genomic tip 100/G DNA isolation 
kit and assessed for appropriate size and purity using agarose gel electrophoresis. Long 
insert DNA library preparation and Pacific Biosciences RS II sequencing was performed 
by McGill University and the Genome Quebec Innovation Centre. Four single molecule 
real-time (SMRT) cells were used. Genome assembly was performed using the 
hierarchical genome assembly process 2 by McGill University and the Genome Quebec 
Innovation Centre157.  
Coding sequences and gene function were predicted using Rapid Annotation 
using Subsystems Technology 2.0 (RAST)158-160. AntiSMASH 3.0.5 was used to annotate 
the secondary metabolite biosynthetic gene clusters present in the genome sequence of K. 
cystarginea161.  
6.2.2 Construction of a cystargolide gene disruption mutant 
The CRISPR/cas9 genome editing plasmid, pCRISP0myces-2 was used to create 
gene disruption mutants162. The pCRISPomyces-2 plasmid was obtained from Addgene 
(Addgene plasmid # 61737), where it was deposited by Huimin Zhao. Genomic DNA 
from K. cystarginea was isolated using a phenol/chloroform/isoamyl alcohol extraction 
method163 for use as template DNA for PCR reactions. PCR primers and DNA 
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oligonucleotides used in this study are listed in Table 6.1. The cystargolide (CyO) spacer 
insert was prepared by annealing 5 µM of the oligonucleotides, CyOG2PS_F and 
CyOG2PS_R in HEPES buffer (30 mM, pH 7.8), to a total volume of 100 µL. The 
oligonucleotide mixture was heated to 95 ºC for 5 min, then cooled to 4 ºC at a rate of 0.1 
ºC/sec. The annealed spacer was cloned into pCRISPomyces-2 using the Golden Gate 
Assembly method164. pCRISPomyces-2 (100 ng) was combined with 0.3 µL of annealed 
insert, 2 µL of ligase buffer (10X), 1 µL of T4 ligase (NEB), 1 µL of BbsI (NEB), and 
sterile H2O to a final volume of 20 µL. A thermocycler (Eppendorf Mastercycler) was 
used the facilitate assembly with the following conditions: Step 1: 37 ºC for 10 minutes 
and 16 ºC for 10 minutes (repeated for 10 cycles), step 2: 50 ºC for 5 min, step 3: 65 ºC 
for 20 minutes, and step 4: 4 ºC for storage. The resulting ligation reaction was used to 
transform chemically competent E. coli NEB 5α cells, and transformants were selected 
on lysogeny broth (LB) agar plates (10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl, 20 
g/L agar) containing apramycin (Apr) (50 µg/mL). Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (100 µM) and 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal) (20 µg/mL) were also included in the medium to facilitate 
identification of recombinant colonies via blue white screening. Recombinant colonies 
were cultured in LB broth containg Apr (50 µg/mL) at 37 ºC for 24h, and plasmid DNA 
was extracted using a plasmid isolation kit (Qiagen) to give pCRISPCyOPS.  
Two homologous arms (0.85 kb) flanking the cystargolide protospacer region 
were amplified by PCR using the primer pairs CyOG2_FL / CyOG2_RL and CyOG2_FR 
/ CyOG2_RR with the conditions listed in Table 6.2. Resulting amplicons were gel-
purified. A three way Gibson assembly was used to clone both the left and right 
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homologous template arms into pCRISPCyOPS. XbaI (NEB) and Shrimp Alkaline 
Phosphatase (rSAP) (NEB) were used to digest and dephosphorylate pCRISPCyOPS 
prior to assembly. To assemble the homologous template arms into pCRISPCyOPS, 23 
ng of each homologous template arm was mixed with 100 ng of linear pCRISPCyOPS in 
2X Gibson Assembly Master Mix (NEB) with a final reaction volume of 20 µL. 
Reactions were incubated at 37 ºC for 60 min followed by 65 ºC for 10 min.  The ligation 
reaction mixture was used to transform chemically competent E. coli NEB 5α cells. 
Transformants were selected on LB agar containing Apr (50 µg/mL). A total of 48 
colonies were patched onto Apr containing LB agar plates, and after 24 hours of growth, 
were screened for the homologous template insert using colony PCR with DMSO 
extracted template DNA and CyOG2_FL and CyOG2_RR PCR primers. PCR conditions 
used are listed in Table 6.2. Transformants yielding a 1.7 kb amplicon were inoculated 
into 10 mL of LB broth containing Apr (50 µg/mL) and cultured at 37 ºC for 24 hours 
with agitation at 200 rpm. pCRISPCyOPSHT plasmid DNA was extracted and correct 
assembly was confirmed using sequencing performed by Eurofins MWG Operon 
(Huntsville AL, USA) using the primers BbsI_Fwd, BbsI_Rev, XbaI_Fwd, XbaI_Rev, 
CyOG2_1.2_SF and CyOG2_1.2_SR. 
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Table 6.1. Oligonucleotides used for PCR, assembly of pCRISPCyOPSHT and 
sequencing. 
Homologous regions are shown in capital letters, non-homologous regions in lower case 
letters and sticky ends are shown as underlined text. 
 
Primer Name Primer Sequence (5’ 3’) 
CyOG2_PS_F ACGCACAGCGGTACGACGTCGGGA 
CyOG2_PS_R AAACTCCCGACGTCGTACCGCTGT 
CyOG2_FL gccgggcgttttttatctaGACCGCGCGGCGTGGACC 
CyOG2_RL ccgcagggTCTTCGCCTACCCGCGCGG  
CyOG2_FR ggcgaagaCCCTGCGGGTCGAGCCGG 
CyOG2_RR tacggttcctggcctctagaCGGGAGCACCGGCGCGGT 
BbsI_Fwd TGTGAATGGCCTGTTCGG 
BbsI_Rev CGAGCGTTCTGAACAAATCC 
XbaI_Fwd CAAGTTAAAATAAGGCTAGTCC 
XbaI_Rev GTCCTGTCGGGTTTCGC 
CyOG2_1.2_SF GGGAACGCGATCCGGTGC 
CyOG2_1.2_SR GGTACCGGTACTGCTGTCG 
CyOG2_0.2_SF GCAGGGCGGTGAAGGTGC 
CyOG2_0.2_SR ACGCTGCTCCCGGTGACC 
16S_27F AGAGTTTGATCMTGGCTCAG 
16S_1525R AAGGAGGTGWTCCARCC 
16S_936R GGGGTTATGCCTGAGCAGTTTG 
 
 
  
156 
 
Table 6.2. PCR conditions showing primer pairs, temperatures used for each step, number 
of cycles and polymerase enzyme that was used.  
Each step was 30 seconds in duration, and each reaction had an initial 2 min denaturation 
step and a final elongation step for 4 min.  
 
Forward Primer  
(5 µM) 
Reverse Primer  
(5 µM)  
D
en
atu
ratio
n
 
T
em
p
 (ºC
) 
A
n
n
ealin
g
 
T
em
p
 (ºC
) 
E
lo
n
g
atio
n
 
T
em
p
 (ºC
) 
# 
Cycles 
Enzyme 
CyOG2_FL CyOG2_RL 95 66 72 30 
Econotaq® Plus 
Green (2X) 
CyOG2_FR CyOG2_RR 95 66 72 30 
Econotaq® Plus 
Green (2X) 
CyOG1_FL CyOG2_RR 95 66 72 30 
Econotaq® Plus 
Green (2X) 
CyOG2_1.2_SF CyOG2_1.2_SR 95 62 72 30 
Econotaq® Plus 
Green (2X) 
CyOG2_0.2_SF CyOG2_0.2_SR 95 67 72 30 
Econotaq® Plus 
Green (2X) 
16S_27F 16S_1525R 95 54 72 30 
Econotaq® Plus 
Green (2X) 
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pCRISPCyOPSHT was used to transform chemically competent E. coli 
ET12567::pUZ8002 and transformants were selected on LB agar plates containing Apr 
(50 µg/mL), kanamycin (Kan) (50 µg/mL) and chloramphenicol (Cml) (25 µg/mL). 
pCRISPCyOPSHT was introduced into K. cystarginea via conjugal DNA transfer. E. coli 
ET12567::pUZ8002::pCRISPCyOPSHT was inoculated in reduced salt LB (1 g/L of 
NaCl) containing Apr, Cml and Kan, and incubated at 37 ºC to an OD600 of 0.4-0.6, then 
rinsed twice with fresh reduced salt LB, and resuspended in 10 % of the culture volume 
with 2XYT (16 g/L of Bacto Tryptone, 10 g/L of yeast extract, 5 g/L of NaCl, pH 7.0). 
An aliquot of 50 µL of K. cystarginea spores (109 cfu/mL) were rinsed with fresh 2XYT 
and mixed with E. coli ET12567::pUZ8002::pCRISPCyOPSHT. Conjugation mixtures 
were plated onto MS agar (20 g/L mannitol, 20 g/L Baker’s soya flour, 20 g/L agar, tap 
water) supplemented with 10 mM MgCl2 and incubated at 30 ºC or 37 ºC. After 18 hours, 
plates were overlaid with 1 mL of sterile H2O containing naladixic acid (Nal) (25 µg/mL) 
and Apr (50 µg/mL). Plates were incubated for an additional 7 days at 30 ºC. 
Exconjugants were patched to ISP2 agar plates. 
6.2.3 Analysis of wild type and mutant strains 
Exconjugants were screened for the production of cystargolides A and B by 
inoculating 10 mL of seed medium (10 g/L of glucose and 10 g/L of yeast extract) with a 
single colony from ISP2 agar plates. Seed cultures were fermented at 30 ºC and 200 rpm 
shaking for three days. 10 mL of lean production medium (1045) (Chapter 2), was 
inoculated with 500 µL of seed cultures and fermented for four days with the same 
growth conditions. Fermentation broths were extracted with 10 mL of ethyl acetate, and 
analyzed by LC-MS using the Kerr lab “chemical screening” method described 
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previously (Chapter 2). Spores of a positive mutant were preserved in 25 % glycerol and 
stored at -80 ºC. Fermentations were repeated for 12 replicates of the positive mutant by 
plating spores onto ISP2, and inoculating broth using a single colony. LC-MS analysis 
was also repeated using the same conditions.  
PCR was used to amplify regions surrounding the predicted mutation. Template 
DNA was extracted using phenol/cholorform/isoamyl alcohol DNA extraction method, 
from 5 day cultures in ISP2 that were inoculated directly with mutant or wild type strains. 
PCR was performed using the CyOG2_1.2_SF / CyOG2_1.2_SR and CyOG2_0.2_SF / 
CyOG2_0.2_SR primer pairs, listed in Table 6.1 using the PCR conditions listed in Table 
6.2. To confirm the taxonomic identity of the mutant and wild type strains, the 16S rRNA 
gene was amplified using PCR (27F and 1525R primers) and sequenced by Eurofins 
MWG Operon (Huntsville AL, USA) using the 936R primer165. 
6.3 RESULTS AND DISCUSSION 
6.3.1 Genome sequence, assembly and annotation 
In order to identify the biosynthetic gene clusters responsible for producing 
cystargolides A and B and cystargamide, the whole genome sequence of K. cystarginea 
was determined using Pacific Biosciences RS II sequencing. The sequencing efforts 
resulted in a total of 313 760 subreads that passed quality control with an average read 
length of 4 707 bp resulting in 164X coverage (assuming a 9 Mb genome size). The 
genome sequence was assembled and consisted of one major contig (8 967 537 bp) and 9 
smaller contigs ranging in size from 286 393 to 813 bp. The total consensus sequence 
consisted of 9 351 686 bp and had a G+C content of 71.3 %.  
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Annotation using the RAST online interface158-160 identified a total of 8 334 
predicted coding sequences (CDSs) spanning 432 subsystems. The number of features for 
each subsystem is summarized in Table 6.3. The closest type strain neighbors of K. 
cystarginea based on the RAST genome annotation were Streptomyces griseus subsp. 
griseus NBRC 13350, Streptomyces avermitillis MA-4680, and Streptomyces 
roseosporus NRRL 11379.  
AntiSMASH was used to predict the secondary metabolite biosynthetic gene 
clusters (BGCs) present in the genome sequence of K. cystarginea. AntiSMASH 
predicted a total of 36 BGCs including four NRPSs, four PKSs (type I and II), three 
terpenes, two bacteriocins, eight lantipeptides, one siderophore, nine hybrids, one 
melanin, one butyrolactone and three uncharacterized gene clusters, which are 
summarized in Table 6.4.  
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Table 6.3. Summary of subsystem features in the genome sequence of Kitasatospora 
cystarginea, predicted using RAST 2.0.  
 
Subsystem Category Subsystem Feature Counts 
Cofactors, vitamins, prosthetic groups, pigments 317 
Cell wall and capsule 203 
Virulence, disease and defense 72 
Potassium metabolism 27 
Miscellaneous 41 
Phages, prophages, transposable elements 4 
Membrane transport 106 
Iron acquisition and metabolism 57 
RNA metabolism 127 
Nucleosides and nucleotides 137 
Protein metabolism 376 
Cell division and cell cycle 37 
Motility and chemotaxis 4 
Regulation and cell signaling 55 
Secondary metabolism 25 
DNA metabolism 135 
Fatty acids, lipids and isoprenoids 284 
Nitrogen metabolism 26 
Dormancy and sporulation 18 
Respiration 151 
Stress response 193 
Metabolism of aromatic compounds 47 
Amino acids and derivatives 639 
Sulfur metabolism 43 
Phosporus metabolism 37 
Carbohydrates 507 
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Table 6.4. Summary of predicted biosynthetic gene clusters present in the genome 
sequence of Kitasatospora cystarginea using AntiSMASH 3.0.5. 
  
Cluster Type 
Similar Known Gene Clusters 
(Percent of genes that show 
similarity) 
1 Other  
2 T1 PKS  
3 TransAT PKS-NRPS  
4 Lantipeptide  
5 Bacteriocin  
6 NRPS  
7 TransAT PKS Migrastain / dorrigocin (100 %) 
8 T2 PKS-oliogiosaccharide-NRPS  
9 T2 PKS Spore pigment (83 %) 
10 NRPS  
11 NRPS  
12 Hybrid Esmeraldin (52 %) 
13 Lantipeptide  
14 NRPS-T1 PKS  
15 Lantipeptide  
16 Bacteriocin  
17 Siderophore  
18 T1 PKS  
19 Butyrolactone  
20 Melanin  
21 Lantipeptide  
22 Lantipeptide  
23 Terpene  
24 Lantipeptide  
25 Other  
26 Lantipeptide  
27 Terpene Hopene (61 %) 
28 Terpene  
29 Siderophore-T3 PKS Desferrioxamine B (100 %) 
30 Lantipeptide  
31 Other  
32 NRPS-Lantipeptide  
33 NRPS-T1PKS-Other  
34 NRPS  
35 Thiopeptide-Lantipeptide  
36 NRPS-T1 PKS  
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Upon review of the predicted BGCs, the genes responsible for producing several 
known compounds were identified in the genome sequence of K. cystarginea (Figure 
6.3). One of the minor metabolites that was purified from fermentation extracts of K. 
cystarginea was migrastatin (discussed in chapter 2). Not surprisingly, one of the BGCs 
that was predicted by AntiSMASH shared sequence homology with the gene cluster 
responsible for producing migrastatin, isomigrastatin and dorrigocin from Streptomyces 
platensis NRRL 18993166. All of the eleven genes present in cluster 7 showed similarity 
to genes responsible for producing migrastatin. The identification of this gene cluster 
within the genome of K. cystarginea strengthened the support that 16505_490 is 
migrastatin, and contributed to annotation of the genome sequence.  
In addition to the migrastatin gene cluster, two other clusters shared homology to 
known BGCs. All of the six genes present in cluster 29 showed similarity to the genes 
responsible for producing the siderophore natural product desferrioxamine B in 
Streptomyces coelicolor M145167. Of the thirteen genes present in cluster 27, 61 % were 
homologous to genes responsible for the terpene natural product, hopene in Streptomyces 
coelicolor A3(2)39,168. These metabolites were not detected in any of the fermentation 
extracts of K. cystarginea, either because they were not produced in the culture 
conditions that were used, or they were not extracted and detected. The presence of these 
gene clusters show that this strain has the potential to biosynthesize these natural 
products, and they may be produced when K. cystarginea is fermented using different 
methods. There are also several BGCs that were predicted by AntiSMASH that show 
very little similarity to known gene clusters. This shows that K. cystarginea has the 
genetic potential to produce many unique natural products that have yet to be identified. 
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This is similar to what has been discovered by the genome sequencing efforts focused on 
the closely related genus, Streptomyces. A similar number of putative biosynthetic gene 
clusters are present in the genome sequences of many Streptomyces spp., which shows 
that Kitasatospora spp. have an equal genetic ability to produce natural products. The 
large number of unique BGCs in the K. cystarginea genome shows that members of this 
genus represent an excellent resource that have largely been underexplored for the 
identification of novel natural products.  
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Figure 6.3. Alignment of biosynthetic gene clusters of known natural products to clusters 
present in the genome sequence of Kitasatospora cystarginea using AntiSMASH. 
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6.3.2 Bioinformatics analysis of putative cystargamide gene cluster 
The peptidic structure of cystargamide suggested that it is biosynthesized using 
NRPSs, so the four NRPS and nine hybrid BGCs predicted by AntiSMASH were 
analyzed further for their potential role in the biosynthesis of this natural product. Cluster 
11 was putatively identified as the gene cluster responsible for producing the lipopeptide 
cystargamide based on the number of NRPS modules and predicted substrates of the A 
domains (Figure 6.4). Details of each gene present in this gene cluster are summarized in 
Table 6.5. Cystargamide is a cyclic lipopeptide that contains 2,3-epoxy decanoic acid 
attached to the N-terminus of a peptide with the following sequence: Thr-Phe-Glu-Htrp-
Hpg-Gly. Within cluster 11, ORF1989 encodes a NRPS that has five modules, each 
containing C, A and T domains. ORF1990 also encodes an NRPS that has a single 
module containing a C, A, T and TE domains. The amino acid sequences of the six 
adenylation domains in ORF1989 and ORF1990 were used to predict the amino acids 
that are incorporated at each elongation step using NRPSpredictor2169. Assuming the 
colinearity rule, the predicted amino acid sequence closely matched the structure of 
cystargamide. NRPSpredictor2 results are summarized in Table 6.6.  
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Figure 6.4. (A) Schematic representation of the 37 kb DNA region spanning cluster 11, the gene cluster putatively responsible 
for the biosynthesis of cystargamide.(B) Proposed mechanism of cystargamide biosynthesis. 
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Table 6.5. Summary of the bioinformatics analysis of the putative cystargamide gene cluster, Cluster 11 and their predictor 
role in biosynthesis.  
ORF 
No. 
Protein 
Length 
Nearest Homologue: 
Descriptiona 
Nearest Homologue: % 
Identity, accession, origina 
Nearest 
Homologue:  
Accessiona 
Putative Function in 
cystargamide biosynthesis 
1975 479 Multidrug transporter 
81%, Streptomyces 
durhamensis 
WP_051926938.1 Transport 
1976 392 Hypothetical protein 
80%, Streptomyces 
durhamensis 
WP_031168828.1  
1977 333 Hypothetical protein 
80%, Streptomyces 
durhamensis 
WP_031168830.1  
1978 281 Alpha/beta hydrolase 
37%, Streptomyces 
afghaniensis 
WP_020275753.1  
1979 491 
Probable long chain fatty acid 
CoA ligase PpuA 
36%, Pseudomonas putida AAM75414.1 Decanoyl-CoA ligase 
1980 228 Type 12 methyltransferase 
59%, Streptomyces 
thermolilacinus 
WP_023588193.1  
1981 309 
LysR family transcriptional 
regulator 
51%, Herbidospora daliensis WP_062435602.1 Transcriptional regulator 
1982 217 
ATP-dependent Clp protease 
proteolytic subunit 
83%, Streptomyces sp. 
NRRL S-384 
WP_030906597.1  
1983 206 
ATP-dependent Clp protease 
proteolytic subunit 
85%, Streptomyces 
griseoplanus 
WP_055588379.1  
1984 342 3-oxoacyl-ACP synthase 
66%, Streptomyces sp. 
TOR3209 
WP_019331099.1 β-ketoacyl synthase III 
1985 580 Acyl-CoA oxidase 
66%, Streptomyces sp. 
NRRL S-455 
WP_051704900.1 Decanoyl-CoA oxidase 
1986 405 3-oxoacyl-ACP synthase 
66%, Streptomyces sp. AcH 
505 
WP_041998922.1 β-ketoacyl synthase II 
1987 81 Acyl carrier protein 
48%, Streptomyces 
coelicolor 
WP_011028857.1 Acyl carrier protein 
1988 54 No significant similarity    
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ORF 
No. 
Protein 
Length 
Nearest Homologue: 
Descriptiona 
Nearest Homologue: % 
Identity, accession, origina 
Nearest 
Homologue:  
Accessiona 
Putative Function in 
cystargamide biosynthesis 
1989 5750 
Non-ribosomal peptide 
synthetase 
50%, Actinoplanes 
friuliensis, 
 
WP_023362360.1 NRPS modules 1-5 
1990 1304 
Non-ribosomal peptide 
synthetase 
56%, Kibdelosporangium sp. 
MJ126-NF4 
CEL16414.1 NRPS module 6 
1991 73 MbtH-Like Protein 79%, Multi Streptomyces WP_015613088.1 
Unknown-A domain activating 
enzyme170 
1992 448 Hypothetical protein 
49%, Kibdelosporangium sp. 
MJ126-NF4 
WP_052478142.1  
1993 368 
α-hydroxy acid oxidizing 
enzyme 
78%, Streptomyces canus WP_020123018.1 4-hydroxymandelate oxidase 
1994 207 
4-hydroxyphenylpyruvate 
dioxygenase 
80%, Streptomyces canus WP_020123017.1 
4-hydroxyphenylpyruvate 
dioxygenase 
1995 164 
4-hydroxyphenylpyruvate 
dioxygenase 
65%, Streptomyces canus WP_020123017.1 
4-hydroxyphenylpyruvate 
dioxygenase 
1996 498 
GntR family transcriptional 
regulator 
69%, Streptomyces lydicus WP_033269185.1 
4-hydroxyphenylglycine 
aminotransferase 
1997 109 No significant similarity    
1998 399 
4-hydroxybenzoate-3-
monooxygenase 
83%, Saccharothrix sp. ST-
888 
WP_045302347.1  
1999 293 Carbon-nitrogen hydrolase 
72%, Streptomyces 
achromogenes 
WP_052423740.1  
2000 159 Hypothetical protein 
64%, Streptomyces 
xanthophaeus 
WP_031143167.1  
aResults generated by BLASTp analysis of non-redundant protein sequences (nr) 
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Table 6.6. The predicted amino acid that is activated by each adenylation domain using 
NRPSpredictor2. 
 
ORF 
Adenylation 
Domain 
Sequence 
NRPSpredictor 2 Nearest 
Neighbor 
Score 
(Percent) 
1989 1 Threonine 90 
1989 2 Phenylalanine 90 
1989 3 Asparagine 50 
1989 4 Phenylalanine 60 
1989 5 Hydroxyphenylglycine 80 
1990 6 Glycine 90 
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Four of the six predicted amino acids have high scores of 80 or 90 %. The identity 
of these amino acids that are predicted with the highest confidence match the location and 
identity in the observed structure of cystargamide. The two amino acids with lower 
confidence levels of 50 and 60 % do not match the structure of cystargamide. However, 
both predicted amino acids are similar to the amino acids present in the structure of 
cystargamide at those locations. NRPSpredictor 2 predicted a second phenylalanine at 
position four, which as a hydrophobic aromatic amino acid, is in the same category as 
hydroxytryptophan. The rarity of hydroxytryptophan in the structure of natural products 
makes it difficult for bioinformatics programs to predict its identity. Therefore since an 
amino acid similar to Htrp was predicted, it can be suggested that this adenylation 
domain is responsible for the incorporation of Htrp at this position. At position 3, 
NRPSpredictor2 predicted the incorporation of asparagine with 50 % confidence. Since 
this predicted amino acid is in the same hydrophilic category as glutamic acid, and the 
confidence level is relatively low, it is reasonable to suggest that this A domain is 
responsible for incorporating glutamic acid instead of asparagine.  
In the fifth module encoded by ORF1989, there is an E domain in addition to the 
C, A and T domains. This suggests incorporation of a D-amino acid at this position. This 
predicted stereochemistry contradicts the structure of cystargamide, which contains L-
Hpg at the fifth position, as determined by Marfey’s method (Chapter 4). This suggests 
that the E domain present in ORF1989 is inactive. E domains are approximately 450 
amino acids in length and contain seven highly conserved core motifs (E1-E7) that are 
essential for catalytic activity110. The amino acid sequence of ORF1989 contains six of 
the seven conserved motifs (E2-E7) but lacks conserved motif E1 (PIQxWF). It can 
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therefore be deduced from the stereochemistry observed in the structure of cystargamide, 
and the lack of an E1 motif that the E-domain present in ORF1989 is inactive. 
ORF1990 encodes a NRPS that contains C, A, T and TE domains. The 
thioesterase domain is responsible for termination and cleavage of the peptide chain from 
the NRPS. The cyclization of macrolactone peptides is often catalyzed by the TE domain, 
where cleavage and cyclization occur in a single step, using a threonine or serine 
hydroxyl group for intramolecular nucleophilic attack171. This is likely the mechanism for 
cystargamide biosynthesis, since the TE domain is present in the final module that 
incorporates glycine, which is cyclized with the threonine side chain in the final structure 
of cystargamide.  
This gene cluster also possesses several genes that are likely involved in 
lipoinitiation during the biosynthesis of cystargamide. ORF1987 encodes a protein with 
amino acid sequence homology to an acyl carrier protein (ACP), ORF1986 has sequence 
homology to 3-oxoacyl-ACP synthase (or β-ketoacyl-ACP synthase II, KASII) and 
ORF1984 is homologous to 3-oxoacy-ACP synthase (or β-ketoacyl-ACP synthase III, 
KASIII). These three enzymes are involved in the biosynthesis of fatty acids and are 
likely involved in the biosynthesis of decanoyl-ACP. Other enzymes involved in the 
biosynthesis of decanoic acid may be borrowed from primary metabolism since they are 
not present in close proximity to the rest of the cystargamide gene cluster. Enzymes 
involved in biosynthesis of fatty acid portions of lipopeptides are often absent from 
BGCs and it is common for microbes to recruit enzymes from primary metabolism124. 
Calcium dependent antibiotic (CDA) contains a 2,3-epoxyhexanoic acid group, and 
contains the same gene organization for fatty acid biosynthesis compared to cluster 11. 
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The CDA gene cluster contains genes encoding ACP, KASII and KASIII enzymes, and is 
also missing the genes encoding acetyl and malonyl transacylases, β-ketoacyl reductase, 
β-hydroxylacyl dehydratase and enoyl reductase, which are respsonsible for reduction of 
β-carbonyls during fatty acid biosynthesis124.  
Also present in cluster 11 are genes that encode enzymes involved in β-
hydroxylation of fatty acids. ORF1979 encodes an enzyme that is homologous to putative 
fatty acid CoA ligases. Fatty acid CoA ligases are responsible for catalyzing the addition 
of coenzyme-A to free fatty acids, which is the first step in β-hydroxylation of fatty acids 
in the degradation pathway172. ORF1985 is homologous to acyl-CoA oxidase and shares 
65 % sequence identity to hxcO (SCO3247) present in the calcium dependent antibiotic 
gene cluster in the genome of S. coelicolor A3(2)39. Acyl-CoA oxidases are also involved 
in the second step of hydroxylation of fatty acids, and are responsible for catalyzing the 
unsaturation of acyl-CoAs to trans-enoyl-CoAs. The presence of these enzymes suggest a 
possible mechanism for 2,3-epoxydecanoic acid may involve CoA linked intermediates 
(Figure 6.5). This mechanism would involve biosynthesis of decanoyl-ACP, followed by 
cleavage from the ACP using a fatty acid thioesterase (TE) to give free decanoic acid. 
Decanoic acid can then be coupled to CoA, which is desaturated by acyl-CoA oxidase to 
produce trans-decenoyl-CoA. A flavin dependent monooxygenase could then be 
responsible for epoxidation of the trans-decenoyl-CoA resulting in 2,3-epoxydecanoyl-
CoA, which would then get coupled to amino acids to produce cystargamide. Cluster 11 
does not contain a fatty acid thioesterase or any monooxygenase enzymes that are 
directly upstream or downstream of the fatty acid biosynthesis genes. However adjacent 
to the 4-hydroxyphenylglycine cassette is ORF1998, which shares homology with a gene 
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encoding a monooxygenase and therefore this gene may be involved in epoxidation. The 
mechanism involved in the biosynthesis of the epoxy-fatty acid group in CDA differs 
from the typical mechanism for β-oxidation of fatty acids. The biosynthetic gene cluster 
of CDA contains an acyl-CoA oxidase (hxcO) and a flavin dependent monooxygenase 
(hcmO) involved in the biosynthesis of the epoxy-fatty acid group124. Despite the 
sequence similarity of HxcO and HcmO to enzymes that act on CoA linked 
intermediates, the enzymes preferencially act on ACP-linked intermediates173. It was also 
shown that HxcO possesses intrinsic enoyl-ACP epoxidase activity and is sufficient to 
produce the epoxide ring alone, and that HcmO may be involved in an alternate route. 
The similarity between the genes present in the CDA gene cluster and cluster 11 suggests 
that the 2,3-epoxydecanoyl group in cystargamide may be biosynthesized in a similar 
manner to the 2,3-epoxyhexanoyl group in CDA (Figure 6.5). However the cystargamide 
gene cluster contains a fatty acid CoA ligase, which is lacking in the CDA gene cluster. 
At this stage, either mechanism is a possibility for the biosynthesis of 2,3-epoxydecanoic 
acid and it is not clear whether the epoxide ring is formed from a CoA linked 
intermediate, like the typical mechanism of β-oxidation of fatty acids, or from an ACP 
linked intermediate, like CDA.  
This gene cluster also contains genes responsible for biosynthesis of the non-
proteinogenic amino acid 4-hydroxyphenylglycine. The biosynthesis of this amino acid 
involves a cassette that encodes three enzymes that are used to transform 4-
hydroxyphenylpyruvate to 4-hydroxyphenylglycine (Figure 6.6)174. The first step 
involves conversion of 4-hydroyphenylpyruvate to L-4-hydroxyphenylmandelate by 4-
hydroxyphenylpyruvate dioxygenase (HmaS). Cluster 11 contains two genes, ORF1995 
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and ORF1994 with amino acid sequence homology to HmaS. The amino acid sequence 
of ORF1994 shares 62 % identity with the verified HmaS from Amycolatopsis orientalis 
(O52791.1), while ORF1995 shares 43 % sequence identity. This shows that ORF1994 is 
likely the active enzyme responsible for the first step of 4-hydroxyphenylglycine 
biosynthesis in K. cystarginea. The next step in biosynthesis is oxidation of L-4-
hydroxyphenylmandelate to give 4-hydroxybenzoylformate, which is catalyzed by 
hydroxymandelate oxidase (Hmo)174. Hmo is similar to FMN containing glycolate 
oxidase and mandelate dehydrogenase (MDH) and shares 50 and 52 % sequence identity 
respectively. ORF1993 has similar amino acid sequences to this family of oxidizing 
enzymes, with 78 % sequence identity to the α-hydroxyacid oxidizing enzyme from 
Streptomyces canus, 65 % sequence identity to hydroxymandelate oxidase from 
Streptomyces sp. Tue 6075 and 58 % sequence identity to the validated Hmo from 
Amycolatopsis orientalis (O52792.1). This shows that ORF1993 is likely responsible for 
the oxidation of 4-hydroxyphenylmandelate to 4-hydroxybenzylformate, the second step 
in 4-hydroxyphenylglycine biosynthesis. The last biosynthetic step involves the 
conversion of 4-hydroxybenzoylformate to 4-hydroxyphenylglycine using 
hydroxyphenylglycine transaminase (HpgT)174. ORF1996 displays amino acid sequence 
homology to the GntR family of transcription regulators, which are classified as 
pyridoxal phosphate (PLP)-dependent aspartate aminotransferases. HpgT is also a 
member of the PLP-dependent aminotransferases and uses L-Tyr as an amino donor. This 
step results in 4-hydroxyphenylglycine, and regeneration of 4-hydroxyphenylpyruvate 
from L-Tyr, which feeds into a new cycle of 4-hydroxyphenylglycine biosynthesis174. 
ORF1996 shares 56 % sequence identity with the amino acid sequence of HpgT from 
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Amycolatopsis orientalis (O52815.1). This reveals that ORF1996 is likely responsible for 
the final biosynthetic step to generate 4-hydroxyphenylglycine.  
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Figure 6.5. Possible mechanism for the biosynthesis of 2.3-epoxydecanoic acid, an 
intermediate in the biosynthesis of cystargamide.  
 
 
Figure 6.6. Biosynthesis of the non-proteinogenic amino acid 4-hydroxyphenylglycine 
(Adapted from Hubbard et. al.174). 
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 The structure of cystargamide contains an additional non-proteinogenic amino 
acid, 5 hydroxytryptophan (Htrp). Incorporation of this amino acid into microbial natural 
products is much rarer than Hpg, and its biosynthetic origin is unclear175. In humans, 5-
hydroxytryptophan is an intermediate in serotonin biosynthesis and is generated by 
hydroxylation of L-tryptophan using the enzyme tryptophan hydroxylase (EC 
1.14.16.4)176. The method of biosynthesis of Htrp in bacteria is yet to be determined. 
There are no tryptophan hydroxylase homologs present within close proximity to the 
cystargamide cluster suggesting that the gene responsible for hydroxylation of tryptophan 
is located somewhere else in the genome sequence of K. cystarginea. There are several 
genes that are annotated as putative hydroxylases that are present in the genome sequence 
of K. cystarginea that may be responsible for the hydroxylation of tryptophan.  
 In summary, cluster 11 is a gene cluster that was predicted using AntiSMASH and 
is likely responsible for the production of cystargamide. This gene cluster contains two 
multidomain NPRSs that are predicted to produce a peptide with an amino acid sequence 
that is very similar to the sequence of cystargamide. Cluster 11 also contains the gene 
cassette required for biosynthesis of the non-proteinogenic amino acid, Hpg, which is 
present in the structure of cystargamide. In addition, cluster 11 also contains several 
genes involved in the biosynthesis and epoxidation of fatty acids. To experimentally 
confirm the role of cluster 11 in the biosynthesis of cystargamide, deletion of the entire 
gene cluster was attempted using CRISPR/cas9 mediated multiplex genome editing but 
these attempts were unsuccessful due to the difficulty of conjugal DNA transfer to K. 
cystarginea. However, the overwhelming evidence determined by bioinformatics analysis 
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supporting that cluster 11 is responsible for the production of cystargamide rendered 
additional mutation efforts unnecessary. 
6.3.3 Bioinformatics analysis of putative cystargolide gene cluster 
Given the unique structural characteristics of cystargolide A and B, identifying 
the putative gene cluster responsible for production was more challenging than 
cystargamide using bioinformatics predictions. Because of the linear peptide chains that 
are present in the structures of cystargolides A and B, it was hypothesized that NRPS 
enzymes may be involved in the biosynthesis. The NPRS and hybrid gene clusters that 
were predicted by AntiSMASH, were evaluated for their potential role, and one cluster 
was identified as the most likely candidate. Cluster 34 was selected because it contained 
the appropriate number of NRPS modules, three A, and T domains and four C domains. 
Cluster 34 contains five ORFs that encode NRPS-like domains involved in 
peptide biosynthesis (Figure 6.7). All ORFs in cluster 34, and their predicted functions 
are summarized Table 6.7. ORF7573 encodes a stand-alone C domain, ORF7572 encodes 
a single module containing a C, A, and T domain, ORF7570 and ORF7569 each encode 
one A and one T domain, and ORF7568 encodes a C and T domain. NRPS enzymes are 
traditionally classified as large, multi-modular enzymes that contain several domains 
encoded by the same gene153. Each multi-modular NRPS is typically responsible for 
catalyzing several steps in the biosynthesis of peptide natural products. Cluster 34 
diverges from this usual NRPS gene organization in that several genes encode mono- or 
di-domain enzymes. This noncanonical NRPS organization is also observed in the 
biosynthetic gene clusters of the siderophore natural products, enterobactin and 
vibriobactin177. H. Wang and co-workers conducted a comprehensive study to mine all of 
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the available complete genome sequences, spanning three domains of life, for the 
presence of NRPS, PKS and hybrid gene clusters178. They determined that out of 1 428 
NPRS gene clusters identified from bacterial genome sequences, 18 % were organized in 
a non-modular arrangement. They proposed that this non-modular NRPS gene 
organization is more common than originally anticipated and thus, should be re-classified 
as type-II since it resembles the organization of type-II PKSs. The non-modular 
arrangement of the cystargolide biosynthetic gene cluster shows that it falls within this 
proposed group of type-II NRPSs.  
NRPSpredictor2 and Minowa prediction were used to predict the amino acid 
selectivity of each A domain (Table 6.8). The A domain encoded by ORF7569 (A3) was 
predicted using both methods to incorporate Val with 70 % confidence score. No 
consensus could be reached for the remaining two A domains and predictions were made 
with low confidence scores. However, The A domain in ORF7570 (A2) was predicted to 
incorporate a hydrophobic amino acid by both prediction methods and thus may be 
responsible for incorporation of either Ile or Val for cystargolides A and B respectively. 
The low confidence scores using prediction methods is likely due to the promiscuity of 
this A domain, and shows that it may have the ability to activate multiple different amino 
acids. No consenses was reached for the prediction of the amino acid incorporated by the 
A domain in ORF7572 (A1). The commonality between the two prediction methods was 
that the unit is likely hydrophilic in nature. The low confidence score could be a result of 
incorporation of an unusual starter or extender unit179. This aligns with the observed 
structure of cystargolides A and B since they contain an unusual isopropyl and carboxy 
substituted β-lactone group.   
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Figure 6.7. Schematic representation of the 27 kb DNA region spanning cluster 34, the gene cluster involved in the 
biosynthesis of cystargolide A and B. 
A1 A2 A3 
181 
 
Table 6.7. Summary of the bioinformatics analysis of cluster 34, the gene cluster 
involved in biosynthesis of cystargolides A and B.  
 
ORF 
No. 
Protein 
Length 
Nearest Homologue: 
Descriptiona 
Nearest 
Homologue: 
Sequence identity, 
origina 
Nearest Homologue: 
Accessiona 
7557 121 Hypothetical protein 
75%, Streptomyces 
rubellomurinus 
WP_045699647.1 
7558 510 
NAD(P)-dependent 
oxidoreductase 
84%, Kitasatospora 
azatica 
WP_035840390.1 
7559 321 Ribokinase 
65%, 
Streptacidiphilus 
albus 
WP_034086908.1 
7560 263 Enoyl-CoA hydratase 
76%, Streptomyces 
sp. WM6372 
WP_053694337.1 
7561 43 
Hypothetical protein-
YkuD superfamily 
65%, Streptomyces 
albus subsp. Albus 
KUJ67803.1 
7562 70 Cupin 
70%, Streptomyces 
sp. W007 
WP_032791300.1 
7563 270 Methyltransferase 
72%, Streptomyces 
hygroscopicus 
WP_060953975.1 
7564 248 
Short-chain 
dehydrogenase 
84%, Multi 
Kitasatospora 
WP_057235080.1 
7565 516 
Hypothetical protein-
Peptidases_S53 
superfamily 
69%, Multi 
Streptomyces 
WP_043389144.1 
7566 149 
Hypothetical protein 
AQJ27 49940 
62%, Streptomyces 
olivochromogenes 
KUN33597.1 
7567 278 
Hypothetical protein-
aliginate lyase 
superfamily 
74%, Saccharothrix 
sp. ST-888 
WP_052681550.1 
7568 946 NRPS 
83%, Saccharothrix 
sp. ST-888 
WP_045299923.1 
7569 599 NRPS 
80%, Saccharothrix 
sp. ST-888 
WP_045299925.1 
7570 612 NRPS/PKS hybrid 
85%, Saccharothrix 
sp. ST-888 
WP_045299927.1 
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ORF 
No. 
Protein 
Length 
Nearest Homologue: 
Descriptiona 
Nearest 
Homologue: 
Sequence identity, 
origina 
Nearest Homologue: 
Accessiona 
7571 390 
Acyl-CoA 
dehydrogenase 
96%, Saccharothrix 
sp. ST-888 
WP_045299929.1 
7572 1039 NRPS 
85%, Saccharothrix 
sp. ST-888 
WP_045299931.1 
7573 423 
Hypothetical protein-
Condensation 
Supefamily 
83%, Saccharothrix 
sp. ST-888 
WP_045299987.1 
7574 462 MFS transporter 
77%, Kitasatospora 
sp. MY 5-36 
WP_049659092.1 
7575 707 Mannosyltransferase 
51%, Streptomyces 
sp. 769 
WP_052287171.1 
7576 42 
No significant 
similarity 
  
7577 119 Hypothetical protein 
73%, Streptomyces 
caatingaensis 
WP_049716363.1 
7578 129 Hypothetical protein 
91%, Saccharothrix 
sp. ST-888 
WP_045304688.1 
aResults generated by BLASTp analysis of non-redundant protein sequences (nr) 
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Table 6.8. The predicted amino acid that is activated by each adenylation domain using 
NRPSpredictor2 and Minowa prediction. 
 
ORF 
Adenylation 
Domain 
Sequence 
NRPSpredictor 
2: Nearest 
Neighbor 
Score 
(Percent) 
NRPSpredictor2: 
Three clusters 
Minowa 
prediction 
7572 1 Thr 50% Hydrophilic Lys 
7570 2 Phe 50% -- Leu 
7569 3 Val 70% 
Hydrophobic-
aliphatic 
Val 
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In addition to incorporation of the proteinogenic amino acids valine and 
isoleucine, cystargolides A and B also contain the very unusual isopropyl and carboxy-
substituted β-lactone moiety. To the best of our knowledge, there are no other known 
natural products that contain a β-lactone with this substitution pattern. The most similar 
structures to cystargolide A and B are the belactosins, however their biosynthesis remains 
undetermined130. The biosynthesis of macrolactones in NRPs and PKs has largely been 
investigated and as a result is a well characterized step in natural product biosynthesis153. 
Macrocyclization is often the final step in biosynthesis and involves intramolecular 
nucleophilic attack of a hydroxyl on the enzyme bound carbonyl and is often catalyzed by 
a terminal thioesterase domain. This results in cleavage of the thioester for release from 
the enzyme and cyclization in a single step. However the formation of 4-membered 
lactone rings is less extensively studied and consequently the mechanisms and genes 
involved are not yet fully understood. The biosynthetic gene clusters involved in the 
formation of the β-lactone containing natural products, ebelactone180, salinosporamide 
A181, lipstatin182 and oxazolomycin183 have been investigated and resulted in the proposal 
of different mechanisms for β-lactone formation. The proposed mechanism of β-lactone 
biosynthesis in salinosporamide A does not involve the thioesterase that is present in the 
gene cluster and instead is formed in conjunction with the fused γ-lactam ring after 
generation and nucleophilic attack of a β-oxyanion184. The proposed formation of the β-
lactone group in oxazolomycin biosynthesis involves intramolecular cyclization of a 
serine residue that is hypothesized to involve a terminal condensation domain instead of a 
thioesterase domain183. Ebelactone is a polyketide with a terminal β-lactone that is 
formed in a spontaneous manner without the use of a thioesterase180. Lipstatin also 
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contains a β-lactone group that is formed spontaneously following the reduction of a 3-
keto group using a dehydrogenase182. In all of the examples mentioned above, β-lactone 
formation is one of the final steps in biosynthesis, and it is suggested that formation 
involves hydrolysis of the thioester that cleaves the natural product from the carrier 
protein. The variation in the enzymes proposed to be involved in the formation of these β-
lactones suggests that a conserved method is not utilized by all bacteria for the formation 
of β-lactones in natural product biosynthesis. The formation of β-lactones in natural 
products remains unclear and is an area that requires further investigation to fully 
elucidate and characterize the mechanisms involved. 
Given the noncanonical organization of the cystargolide gene cluster, the 
colinearity rule does not apply. This makes it difficult to predict the order that 
condensation reactions occur. It is possible that condensation occurs in a linear manner 
where the β-lactone precursor is the initiation subunit, which gets linked to valine, and 
successively to either isoleucine (cystargolide A) or a second valine (cystargolide B). It is 
also possible that the dipeptide is formed first and then gets linked to the β-lactone 
precursor subunit afterward. At this stage it is not clear what order the condensation 
reactions occur to produce cystargolides A and B (Figure 6.8), and thus both of these 
proposed mechanisms remain a possibility.  
Given the evidence provided by the deduced biosyntheses of the β-lactone 
containing natural products ebelactone, salinasporamide A, oxazolomycin and lipstatin, 
β-lactone formation of cystargolide likely occurs via intramolecular condensation of a β-
oxyanion and an activated carbonyl. The mechanisms involved in other β-lactone 
biosyntheses are often the final biosynthetic step, and involve cleavage of a thioester 
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bond that links the molecule to the carrier protein. The cystargolide gene cluster lacks a 
TE domain, and thus if this is the mechanism that is involved, cyclization and release 
would occur in a spontaneous manner like ebelactone and lipstatin or would be catalyzed 
by a different enzyme like oxazolomycin180,182. Cluster 34 contains a stand alone 
condensation domain that may catalyze this cyclization reaction. If formation of the β-
lactone ring is caused by cleavage from the carrier protein, then two of the three 
adenylation domains present in the gene cluster would be responsible for activating both 
the 1-carboxyl group for condensation with the dipeptide, and the 4-carboxy group for 
intramolecular condensation and cyclization (Figure 6.9). This proposed mechanism 
would require that a single, promiscuous adenylation domain is responsible for activation 
of both isoleucine and valine for cystargolide A, and both valine residues for cystargolide 
B in an iterative manner. There are some genes in close proximity to those that encode 
the NRPSs in cluster 34 that suggest the involvement of a carrier-protein bound 
intermediate. ORF7564 encodes a gene with amino acid sequence homology to a 3-
oxoacyl-ACP dehydratase/reductase (short chain dehydrogenase) that may be involved in 
modification of a CP-bound precursor (Figure 6.9). This family of enzymes is responsible 
for reduction of β-keto groups in fatty acid biosynthesis, and if it is involved in 
biosynthesis of cystargolide, could be responsible for reducing 2-isopropyl-3-
oxosuccinate-ACP to 3-isopropyl malate-ACP. If this step is involved, then reduction of 
the β-keto followed by cyclization with the β-hydroxyl group would occur in a manner 
analogous to β-lactone formation in lipstatin. 2-Isopropyl-3-oxosuccinate is an 
intermediate in the leucine biosynthesis pathway and therefore could be recruited from 
primary metabolism for the production of cystargolide185. It may also be possible that 
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reduction of the β-keto group and cyclization occurs after condensation with the amino 
acids, since this family of enzymes is able to act on a variety of different substrates.  
Alternatively, one adenylation domain could be responsible for activation of the 
1-carboxyl group involved in condensation with the dipeptide chain, and the 4-carboxy 
group could be activated by a group other than an adenylate group. This proposed 
mechanism necessitates the involvement of additional modification enzymes for β-
lactone formation. There are some genes in close proximity to those that encode the 
NRPSs in cluster 34 that may be involved in the modification of a cystargolide precursor 
or intermediate. The presence of a gene that encodes a putative acyl-CoA dehydrogenase 
(ORF7571) homolog located between the NRPS (ORF7572) and NRPS/PKS hybrid 
(ORF7570) suggests that formation of an acyl-CoA intermediate may be involved in 
biosynthesis. This is also supported by the presence of a gene encoding a putative enoyl-
CoA hydratase (ORF7560) homolog that is located downstream of the gene cluster. If 
these genes are involved, the β-lactone could be formed by unsaturation of isopropyl 
succinate-CoA using acyl-CoA hydrogenase, followed by hydroxylation using enoyl-
CoA hydratase to give 3-isopropyl malate-CoA. Cyclization could then occur through 
nucleophilic attack of the β-hydroxyl and cleavage of CoA to afford the final β-lactone 
containing subunit (Figure 6.9). Cluster 34 lacks an acyl-CoA ligase and thus if these 
enzymes are involved, an enzyme encoded elsewhere would have to be utilized to 
generate the CoA linked intermediate. This method involves the unusual isopropyl 
succinate as the initiation unit.  
It may also be possible that none of these modification enzymes are required for 
the biosynthesis of cystargolide A and B. It still remains a possibility that cluster 34 is 
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only responsible for encoding the enzymes involved in the final stages of biosynthesis 
where the three subunits are linked together by NRPS domains, and the other enzymes 
involved are encoded at a different location in the genome. At this stage, it is unclear 
what the mechanism of cystargolide biosynthesis entails and what the boundaries are for 
the biosynthetic gene cluster. The mechanism of β-lactone formation and biosynthesis 
cannot be deduced from this gene cluster alone. Additional experiments including 
precursor feeding experiments, single gene knock outs and enzyme function assays would 
need to be performed to determine the mechanism of cystargolide biosynthesis. 
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Figure 6.8. Possible methods of condensation between subunits for the biosynthesis of 
cystargolide.  
A. A biosynthetic route that involves formation of the dipeptide first, followed by 
condensation with the β-lactone subunit precursor. R groups represent the unknown 
structures present at position 2 and position 5 during condensation. B. A biosynthetic 
route that involves the β-lactone subunit precursor as the initiation subunit, followed by 
condensdation with each successive amino acid in the dipeptide chain.  
  
A 
B 
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Figure 6.9. Possible intermediates involved in the biosynthesis of cystargolide.  
R groups could be –OH if the modifications occur before condensation or the dipeptide 
chain if they occur after condensation. A. Proposed mechanism if short chain 
dehydrogenase is involved. B. Proposed mechanism if acyl-CoA dehydrogenase and 
enoyl-CoA hydratase are involved.  
  
A 
B 
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6.3.4 Gene disruption mutants of the putative cystargolide gene cluster 
Given the unique gene organization of cluster 34, and lack of co-linearity 
typically observed in the organization of NRPS genes, it was determined that 
bioinformatics alone would not be sufficient to determine if cluster 34 is involved in the 
biosynthesis of cystargolide A and B, and that gene disruption mutants would need to be 
generated for confirmation. 
A K. cystarginea gene disruption mutant was created using the recently developed 
CRSIPR/cas9 genome editing technique162. The plasmid pCRISPomces-2 was designed 
to be efficiently altered to edit specific regions within the genome and was optimized for 
use in actinobacteria (Figure 6.10). In order to create a mutant strain that contained a 
small deletion in cluster 34, a sgRNA sequence that was adjacent to a PAM (NGG) 
sequence was selected as the protospacer region, and cloned into pCRISPomyces-2 to 
produce pCRISPCyOPS (CyOG2_PS_F and R). Two homologous template repair arms 
that were 0.85 kb upstream and downstream of the protospacer were amplified using PCR 
(CyOG2_L and R primer pairs) and then cloned into linear pCRISPCyOPS using the 
Gibson Assembly Method. The assembled plasmid was then introduced into K. 
cystarginea using conjugal DNA transfer from E. coli ET12567::pUZ8002, and selected 
for based on apramycin resistance. A total of 22 exconjugants were evaluated for the 
production of cystargolides A and B. 
 All exconjugants and the wild type strain were fermented using the cystargolide 
production conditions, and extracted with EtOAc. Extracts were analyzed by LC-MS for 
the presence or absence of cystargolide A and B. A single exconjugant (Ex-CyO12) 
produced no cystargolide A and B, and still retained production of cystargamide. To 
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ensure this positive result was reproducible, a spore stock of K. cystarginea Ex-CyO12 
was prepared, and twelve replicates of the fermentations were repeated using single 
colonies from plates that were inoculated with the spore stock to ensure only a pure 
mutant culture. The extracts from the twelve replicate fermentations of K. cystarginea 
Ex-CyO12 were analyzed by LC-MS, which revealed production of cystargamide was 
retained, and production of cystargolide A and B was lost in all twelve replicates. This 
shows that the cystargolide biosynthetic gene cluster was disrupted and confirms the 
involvement of the locus in cystargolides biosynthesis. (Figure 6.11).  
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Figure 6.10. Plasmid map of pCRISPomyces-2 that was developed by R.E. Cobb for 
targeted genome editing in Streptomyces162. 
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Figure 6.11. LCMS chromatograms of wild type Kitasatospora cystarginea and K. 
cystargineaΔcyo. 
Retention of cystargamide (●) production in both strains, but loss of cystargolide A (♦) 
and B (▼) production compared to the wild type strain. 
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 To confirm that the mutation in the genome of K. cystarginea ExCyO12 occurred 
in cluster 34, PCR was used to amplify a 1.2 kb region centered on the protospacer region 
(CyOG2_1.2_SF and R). The PCR primers used successfully amplified a 1.2 kb amplicon 
in the wild type strain, however were unable to amplify a smaller band expected from any 
of the replicates of the mutant strain. PCR was attempted again using a second set of 
primers to amplify a 200 bp amplicon (CyOG2_0.2_SF and R), as well as the 
homologous template primers (1.7 kb amplicon using CyOG2_FL and CyOG2_RR), and 
again both were unsuccessful at amplifying the mutant strain. These results suggested 
that the entire region of the genome that contains the homologous arms has been removed 
in the mutant strain instead of just the desired protospacer region. It is unlikely that the 
observed lack of cystargolide production was caused by contamination of another 
bacterium because cystargamide was still detected in all of the extracts. However, to 
ensure that contamination did not occur, the 16S rRNA sequences were amplified 
(16S_1525R and 16S_27F), sequenced (16S_936R) and compared to the wild type strain. 
BLASTn analysis revealed that all replicates of the K. cystarginea ExCyO12 and the wild 
type strain were K. cystarginea. This confirms that the lack of cystargolides production 
was caused by a gene mutation, and not contamination. 
The unexpected results from PCR amplification suggested that the desired 
deletion of the protospacer region (20 bp) using the cas9 generated double strand break 
and homologous template repair did not occur in the anticipated manner to produce the 
mutant strains. Instead, it suggested that the gene mutation was much larger, and a region 
containing the entire 1.7 kb homologous template was altered. Instead of the expected 
method of homology directed repair (HDR), non-homologous end joining (NHEJ) could 
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have occurred, which could have introduced a random sequence where the double strand 
break occurred162. This method can introduce additional base pairs, but they are usually 
small additions. The large mutation could have also been a result of homologous 
recombination. At this time it is unclear what the size of the mutation is, but it is clear 
that the mutation occurred within cluster 34. Despite the unexpected method of mutation 
that occurred, cluster 34 was still rendered inactive. This resulted in loss of cystargolides 
production, revealing that cluster 34 is involved in the biosynthesis of cystargolide A and 
B. 
6.4 CONCLUSIONS 
 The genome sequence of K. cystaringea revealed the presence of several putative 
natural product biosynthetic gene clusters. The clusters responsible for the production of 
the novel lipopeptide cystargamide were identified using bioinformatic annotations of 
putative gene functions. Cluster 11 displayed similarities to the calcium dependent 
antibiotic gene cluster, especially with regards to the genes involved in 2,3-
epoxydecanoic acid biosynthesis and lipoinitiation. This cluster also contained the gene 
cassette required to produce the non-proteinogenic amino acid 4-hydroxyphenylglycine. 
Interestingly, the structure of cystargamide also contains the rare nonproteinogenic amino 
acid 5-hydroxytryptophan. The genes involved in hydroxylation of tryptophan to produce 
Htrp in bacteria are less extensively studied, and it is unclear if the gene is present within 
cluster 11.  
As discussed in Chapter 4, cystargamide has demonstrated the ability to affect the 
metabolite production of other actinomycetes. Determining the gene cluster responsible 
for biosynthesis could allow for the generation of a library of analogs using synthetic 
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biology. The gene cluster could be altered so that different amino acids or fatty acids get 
incorporated. This could improve the biological activity and result in the generation of a 
more potent inducer molecule that could be used in drug discovery platforms to assist in 
the isolation of novel cryptic natural products from other actinomycetes.  
 The genome sequence of K. cystarginea was also used to determine the 
biosynthetic gene cluster responsible for producing the β-lactone containing natural 
products, cystargolides A and B. Given the unique structure of the cystargolides, 
bioinformatics alone was insufficient to determine the cystargolide gene cluster. The new 
CRISPR/cas9 genome editing technique was used to introduce a mutation to the genome 
within the predicted cystargolide gene cluster. Despite the unexpected size of the 
mutation that occurred, cluster 34 was still altered, which resulted in a loss of 
cystargolide A and B production. This shows that this gene cluster encodes enzymes that 
are involved in the biosynthesis of these natural products. Further investigation will be 
required to determine the method by which this gene disruption occurred. Not 
surprisingly, these unique natural products are produced by a unique gene cluster that 
differs from the typical genes that encode NRPs. The NRPS domains are encoded in a 
non-modular way, and do not follow the co-linearity rules of typical NRPS gene clusters. 
This makes it difficult to predict the order that condensation reactions between subunits 
occur, and makes it challenging to predict the mechanism involved in coupling of the 
peptide chain to the β-lactone subunit. The amino acids or subunits that are activated by 
two of the three adenylation domains could not be confidently predicted using 
bioinformatics software. This shows that they differ from the conserved regions of 
predictable adenylation domains and shows that they may display substrate promiscuity 
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or activate unusual subunits. This makes it challenging to predict if the β-lactone 
containing subunit is cyclized before condensation with the dipeptide occurs, or if it is 
modified and cyclized after. There are genes present in cluster 34 that may play a role in 
the biosynthesis of the substituted β-lactone subunit. A short chain dehydrogenase may 
be involved in reduction of a β-keto group to a β-hydroxyl that then cyclizes with a 
terminal carbonyl to cleave the carrier protein linked thioester. It could also be possible 
that an acyl-CoA dehydrogenase and enoyl-CoA hydratase are involved in β-unsaturation 
and hydroxylation, which then forms the β-lactone in a similar manner described above 
with cleavage of CoA. In order to determine the mechanism of biosynthesis and the 
boundaries of the cystargolide gene cluster, in frame single gene knockouts need to be 
generated, and the resulting intermediate metabolites would need to be characterized. 
Identification of the involvement of cluster 34 in the biosynthesis of cystargolides A and 
B is an exciting discovery that highlights the diverse biosynthetic ability of Kitasatospora 
bacteria. Determining the biosynthetic gene clusters of unique natural products helps to 
broaden our understanding of these capabilities. With the growing access and 
affordability of whole genome sequencing, genome based drug discovery programs are 
becoming more effective and more popular. The more information we know about BGCs, 
the more effective these genome based discovery programs will be. The divergence of the 
cystargolide gene cluster from the extensively characterized NRPS gene clusters reveals 
that there are still many natural product biosynthetic capabilities that remain unknown.  
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CHAPTER 7: CONCLUDING REMARKS 
AND FUTURE DIRECTIONS 
  
200 
 
7.1 Use of an LC-MS/PCA based screening approach for prioritization 
of bacterial libraries 
In order to improve the efficiency of natural products drug discovery programs 
and avoid re-isolating known metabolites, new screening approaches that involve 
untargeted metabolomics have been recently developed21,22. By using high resolution LC-
MS to analyze samples, and multivariate analyses like PCA to visualize the resulting 
data, strains that produce similar metabolites were grouped together, and strains that 
produce unique metabolites were prioritized. This method also provided information 
about the molecular weights of the metabolites, which allowed for the dereplication 
against known natural products, and assisted with the identification of putatively novel 
compounds. When this technique was applied to two bacterial libraries, it was successful 
at identifying two strains that produced three novel metabolites. Compared to traditional 
bioassay screening methods that were initially used, this technique was much more 
effective at identifying new natural products. Metabolites that were prioritized using 
bioassay results alone only resulted in the isolation of known compounds. These results 
show that using a chemo-centric approach to natural products discovery provided more 
information about the putative novelty of metabolites and allowed for better informed 
prioritization. This reduced the amount of time and resources spent reisolating known 
compounds. The metabolomics method is highly adaptable for high throughput platforms 
and thus can help improve the efficiency and success of natural product drug discovery 
programs.  
 This metabolomics based screening method was able to identify the production of 
three novel metabolites in two bacterial fermentation extracts. These metabolites are 
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among the first novel natural products to be identified and reported using this untargeted 
approach. Future expansions of this method are currently being investigated by other 
members of the Kerr lab to improve methods for the discovery of novel natural products. 
Recent advances have focused on adapting the multivariate analyses to include a targeted 
metabolomics approach that is used to highlight metabolites whose production is induced, 
or increased under different conditions. Several members of the Kerr lab are investigating 
methods to access cryptic natural products using techniques such as co-cultures, 
epigenetic modifiers and signalling molecules, and different stressors including salt, 
temperature variation or UV radiation. Continuing efforts are focusing on improving 
metabolomics based screening methods for identification of new compounds.  
7.2 Characterization of novel natural products 
 One of the novel metabolites whose identification and characterization was 
described in this thesis was a lasso peptide natural product. This group of ribosomally 
synthesized post-translationally modified peptide natural products (RiPPs) is a relatively 
new group, and has garnered a lot of excitement because of their extreme stability under 
physiological conditions84. The threaded nature of lasso peptides makes them much more 
stable to degradation than linear or even cyclic peptides. Degradation of peptides by 
protease enzymes is one of the limiting factors that prevents many peptides from 
becoming clinically used drugs. The threaded structures of lasso peptides and the stability 
that these conformations afford helps to overcome this limitation and shows that they are 
exciting metabolites to investigate for their potential pharmaceutical applications.  
 The discovery of RKKD790_1592 represented a significant contribution to the 
group of lasso peptides because it was the smallest lasso peptide to be described. Its 
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structure provided information about the minimum requirements to create this 3D 
conformation. During the preparation of the manuscript describing the isolation of this 
interesting new metabolite, another research group published the isolation of this 
compound in the Journal of Natural Products107, which was the recipient of the Jack L. 
Beal Award for excellence. This shows that the discovery of this new lasso peptide was 
an exciting discovery, and a significant contribution the field of natural products. 
Another new metabolite that was identified and characterized was the lipopeptide, 
cystargamide, which was produced by the bacterial strain K. cystarginea. This natural 
product had interesting structural features including the nonproteinogenic amino acid 4-
hydroxyphenyl glycine, the very rare amino acid 5-hydroxytryptophan and the interesting 
oxidized fatty acid, 2,3-epoxydecanoic acid. Preliminary results from our laboratory 
show that this metabolite displayed interesting effects on natural product production 
when added to fermentations of other actinomycetes. This demonstrates that 
cystargamide may be involved in bacterial communication. Cystargamide may be utilized 
as an inducer of secondary metabolite production, and could be applied to fermentations 
of large bacterial libraries in order to help access otherwise silent natural products. Future 
investigations of this exciting application will involve further characterization of the 
induction properties including determination of the molecular target and cellular pathway 
that cystargamide interacts with, and application to a larger number of actinomycetes and 
other bacterial phyla.  
Cystargolides A and B are β-lactone containing peptides that were also isolated 
from the fermentation broth of K. cystarginea. These novel metabolites contained a 
unique β-lactone group that bears isopropyl and carboxyl substituents. There are very few 
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natural products that have been previously described that have similar structural features 
to cystargolide A and B. The characterization of these very unique natural products 
greatly increases our knowledge of the structural diversity of natural products that 
bacteria are capable of biosynthesizing.  
Cystargolide A and B displayed potent inhibition of the human 20S proteasome in 
an in vitro enzyme assay. When evaluated in cancer cell-line based assays, the potency of 
these compounds decreased. Future studies involving a medicinal chemistry approach 
will aim at increasing the potency of these compounds and improving the in vivo 
anticancer activity. Modification of the amino acid side chains, as well as the alkyl 
substituent on the β-lactone ring are being evaluated for their potential to increase 
activity. The reactivity and lability of the β-lactone might be the cause of decreased 
potency in the cell line assays so a series of β-lactam analogs are also being produced to 
try and increase stability, but retain inhibition of the proteasome. These studies are being 
conducted by several members of the Kerr lab including an undergraduate student, a 
postdoctoral fellow, and a laboratory manager. 
The discovery of these novel metabolites has attracted the attention of several 
other research groups. The group led by Dr. Tello-Aburto has completed a total synthesis 
of these β-lactone containing peptide147. In addition to the synthesized natural products, 
this research group also evaluated a benzyl ester derivative for antiproliferative activity, 
which resulted in IC50 values 100 times more potent that the natural products. This shows 
that simple derivatizations can greatly improve activity and thus there is potential for 
further structural modifications. The discovery of these natural products has also led to a 
collaboration with Dr. Barrie Wilkinson who is conducting isotopically labelled precursor 
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feeding experiments to determine biosynthetic intermediates, and mechanisms 
responsible for the biosynthesis of cystargolide A and B. This shows that there is interest 
in these compounds in the scientific community and that their discovery significantly 
contributes to the field of natural products.  
7.3 Identification of biosynthetic gene clusters in the genome sequence 
of Kitastospora cystarginea 
The biosynthetic gene clusters of cystargamide and cystargolides were identified 
from the genome sequence of K. cystarginea using bioinformatics predictions and gene 
disruption techniques. Identifying the biosynthetic gene clusters responsible for 
producing these novel natural products is important because it allows us to better 
understand the basic principles of how natural products are produced by bacteria. The 
more knowledge that is gained about the genes and mechanisms involved in the 
biosynthesis of metabolites, the better able we are to predict unknown gene clusters, and 
the metabolites they produce. This allows for advances in genome based natural products 
discovery programs, and contributes to the development of improved ways of natural 
products based drug discovery programs18. It also allows for the generation of analog 
libraries using synthetic biology techniques. This helps to create analogs that are 
unattainable using synthetic approaches, which may contribute to the development of 
analogs with improved potency or other pharmacological properties. Determining the 
biosynthetic gene clusters also allows for genetic engineering for strain optimization and 
improved yields. This is important for commercialization of strains used to produce mass 
quantities of a drug candidate. Determining the biosynthetic gene clusters responsible for 
producing cystargamide and cystargolides in the genome sequence of K. cystarginea has 
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increased the basic understanding of bacterial genetics, revealed insights into the 
mechanisms of biosynthesis of these novel metabolites, and opened the doors for future 
experiments to determine the boundaries of these gene clusters and enzyme function 
encoded by each gene present in the gene clusters. The Wilkinson research group is 
currently undertaking these labelled feeding experiments to ascertain subunits and 
intermediates involved in the biosynthesis of cystargolides A and B. Together with the 
gene cluster that was identified, the results of these experiments will reveal the 
biosynthesis of these unique natural products.  
7.4 Summary 
The research described in this thesis outlines the discovery of three novel bacterial 
natural products using an innovative LC-MS/PCA based screening approach. The 
structures of these natural products were elucidated and their potential biological 
applications were assessed in several bioassays. It was determined that the lipopeptide, 
cystargamide displayed promising activity as a bacterial signalling molecule that may be 
used to induce metabolite production in other bacteria, and the β-lactone containing 
peptides, cystargolides A and B are inhibitors of the 20S proteasome that may be used as 
antiproliferating agents. The whole genome sequence of the producing strain K. 
cystarginea was sequenced, annotated, and the gene cluster responsible for production of 
these novel metabolites were identified. This discovery of these novel metabolites from 
this unique strains shows that members of the genus Kitasatospora represent a prolific 
and underexplored resource for the discovery of novel compounds. These novel natural 
products and their biosynthetic gene clusters have inspired several other research projects 
in the Kerr lab, and other labs internationally. This shows that the discovery of these 
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metabolites, their characterization and determination of their biosynthesis is an exciting 
and significant contribution to the field of microbial natural products. 
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APPENDIX 
8.1 NMR and MNn Spectra of Known Compounds Isolated from RKKD 
and Kitasatospora Libraries 
 
 
Figure 8.1. 1H NMR spectrum of RKKD234_467, staurosporine.  
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Figure 8.2. HSQC spectrum of RKKD240_401, PM05046. 
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Figure 8.3. Summary of MSn fragments used to determine that the structure of 
RKKD790_1128 was valinomycin.  
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Figure 8.4. HSQC spectrum of 16505_211, 1-acetyl β-carboline. 
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Figure 8.5. HSQC spectrum of 16505_490, migrastatin. 
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Figure 8.6. HSQC spectrum of 16505_1501, fattiviracin FV13. 
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Figure 8.7. HSQC spectrum of 24284_720, naphthomycin A   
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Figure 8.8. 1H NMR spectrum of 16109_686, pepstatin A. 
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8.2 NMR and MS Spectra Used to Elucidate the Structure of 
RKKD790_1592 
Figure 8.9. Chromatograms of the crude extract from a large scale fermentation of 
RKKD-790 grown in ISP2.  
A. Three detectors were used to generate 3 chromatograms for the same sample: PDA, 
ELSD and +ESI-MS. B. The high resolution mass spectrum of RKKD790_1592.  
A 
B 
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Figure 8.10. The MS2 spectrum of RKKD790_1592 that was used to confirm the 
sequence of amino acids, and the lasso conformation.  
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Figure 8.11. 1H NMR (600MHz, DMSO-d6) spectrum of RKKD790_1592. 
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Figure 8.12. The COSY NMR spectrum of RKKD790_1592. 
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Figure 8.13. The TOCSY NMR spectrum of RKKD790_1592. 
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Figure 8.14. The ROESY NMR spectrum of RKKD790_1592. 
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Figure 8.15. The NOESY NMR spectrum of RKKD790_1592. 
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Figure 8.16. The HSQC NMR spectrum of RKKD790_1592. 
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Figure 8.17. The HMBC NMR spectrum of RKKD790_1592. 
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Figure 8.18. Marfey’s Analysis to determine the absolute stereochemistry of amino acids. 
SIM +ESIMS chromatograms of derivatized amino acid standards.  
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Figure 8.19. Marfey’s Analysis of RKKD790_1592. SIM +ESIMS chromatograms of 
derivatized RKKD790_1592. 
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8.3 NMR and MS Spectra Used to Elucidate the Structure of 
Cystargamide 
 
 
Figure 8.20. Chromatograms of the crude extract from a large scale fermentation of 
Kitasatospora cystarginea grown in 1045 medium.  
Three detectors were used to generate 3 chromatograms for the same sample: PDA, 
ELSD and +ESI-MS. 
  
239 
 
 
 
Figure 8.21. Figure 4.7. +ESI HRMS of cystargamide. 
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Figure 8.22. MS2 spectrum of cystargamide. 
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Figure 8.23. Chromatograms of L-FDAA derivatized amino acid standards. 
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Figure 8.24. Chromatograms of L-FDAA derivatized hydrolysate of cystargamide. 
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Figure 8.25. 1H NMR (600MHz, DMSO-d6) spectrum of cystargamide. 
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Figure 8.26. COSY NMR spectrum of cystargamide.   
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Figure 8.27. TOCSY NMR spectrum of cystargamide.  
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Figure 8.28. NOESY NMR spectrum of cystargamide.  
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Figure 8.29. HSQC NMR spectrum of cytargamide. 
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Figure 8.30 HMBC spectrum of cystargamide. 
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8.4 NMR and MS Spectra Used to Elucidate the Structures of 
Cystargolides A and B 
 
 
Figure 8.31. Chromatograms of the crude extract from a large scale fermentation of 
Kitasatospora cystarginea grown in 1045 medium.  
Three detectors were used to generate 3 chromatograms for the same sample: PDA, 
ELSD and +ESI-MS. 
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Figure 8.32. +ESI-HRMS of cystargolide A. 
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Figure 8.33. +ESI-HRMS of cystargolide B. 
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Parent Ion m/z 353  
 
Figure 8.34. MS3 spectrum of cystargolide A. 
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Parent Ion m/z 339  
 
Figure 8.35. MS3 spectrum of cystargolide B. 
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Figure 8.36.1H NMR (600 MHz, DMSO-d6) spectrum of cystargolide A. 
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Figure 8.37. 13C NMR (150 MHz, DMSO-d6) spectrum of cystargolide A.  
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Figure 8.38. COSY NMR (1H, 600 MHz, DMSO-d6) spectrum of cystargolide A.  
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Figure 8.39. NOESY NMR (1H, 600 MHz, DMSO-d6) spectrum of cystargolide A. 
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Figure 8.40. HSQC NMR (1H 600 MHz, 13C 150 MHz, DMSO-d6) spectrum of 
cystargolide A. 
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Figure 8.41. HMBC NMR (1H 600 MHz, 13C 150 MHz, DMSO-d6) spectrum of 
cystargolide A. 
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Figure 8.42. 1H NMR (600 MHz, DMSO-d6) spectrum of cystargolide B 
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Figure 8.43. 13C NMR (150 MHz, DMSO-d6) spectrum of cystargolide B. 
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Figure 8.44. COSY NMR (1H, 600 MHz, DMSO-d6) spectrum of cystargolide B. 
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Figure 8.45. NOESY NMR (1H, 600 MHz, DMSO-d6) spectrum of cystargolide B. 
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Figure 8.46. HSQC NMR (1H 600 MHz, 13C 150 MHz, DMSO-d6) spectrum of 
cystargolide B. 
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Figure 8.47. HMBC NMR (1H 600 MHz, 13C 150 MHz, DMSO-d6) spectrum of 
cystargolide B. 
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Figure 8.48. Marfey’s Analysis. SIM chromatograms of L-FDAA derivatized amino acid 
standards. 
 
 
Figure 8.49. Marfey’s Analysis. SIM chromatograms of L-FDAA derivatized hydrolysate 
of cystargolide A.  
 
 
Figure 8.50. Marfey’s Analysis. SIM chromatogram of L-FDAA derivatized hydrolysate 
of cystargolide B.  
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Figure 8.51. IR spectrum of cystargolide A (MeOH, film). 
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Figure 8.52. IR spectrum of cystargolide B (MeOH, film). 
 
